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OBJECTIVES 
 
OBJECTIVES 
 
 
Tablets are still the most commonly used dosage form because of the ease of manufacturing, 
convenience in administration, accurate dosing and excellent stability. Direct compression is 
the preferred method for the preparation of tablets. However, it has been estimated that less 
than 20 percent of the active pharmaceutical ingredients (API) can be processed into tablets 
via direct compression since the majority of API lack the flow, cohesion or lubricating 
properties required for direct compression. Therefore, the formulator has to resort to (wet) 
granulation techniques to obtain API/excipient agglomerates with suitable properties for 
compression. This involves several processing steps (dry mixing, granulation, drying), 
different equipment, numerous written procedures to be followed and extensive downstream 
testing for powder homogeneity/segregation. In addition, wet granulation is a batch process 
and scaling-up of this technique is a labour-intensive and time-consuming process. 
In this study an alternative method to improve the compactability of API will be developed 
through coprocessing of API and excipients via spray drying in order to obtain a fully 
continuous manufacturing process without granulation, milling and/or blending steps in 
between spray drying and compaction. This technique has already been used to develop 
excipient mixtures having superior properties (flowability, hygroscopicity and 
compactability) compared to the individual excipients or their physical mixtures. However, 
this concept has not been extended to the coprocessing of drug and excipient(s) to alter the 
physical properties of the drug. Co-spray drying is applied to generate a unique particle size, 
particle shape and physic-ochemical properties of the spray dried mixtures. Using this 
technique the number of unit operations is reduced, improving production efficiency and 
reducing costs, especially since spray drying is a technique which can be easily automated 
and equipped for in-line product analysis. In addition, spray drying can be considered a 
continuous process. These features of coprocessing via spray drying offer many obvious 
economic benefits for a pharmaceutical production facility. 
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Abstract 
Spray drying is an interesting manufacturing technique for the pharmaceutical industry since 
it uses a one-step process for formation and drying of powders. Using this technique the 
number of unit operations is reduced, improving production efficiency and reducing costs, 
especially since spray drying is a technique which can be easily automated and equipped for 
in-line product analysis. In addition, spray drying can be considered a continuous process, 
thus reducing time-to-market because of scale-up benefits and better quality.  
Spray drying has a wide range of applications in the pharmaceutical and biotech industry. It is 
a convenient method to produce (coprocessed) excipients. Spray drying is applied to improve 
the compactability of drugs and to perform microencapsulation, granulation and complex 
formation. In addition, spray drying is successfully used for the modification of 
biopharmaceutical properties and the formulation of dry powder aerosols and heat sensitive 
materials.  
 
Keywords: Spray drying; Directly compressible powders; Encapsulation; Improved 
bioavailability; Dry powder aerosol; Heat sensitive materials 
 
INTRODUCTION 
4
SPRAY DRYING IN PHARMACEUTICAL INDUSTRY 
 
INTRODUCTION 
SPRAY DRYING IN PHARMACEUTICAL INDUSTRY:                                   
A LITERATURE REVIEW 
 
 
1 Introduction 
 
Spray drying is a very widely applied technique used to dry aqueous or organic solutions, 
suspensions and emulsions in the food, chemical, electronics, pharmaceutical and 
biopharmaceutical industry. Within the food industry spray drying is used to prepare a wide 
range of products, e.g. baby and infant food, instant coffee, dried milk products, tomato paste. 
The chemical industry applies spray drying to manufacture aluminium chlorohydrate, 
ammonium nitrate, ammonium phosphate, magnesium hydroxide, zinc oxide, zinc sulphate, 
bleach powders, carbides (titanium, silicon, tantalum, niobium), catalysts for inorganic and 
organic chemical reactions, ceramic metals, detergents, dyestuffs, pigments, … . Electrical 
insulating material consists of spray dried aluminium oxide. Within pharmaceutical and 
biopharmaceutical industry spray drying is often selected to transform the active 
pharmaceutical ingredients in a powder and to manufacture solid dosage forms containing 
peptides, proteins or poorly water soluble active pharmaceutical ingredients. For example, 
antibiotics such as ampicillin, auremycin, penicillin, streptomycin, terramycin and 
tetracycline are spray dried, despite some activity loss (2–10%) during processing [1]. 
 
2 Spray drying process 
 
Spray drying involves the spraying of a liquid feed formulation (solutions, suspensions, 
emulsions) into a hot drying medium (air, nitrogen). The droplets formed by the atomisation 
process are dried through solvent evaporation to form particles which are collected as a dry 
powder (Fig. 1) [1]. The drying of the spray continues until the desired moisture content in the 
dried particles is achieved, and the product is recovered from the air. It is a unique drying 
process since it involves both particle formation and drying. Process parameters such as inlet 
and outlet temperature of the drying medium and the atomisation pressure influence the 
physico-chemical properties of the produced powders. The characteristics of the spray dried 
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powder can be controlled, and the powder properties can be maintained constant throughout 
the continuous operation. With the different designs of spray dryers available, it is possible to 
select a dryer layout to produce either fine or coarse particle powders, agglomerates or 
granulates [1]. 
 
 
Fig. 1. Schematic overview of a spray dryer (www.niro.com) 
 
The manner is which the spray contacts the drying air is an important factor in spray dryer 
design, as this had great bearing on dried product properties by influencing droplet behaviour 
during spray drying [1]. The different spray drying systems are open cycle, closed cycle and 
semi-closed cycle (Fig. 2). Open cycle systems are applied to spray dry aqueous feeds. The 
majority of the industrial spray dryers handle aqueous feeds and use this system. Air for 
drying is drawn from atmosphere and the exhaust drying air is discharged to atmosphere [2]. 
Before discharge the exhaust air is cleaned using combinations of cyclones, bag filters, 
electrostatic precipitators and scrubbers. Direct and indirect heating are applicable. Closed 
cycle spray dryers are used to handle flammable solvents, highly toxic products and oxygen 
sensitive products to avoid atmospheric pollution and/or to establish complete recovery of the 
evaporated solvent. The closed cycle system is based upon recycling and reusing the gaseous 
drying medium, which usually is an inert gas such as nitrogen. Drying chambers are 
incorporated with a cyclone/bag filter, solvent vapour condenser, exhaust drying medium 
particulate cleaning in wet scrubbers and indirect drying medium heating [2]. Semi-closed 
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cycle systems are classified into either the partial recycle mode (recycling of up to 60% of the 
exhaust air as inlet air to the dryer, for effective heat utilization) or the self-inertising mode. 
 
 
Fig. 2. Schematic outline of spray drying systems: open cycle (A), closed cycle (B) and semi-
closed cycle (C) (www.niroinc.com) 
 
Spray drying consists of 4 process stages. In the first stage the liquid feed is atomised into a 
spray of droplets. The atomisation stage must create a spray that when in contact with the 
drying medium creates optimal conditions for evaporation leading to a dry wall operation and 
discharging a dried product of the required properties from the drying chamber and associated 
dry particulate collectors [1]. The are 3 basic designs of atomisers, defined by the source of 
energy utilised in the droplet formation process: centrifugal energy in rotating wheel or disc 
atomisers, kinetic energy in pneumatic nozzle atomisers and pressure energy in pressure 
nozzle atomisers. Atomisers are selected according the droplet sizes to be produced in order 
to meet the powder specifications (Table 1) [2].  
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Table 1 – Median droplet size of different atomisation devices [2] 
Atomisation device 
Median Droplet Size 
(µm) 
Rotary atomiser (wheel) 10 – 200 
Pneumatic nozzle (two/three-fluid) 5 – 100 
Pressure nozzle 30 – 350 
 
Rotary atomisers (Fig. 3C) consist of a rotating wheel or disc. The liquid feed is introduced 
centrally. Rotary atomizers are reliable, easy to operate and can handle fluctuating feed rates. 
Further advantages include their ability to handle high feed rates and abrasive feeds [1].  
 
 
Fig. 3. Schematic outline of atomisation devices: two-fluid nozzle (A), pressure nozzle (B) and 
rotary atomiser (C) (www.niro.com) 
 
Pneumatic nozzle atomisation (Fig. 3A) uses compressed air to creating high frictional forces 
over liquid surfaces causing liquid disintegration into spray droplets, while pressure nozzle 
atomisation (Fig. 3B) applies liquid feed under pressure. The feed is forced to rotate within 
the nozzle, resulting in cone-shaped spray patterns emerging from the nozzle orifice. Sprays 
from pressure nozzles are generally less homogeneous and coarser than sprays from wheels 
[1].  
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Fig. 4. Schematic outline of spray-air contact modes: co-current (A), counter-current (B) and 
mixed flow (C) chamber (www.buchi.com) 
 
The second stage involves the spray-air contact, mixing and droplet/particle flow. In a co-
current flow (Fig. 4A), the feed is atomised and sprayed through the drying chamber in the 
same direction as the flow of the heated drying medium. The droplets come into contact with 
the heated drying medium resulting in an optimal solvent evaporation for spray drying of 
heat-sensitive materials such as enzymes, peptides and proteins. In a counter-current flow 
design (Fig. 4B), the atomised feed and heated drying medium move in the opposite direction 
through the drying chamber. A counter-current flow design combines a heat treatment and 
also a particle agglomeration effect, resulting in increased powder flowability and median 
particle size for non-heat-sensitive products [1]. Spray dryer designs that combine co-current 
and counter-current flow modes are classified as mixed flow spray dryers (Fig. 4C). The 
typical fountain-type system yields coarse free-flowing spray dried powders that can be 
produced in drying chambers of relatively small dimensions, but the powders are subjected to 
higher particle temperature because partially dried particles enter the hottest region of the 
drying chamber near the drying medium dispenser.  
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The third stage combines drying and particle formation. Evaporation of the solvent takes 
place immediately after contact between spray droplets and the drying air. Diffusion of 
solvent from within the droplet maintains saturated surface conditions, resulting in a constant 
drying rate. When the solvent content becomes too low to maintain a saturated surface, a dry 
layer starts to form at the droplet surface. The atomisation of a concentrated feed suspension 
decreases the drying load since less water in a droplet needs to be evaporated. In addition, it is 
easier to achieve moisture removal from suspension-type droplets than solution-type droplets 
especially when the latter involves diffusion-limited film-forming characteristics at the 
surface [1].  
Finally, particle separation from the drying air and dried product discharge takes place in the 
drying chamber and associated particle collection systems (cyclone, filter bag, scrubber). 
 
3 Applications in pharmaceutical technology and drug 
delivery 
 
3.1 Directly compressible powder 
 
3.1.1 Excipient and coprocessed excipient production 
 
Spray drying can be used to modify the size distribution, crystal habit, crystallinity content, 
polymorphism and moisture content if particles resulting in improved compactability. 
Spray dried lactose is by far the most commonly encountered spray dried pharmaceutical 
excipient and is produced by spray drying a slurry containing lactose crystals. The spray dried 
product contains a mixture of crystals of α-lactose monohydrate and spherical agglomerates of 
small crystals held together by amorphous lactose [3]. Spray dried lactose was found to have 
significantly improved compaction properties compared to its crystalline forms. De Boer et al. 
[4] stated that amorphous lactose consolidated rather by plastic deformation than by particle 
fragmentation.   
However, as specific material properties are required to allow direct compression, materials 
have been coprocessed via spray drying to obtain compounds having superior properties 
(flowability, hygroscopicity and compactability) for direct compression compared to the 
individual excipients or their physical mixtures [5]. During coprocessing no chemical changes 
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occur and all the reflected changes show up in the physical properties of the particles [3]. 
Several co-spray dried excipients for direct compression are commercially available: Starlac® 
(α-lactose monohydrate and maize starch), Cellactose® (α-lactose monohydrate and powdered 
cellulose), Microcelac® (α-lactose monohydrate and microcrystalline cellulose), Prosolv® 
(microcrystalline cellulose and silicon dioxide) and F-Melt® (mannitol, xylitol, inorganic 
excipient and disintegrating agent, developed for fast dissolving dosage forms) [6]. 
Cellactose®, a coprocessed spray dried filler/binder for direct compression and composed of 
25% w/w powdered cellulose and 75% w/w α-lactose monohydrate, had a higher tablet tensile 
strength compared to physical powder mixtures containing 25% w/w Elcema P-100 and 75% 
w/w lactose for direct compression (Tablettose®) [7].  
Gohel and Jogani [5] developed a multifunctional coprocessed directly compressible excipient 
containing lactose, polyvinylpyrrolidone and croscarmellose sodium. This product had a 
better flowability, compactability and tablet disintegration than α-lactose monohydrate. 
Hauschild and Picker [8] evaluated a coprocessed compound based on α-lactose monohydrate 
and maize starch for tablet formulation. Compared to its physical mixture the coprocessed 
material had a better flowability, a higher tablet crushing force and a faster tablet 
disintegration. Heckel analysis showed that the spray dried mixture deformed plastically with 
limited elasticity, whereas the physical mixture exhibited a predominantly elastic behaviour. 
Microcelac® 100, a coprocessed spray dried filler/binder for direct compression and 
composed of 25% w/w microcrystalline cellulose and 75% w/w α-lactose monohydrate, 
showed superior flow and binding properties compared to physical mixtures of 
microcrystalline cellulose with different lactoses grades e.g. α-lactose monohydrate 
(lactose 100M), anhydric β-lactose (Pharmatose® DCL21) and spray dried lactose 
(Pharmatose® DCL11)[9].  
 
3.1.2 Improved drug compressibility 
 
Acetazolamide, an inhibitor of carbonic anhydrase, is a poorly compressible drug and usually 
produced through a wet granulation process. It is soluble in boiling water and in an alkaline 
solution. Di Martino et al. [10] compared the compressibility of acetazolamide crystals 
obtained by three different crystallisation processes. Firstly acetazolamide crystals were 
dissolved in a diluted ammonia solution and recrystallized by neutralisation with a 
hydrochloridric solution. Crystals of polymorphic form II were obtained. Secondly 
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acetazolamide crystals were dissolved in boiling demineralised water and afterwards cooled 
down slowly to room temperature. Only crystals of polymorphic form I were detected. Finally 
an ammonia solution of acetazolamide was spray dried and by this method a mixture of 
polymorphic form I and II was obtained. The spray dried crystals were characterised by an 
excellent compressibility and the absence of capping tendency while the pure polymorphic 
forms I and II could not be compressed into tablets [10]. 
 
3.2 Encapsulation 
 
A microcapsule can be either an individually coated solid particle or liquid droplet, or a 
matrix containing many small, fine core particles. Matrix microcapsules containing drug 
substance and a biodegradable polymer are usually prepared by spray drying in order to 
obtain controlled drug release formulations [11]. 
Palmieri et al. [12] coprocessed ketoprofen and common pH dependent polymers (Eudragit® 
S and L, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), 
hydroxypropylmethylcellulose phthalate (HPMCP)) via spray drying in order to prepare 
ketoprofen gastro-resistant microspheres. Acrylic polymers (Eudragit® S and L) showed a 
compactability comparable with ketoprofen/Avicel® PH 101 mixtures in contrast with the 
poor compactability of binary spray dried microspheres containing CAP, CAT and HPMCP. 
Gastro-resistance was obtained for all microspheres, although changes in drug release at low 
pH values were observed. Drug release was lower for microspheres containing acrylic 
polymers in comparison with the enteric cellulose derivates. 
Binary microspheres (drug/polymer ratio: 1/2, 1/1, 2/1, 3/1, 4/1, 6/1, 9/1, 19/1) containing 
acetaminophen and a polymer (Eudragit® RS and RL, ethylcellulose) were manufactured via 
co-spray drying to prepare controlled-release solid dosage forms [13]. The compaction 
properties gradually improved when decreasing the acetaminophen concentration, 
independent of the type of polymer present in the microspheres. Although the dissolution 
behaviour of the microspheres was similar to that of the pure drug, tablets containing drug 
substance and polymer (Eudragit® RS and RL, ethylcellulose) showed controlled drug release. 
Eudragit® RL was less effective in slowing down the acetaminophen release because of its 
permeable and swellable properties. 
Burke et al. [14] compared spray drying and spray-freeze drying to encapsulate darbepoetin 
alfa in poly(lactide-co-glycolide). In vitro and in vivo drug release was evaluated for all 
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microsphere formulations. Formulations prepared via spray drying and spray-freeze drying 
showed similar in vitro drug release, while in vivo studies detected darbepoetin alfa in serum 
during 4 weeks. 
Feed solutions of ketoprofen/polymer (cellulose acetate butyrate (CAB), hydroxypropyl-
methylcellulose phthalate (HPMCP)) mixtures in different weight ratios were spray dried in 
order to study the in vitro release behaviour [15]. The microparticles were formulated in hard 
gelatine capsule shells or compacted into tablets with the addition of maltose or 
hydroxypropylmethylcellulose (HPMC). All microsphere-filled capsules resulted in a rapid 
drug release although the microparticles with the highest concentration of CAB had the 
lowest release rate. In addition, tablets containing HPMC showed an initial quick release of 
ketoprofen during the first hour followed by a prolonged release. 
 
3.3 Increased bioavailability 
 
Spray drying can be used to enhance the solubility and dissolution rate of poorly soluble 
drugs. This usually occurs via the formation of pharmaceutical complexes or via the 
development of solid dispersions [11]. 
 
3.3.1 Complex formation 
 
Cyclodextrins can be used to increase the solubility and bioavailability of poorly water 
soluble drug substances. Physical mixtures (1/1) containing carbamazepine and β-
cyclodextrin were compared with identical solid complexes prepared via spray drying and 
freeze drying. These binary mixtures were blended with hydroxypropylmethylcellulose prior 
to compression [16]. Evaluation was based on solubility studies and in vitro release profiles. 
The water solubility of carbamazepine increased with increasing β-cyclodextrin content. A 
stronger interaction between drug substance and β-cyclodextrin was obtained in the solid 
complexes rather than in a simple physical mixture. In addition, binary complexes prepared 
via spray drying and freeze drying showed faster drug release in comparison with the physical 
mixtures because of an improvement in drug solubility. 
Suihko et al. [17] studied the physico-chemical properties of physical mixtures, and spray 
dried and freeze dried solid complexes of tolbutamide and hydroxypropyl-β-cyclodextrin. 
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Pure hydroxypropyl-β-cyclodextrin and its tolbutamide complex were amorphous, whereas 
spray dried and freeze dried tolbutamide were polymorphic forms I and II, respectively. 
3.3.2 Formation of solid dispersions 
 
Valdecoxib is a selective cyclooxygenase-2 inhibitor, administered orally as an analgesic and 
anti-inflammatory drug. It is relatively insoluble in water. Ambike et al. [18] developed solid 
dispersions of valdecoxib and a hydrophilic polymer by co-spray drying. The selected 
hydrophilic carriers were polyvinylpyrrolidone K30 (PVP) and hydroxypropylcellulose 
(HPC). The saturation solubility, dissolution rate and stability of the spray dried drug, the 
solid dispersions and their corresponding physical mixtures were compared with the pure drug 
substance. All spray dried samples as well as the physical mixtures suggested increased 
saturation solubility and dissolution rate immediately after processing. Additionally DSC and 
XRPD experiments of the spray dried valdecoxib and the solid dispersions showed the 
generation of an amorphous form of the drug. During stability testing, the saturation solubility 
and dissolution rate of the solid dispersions decreased gradually over a testing period of three 
months. Drug crystallinity was discovered after 1 month and 15 days for respectively the 
drug/PVP and drug/HPC solid dispersion. The pure spray dried valdecoxib was characterized 
by a drastical drop in saturation solubility within 15 days.    
Takeuchi et al. [19] obtained solid dispersions of indomethacin with non-porous (Aerosil® 
200) and porous silica (Sylysia® 350) by spray drying an ethanol solution of indomethacin 
and suspended silica particles. The solid dispersions were compared with pure spray dried 
indomethacin concerning dissolution rate and stability. The crystallinity of spray dried 
indomethacin was lower, probably because of the rapid drying rate from the ethanol solution. 
Spray drying an ethanol solution of indomethacin in combination with silica obtained the drug 
in an amorphous state irrespective of the type of silica formulated. Additionally the 
dissolution properties of indomethacin were improved with both types of silica. Both solid 
dispersions and the pure spray dried indomethacin were stored for 2 months at 40°C and 75% 
RH. The solid dispersions with silica did not crystallise, whereas the pure spray dried form 
did. 
Curcumin, a naturally occurring highly lipophilic molecule, has a very low aqueous solubility. 
Paradkar et al. [20] used spray drying to produce solid dispersions of curcumin in different 
ratios with polyvinylpyrrolidone (PVP). They compared the solid dispersions with their 
corresponding physical mixtures. Dissolution properties of the spray dried powders improved 
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due to the formation of an amorphous drug. Physical mixtures of curcumin and PVP showed 
negligible release even after 90 min, while the spray dried particles were characterised by a 
complete release within 30 min. 
Palmieri et al. [21] carried out in vivo and in vitro studies with solid dispersions of 
lonidamine in polyethylene glycol 4000 (PEG) and polyvinylpyrrolidone K29/32 (PVP) for 
several drug/polymer ratios ranging from 1/9 to 9/1. They evaluated the dissolution rate and 
water solubility improvement of the drug/PEG and drug/PVP solid dispersions and compared 
their results with the corresponding physical mixtures. The water solubility of lonidamine was 
increased by the solid dispersion formation, the highest increase in solubility corresponded to 
the highest polymer content. During in vivo testing, they recorded an increase in 
bioavailability after administration of lonidamine solid dispersions in PEG and PVP.   
 
3.4 Dry powder aerosols & heat sensitive materials 
 
Spray drying is an excellent method for the production of dry powder formulations since 
particle size distribution and residual moisture content of the spray dried powders can be 
easily controlled by the process conditions. In addition, the processing of heat sensitive 
materials is feasible because the cooling effect caused by the solvent evaporation. Hence, the 
actual temperature of the dried product is far below the outlet temperature of the drying air.  
Bosquillon et al. [22] developed an aerosol formulation for the systemic delivery of human 
growth hormone in rats. Spray drying a mixture of human growth hormone, lactose and 
dipalmitoylphosphatidylcholine yielded dry powders for pulmonary administration. Dry 
powder inhalation resulted in high absorption of human growth hormone, the absolute 
bioavailability reached 23% and the bioavailability relative to a subcutaneous injection was 
56%. In contrast intratracheal instillation of a human growth hormone solution had a threefold 
lower systemic absorption. 
Coprocessing via spray drying of bovine serum albumin (BSA) and maltodextrin (ratio: 1/1) 
was applied to produce dry powder aerosols for inhalation of proteins after blending with α-
lactose monohydrate, modified lactoses (containing between 2.5 and 10% w/w fine particle 
lactose) or micronised polyethylene glycol 6000 [23].  
Adler and Lee [24] investigated process stability, storage stability and surface activity of 
lactate dehydrogenase in co-spray dried powders. Trehalose was used as stabilising carrier.  
At higher inlet drying air temperature, the resulting lower residual moisture content of the 
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spray dried powder provided excellent storage properties, although more protein inactivation 
occurred. The addition of stabilising carriers (e.g. carbohydrates, amino acids) reduced the 
protein inactivation during spray drying. In addition, Coppi et al. [25] developed an oral 
formulation for lactate dehydrogenase using alginate microparticles were as a carrier to 
protect lactate dehydrogenase against inactivation in the gastro-intestinal tract and to improve 
enzyme absorption. In addition, stabilising agents (carboxymethylcellulose sodium, 
polyacrylic acid sodium, lactose) were added to overcome the enzymatic activity loss during 
spray drying. 
Broadhead et al. [26] evaluated the spray drying of β-galactosidase and the influence of 
process and formulations parameters. Process yield was maximised at high outlet drying air 
temperature, although a strong decrease in enzymatic activity was measured. In addition, 
different stabilisers (mannitol, sucrose, arginine hydrochloride, trehalose) were tested to 
improve enzymatic activity, identified trehalose as the most suitable.  
Sucrose was selected as suitable stabilising agent during spray drying of oxyhemoglobin and 
trypsinogen [27, 28]. In the absence of sucrose spray drying of oxyhemoglobin approximately 
50% methemoglobin was formed, which is not suitable to transport oxygen. However, the 
addition of sucrose (0.25 M) as a protective agent to the feed reduced the methemoglobin 
production to 4%.  
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Abstract 
Continuous production of directly compressible powders was achieved by coprocessing 
acetaminophen and carbohydrates via spray drying. Binary and ternary powder mixtures 
containing drug substance and carbohydrates were prepared by co-spray drying and evaluated 
on spray drying processibility, powder hygroscopicity, flowability and compactability. The 
influence of process parameters during spray drying on the compaction behaviour of 
drug/excipient mixtures was investigated via Heckel analysis. Erythritol, lactose, maltodextrin 
and mannitol were efficient in co-spray drying with acetaminophen. However, lactose 
mixtures showed poor flowability. Spray dried mixtures containing mannitol and erythritol 
were characterised as non-hygroscopic, highly dense and good flowing powders. Mannitol 
increased tablet tensile strength in contrast with the poor compactability of erythritol. 
Maltodextrin was selected for further experiments because it provided excellent tablet tensile 
strength. The use of erythritol, maltodextrin and mannitol in binary drug/excipient mixtures 
resulted in high process yields. Compacts of erythritol, mannitol and maltodextrin were 
characterised by higher tablet tensile strength at higher spray drying temperatures due to the 
increased particle fragmentation of erythritol and mannitol mixtures and to the increased 
plastic deformation of maltodextrin formulations. A combination of erythritol, maltodextrin 
and mannitol was selected for further formulation and process optimisation of co-spray dried 
powders for direct compression.  
 
Keywords: Coprocessing; Spray drying; Compression; Acetaminophen; Carbohydrates 
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CHAPTER 1 
DEVELOPMENT OF DIRECTLY COMPRESSIBLE POWDERS VIA 
CO-SPRAY DRYING 
 
 
1 Introduction 
 
Tablets are still the most commonly used dosage form because of the ease of manufacturing, 
convenience in administration, accurate dosing and stability compared to oral liquids. Direct 
compression is the preferred method for the preparation of tablets because of several 
advantages. However, as specific material properties are required to allow direct compression, 
materials have been coprocessed via spray drying to obtain compounds having superior 
properties (hygroscopicity, flowability and compactability) for direct compression compared 
to the individual excipients or their physical mixtures [1]. During coprocessing no chemical 
changes occur and all the reflected changes show up in the physical properties of the particles 
[2]. Several coprocessed excipients for direct compression are commercially available: 
Ludipress® (α-lactose monohydrate, polyvinylpyrrolidone and crospovidone), Cellactose® (α-
lactose monohydrate and powdered cellulose), Microcelac® (α-lactose monohydrate and 
microcrystalline cellulose), Cel-O-Cal® (cellulose and calciumsulphate), Prosolv® 
(microcrystalline cellulose and silicon dioxide) and F-Melt® (mannitol, xylitol, inorganic 
excipient and disintegrating agent, developed for fast dissolving dosage forms) [3].  
The purpose of this research work is to improve the compactability of a poorly compressible 
drug substance by coprocessing with carbohydrates via spray drying.  
This chapter describes the influence of different excipients on the spray drying processibility 
and the physico-chemical properties (hygroscopicity, flowability and compactability) of 
binary and ternary mixtures containing drug substance and carbohydrates. 
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2 Materials and methods 
 
2.1 Materials 
 
2.1.1 Acetaminophen 
 
Acetaminophen (median particle size: 50 µm) was received from Mallinckrodt Chemical 
(Hazelwood, USA). It has an aqueous solubility of 14 g/l and a melting point of 168-172°C 
(Martindale, The Extra Pharmacopoeia 28th Ed.). It is a highly dosed, poorly compressible 
active pharmaceutical ingredient. Acetaminophen has analgesic and antipyretic properties but 
it has no useful anti-inflammatory properties. 
 
2.1.2 Monosaccharide polyols 
 
Erythritol (C*Eridex 16955), mannitol (C*Mannidex 16700) and sorbitol (C*Sorbidex 16616) 
were donated by Cerestar (Mechelen, Belgium). Xylitol (Xylisorb® 90) was a gift from 
Roquette (Lestrem, France). The molecular weight, melting point, glass transition 
temperature, hygroscopicity and aqueous solubility of these compounds are shown in Table 1. 
Polyols are found in various fruits and vegetables and exhibit an outstanding chemical and 
microbiological stability. They are used as sugar substitutes because of their sweetness and 
reduced calorie content. In addition, the majority of these polyols can be consumed by 
diabetics without any significant increase in body glucose, insulin or lactic acid concentration 
unlike the conventional saccharides such as sucrose, glucose and lactose [4]. Mono- and 
disaccharide polyols have noncariogenic characteristics.  
 
Table 1 – Physico-chemical properties of monosaccharide polyols 
 Erythritol Mannitol Sorbitol Xylitol 
Molecular weight 122 182 182 152 
Melting point (°C) 121 165 97 94 
Glass transition temperature (°C) -42 -39 -5 -22 
Hygroscopicity Very low Very low High Low 
Aqueous solubility (% w/w) 36 18 72 66 
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Erythritol (Fig. 1) was the first polyol to be industrially produced by a natural fermentation 
process. It is a tetrahydric polyol. Erythritol crystals are non-hygroscopic, which is of interest 
in applications such as tablets and dry powder aerosol formulations [5]. 
 
 
Fig. 1. Chemical structure of erythritol 
 
Mannitol (Fig. 2) is the least soluble crystalline polyol, while sorbitol (Fig. 3) has the highest 
water solubility. Both are open-chain hexahydric polyols related to mannose. Because of its 
non-hygroscopic properties, mannitol is an excellent excipient for active pharmaceutical 
ingredients sensitive for moisture. They are widely used in food products and pharmaceutical 
formulations as diluents in direct compression [6–9] and wet granulation [10]. Spray dried 
and granular mannitol is used as direct compression excipient. Chewable tablets are generally 
containing mannitol or sorbitol [11] because of its sweet taste and cooling sensation. In 
addition, mannitol and sorbitol are used to process thermosensitive drugs via lyophilisation 
[12]. 
 
 
Fig. 2. Chemical structure of mannitol 
 
Mannitol shows polymorphism (α-, β-, δ-mannitol and mannitol hemi-hydrate), while four 
crystalline polymorphs and one amorphous form of sorbitol have been identified [13]. 
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Fig. 3. Chemical structure of sorbitol 
 
Xylitol (Fig. 4) exhibits the highest sweetness among the polyols, equal to sucrose. Therefore, 
it is a good candidate for chewable tablets. It is a pentahydric alcohol and is incorporated in 
tablets, syrups and coatings as sweetening agent [6, 8]. Xylitol is commercially available in 
powdered form and in several directly compressible granular forms. 
 
 
Fig. 4. Chemical structure of xylitol 
 
2.1.3 Disaccharide polyols 
 
Isomalt (C*Isomaltidex 16500) was donated by Cerestar (Mechelen, Belgium), while lactitol 
(FinlacTM DC) was supplied by Danisco (Copenhagen, Denmark). Maltitol (Maltisorb® P90) 
was a gift from Roquette (Lestrem, France). The molecular weight, melting point, glass 
transition temperature, hygroscopicity and aqueous solubility are shown in Table 2. 
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Table 2 – Physico-chemical properties of disaccharide polyols 
 Isomalt Lactitol Maltitol 
Molecular weight 344 344 344 
Melting point (°C) 147 122 150 
Glass transition temperature (°C) 34 33 47 
Hygroscopicity Low Medium Low 
Aqueous solubility (% w/w) 28 58 60 
 
Isomalt (Fig. 5) is mixture of hydrogenated mono- and disaccharides whose principal 
components are the disaccharide alcohols 1,6-glucopyranosyl-D-sorbitol (GPS) and 1,1-
glucopyranosyl-D-mannitol (GPM). Isomalt is a non-cariogenic excipient used in a variety of 
pharmaceutical preparations including tablets, capsule coatings and suspensions. Isomalt has 
been used for extrusion purposes to develop a directly compressible excipient [14–15]. 
Isomalt crystals are non-hygroscopic, which is a significant property for their use in hard 
candies and coatings. Based on its glass transition temperature of 34°C, isomalt is in a glassy 
state at room temperature and it does not crystallise under these conditions.  
 
 
Fig. 5. Chemical structure of isomalt 
 
Lactitol (Fig. 6) is a disaccharide with many similar characteristics to sucrose, hence it can be 
a direct replacement for sucrose in many applications. It occurs as orthorbombic crystals and 
shows polymorphism [16]. Today oral tablets and lozenges are not only produced using 
conventional saccharides (sucrose, glucose and lactose), but also, to increasing extent, using 
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sugar substitutes (mono- and disaccharide alcohols, also called polyols) like sorbitol, xylitol, 
lactitol or isomalt [17]. 
 
 
Fig. 6. Chemical structure of lactitol 
 
Maltitol (Fig. 7) is used as a carrier in dry powder inhalers [18]. In addition, maltitol is 
incorporated as a diluent in different oral dosage forms prepared via wet granulation and 
direct compression [19]. 
 
 
Fig. 7. Chemical structure of maltitol 
 
2.1.4 Lactose 
 
Lactose (Respitose® SV003) was obtained from DMV International (Veghel, The 
Netherlands). Several forms are commercially available: anhydrous α-lactose, α-lactose 
monohydrate and to a lesser extent anhydrous β-lactose. Its melting point depends on its 
forms (anhydrous α-lactose: 223°C, α-lactose monohydrate: 201°C, anhydrous β-lactose: 
252°C). Various lactose grades (e.g. spray dried and granulated) characterised by different 
particle size distribution, particle shape and density are commercially available [20]. Spray 
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dried lactose contains approximately 85% α-lactose monohydrate and 15% amorphous 
lactose, resulting in improved compactability. In addition, coprocessed excipients for direct 
compression containing lactose are commercially available: Starlac® [21] (α-lactose 
monohydrate and maize starch), Cellactose® [22] and Microcelac® [23] (α-lactose 
monohydrate and cellulose).  
Lactose (Fig. 8) is widely used as a diluent in capsules and tablets prepared via wet or dry 
granulation and direct compression [24–26]. In addition, applications include lactose as a 
carrier in dry powder formulations produced via lyophilisation and/or spray drying [27–29]. 
 
 
Fig. 8. Chemical structure of lactose 
 
2.1.5 Maltodextrin 
 
Maltodextrin (Glucidex® 2) was a gift from Roquette (Lestrem, France). Maltodextrin, a 
starch conversion product, is a nutritive saccharide mixture of polymers that consist of D-
glucose units, with a dextrose equivalent (DE) less than 20. These units are linked primarily 
by (α-1,4)-bonds, but there are branched segments linked by (α-1,6)-bonds. Similar to starch, 
maltodextrin is composed of a mixture of amylose and amylopectin (Table 3), the ratio of 
both products affecting the physico-chemical properties of maltodextrins. 
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Table 3 – Physico-chemical properties of amylose and amylopectin 
Characteristic Amylose Amylopectin 
Shape Essential linear Branched 
Linkage α-1,4 (some α-1,6) α-1,4 and α-1,6 
Molecular Weight < 0.5 million 50-500 million 
Film forming Strong Weak 
Gelling Firm Soft 
Colour with Iodine Blue Reddish Brown 
Starch Amylose (%) Amylopectin (%) 
Maize (corn) 25 75 
Waxy maize 1-5 95-99 
Wheat 25 75 
Potato 20 80 
Tapioca 17 83 
High Amylose Maize 50-70 30-50 
 
Amylose (Fig. 9) is an essential linear polysaccharide of α-D-glucose. Amylopectin (Fig. 10) 
is a highly branched polysaccharide of α-D-glucose, differs from amylose in being highly 
branched and is completely insoluble in water. 
 
 
Fig. 9. Chemical structure of amylose 
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Fig. 10. Chemical structure of amylose 
 
The properties of maltodextrin vary with its grade and DE value. Maltodextrin is a 
hygroscopic and freely soluble excipient. The solubility, hygroscopicity and sweetness of this 
excipient increase as the DE value increases, while the compressibility decreases. It is a 
coating agent, viscosity-enhancing agent, tablet diluent and binder used in direct compression 
and wet granulation [30–32]. 
 
2.1.6 Colloidal silicon dioxide 
 
Colloidal silicon dioxide (Aerosil® 200) was purchased from Federa (Brussels, Belgium). It is 
applied to improve the flow properties of powders intended for tablet and capsule 
manufacturing.  
 
2.1.7 Magnesium stearate 
 
Magnesium stearate was purchased from Federa (Brussels, Belgium). It is widely used in 
pharmaceutical formulations, primarily as a lubricant in capsule and tablet formulations at 
concentrations between 0.25–5.0% w/w. Magnesium stearate is hydrophobic and may retard 
the drug dissolution from a solid dosage forms. The lowest possible concentration is therefore 
used in tablet and capsule formulations [33–35]. 
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2.2 Methods 
 
2.2.1 Preparation of the spray dried particles 
 
Aqueous solutions of pure acetaminophen (total solid content: 1.2% w/w) and of 
acetaminophen and a carbohydrate (erythritol, isomalt, lactitol, lactose, maltitol, maltodextrin, 
mannitol, sorbitol and xylitol) (drug/carbohydrate ratio: 1/1, total solid content: 2.4% w/w) 
were prepared. Spray drying of these solutions was performed in a lab-scale Mobile Minor 
spray dryer (GEA NIRO, Copenhagen, Denmark). The dimensions of the drying chamber 
were 0.84 m cylindrical height with a diameter of 0.80 m and 60° conical base. The solutions 
were fed to a two-fluid nozzle (diameter: 1 mm) at the top of the spray dryer by means of a 
peristaltic pump, type 520U (Watson Marlow, Cornwall, UK) and a Marprene® tube (inside 
diameter: 4.8 mm) (Watson Marlow, Cornwall, UK). The spray dryer operated in co-current 
air flow. The spray dried particles were collected in a reservoir attached to a cyclone, cooled 
down to room temperature, sieved (375 μm) and stored in sealed vials (room temperature, 
ambient relative humidity) prior to their characterisation and further use. Pure acetaminophen 
and drug/excipient mixtures (1/1) containing erythritol, isomalt, lactitol, lactose, maltitol, 
maltodextrin, mannitol, sorbitol and xylitol were prepared via spray drying using the 
parameters of process 1 (Table 4).  
 
Table 4 – Process conditions during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
Process Parameters  
 Process 1 Process 2 
Feed Rate (g/min) 30.5 38.5 
Inlet Drying Air Temperature (°C)  140 220 
Outlet Drying Air Temperature (°C) 60 80 
Drying Gas Rate (kg/h) 80 80 
Atomising Air Pressure (bar) 1 2 
Compressed Air Flow (%) 55 50 
 
To investigate the influence of spray drying parameters on the compaction behaviour of 
drug/excipient mixtures, binary solutions (1/1) containing erythritol, maltodextrin and 
mannitol were co-spray dried via process 2 (Table 4). These settings were selected in order to 
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decrease the residual moisture content of the spray dried powders using higher drying air 
temperatures and atomisation pressure. 
In addition to the binary drug/carbohydrate powders, ternary powder mixtures were prepared 
via spray drying of aqueous drug/mannitol/excipient solutions and compared with 
drug/mannitol mixtures (1/1) produced according to process 2 (Table 4). Acetaminophen, 
mannitol and a water soluble carbohydrate (erythritol and maltodextrin) were dissolved in 
demineralised water at room temperature (drug/mannitol/excipient ratio: 1/0.7/0.3 and 
1/0.9/0.1, total solid content: 2.6% w/w). These solutions were spray dried according to 
process 2 (Table 4). 
 
2.2.2 Evaluation of spray dried powders 
 
X-ray diffraction (D-500, Siemens, Germany) with CuKλ radiation (0.154 nm) was performed 
on the pure spray dried acetaminophen and the binary spray dried mixtures. The angular range 
(2θ) varied from 10 to 60° with steps of 0.02° and the measuring time was 1s/step.  
The residual moisture content of the spray dried powders was determined via loss-on-drying 
using a Mettler LP16 moisture analyser, including an infrared dryer and a Mettler PM460 
balance (Mettler-Toledo, Zaventem, Belgium). A powder sample of 5 g was dried at 105°C 
during 15 min. 
The hygroscopic behaviour of the powders was investigated by storing the spray dried 
powders in sealed boxes containing saturated salt solutions, which maintained a specific 
relative humidity depending of the salt. The salts used and the corresponding relative 
humidities are magnesium chloride (33.0% RH), magnesium nitrate (52.8% RH), ammonia 
nitrate (65.0% RH), sodium chloride (75.3% RH) and potassium chloride (84.3% RH). The 
moisture uptake was evaluated after 1 month via loss-on-drying (Mettler LP16 moisture 
analyser, including an infrared dryer and a Mettler PM460 balance, Mettler-Toledo, 
Zaventem, Belgium). A sample of 1.5 g was dried at 105°C during 30 min. 
The thermal behaviour of the binary spray dried mixtures was compared with their physical 
mixtures using differential scanning calorimetry. Modulated temperature DSC experiments 
(heating rate: 2°C/min, modulation amplitude: 0.5°C, modulation period: 60 s and 
temperature range: -40–300°C) were performed using a DSC 2920 calorimeter (TA 
Instrument, New Castle, USA) with a DSC refrigerated cooling system (TA Instruments, New 
Castle, USA). 
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The flowability of spray dried powders (n: 5) was measured according to the method 
described in the European Pharmacopoeia 5th Ed. (automated powder flowability analyser, 
Type PTG-2, PharmaTest, Hainburg, Germany) using a 25 mm nozzle. An electrical stirrer 
(speed: 25 rpm) was used to avoid bridging in the funnel for material having poor flowability.  
The bulk density of the spray dried powders was determined via the method described in the 
European Pharmacopoeia 5th Ed. using 20 g of powder and a 100 ml graduated cylinder. 
SEM images were recorded with a Quanta 200 FEG (FEI, Eindhoven, The Netherlands) 
scanning electron microscope operated at an acceleration voltage of 5 kV. The powder was 
deposited onto a carbon carrier substrate. 
 
2.2.3 Tabletting process and evaluation 
 
The spray dried powders were blended (TSA Turbula mixer, W.A. Bachofen 
Maschinenfabrik, Basel, Switzerland) with 0.3% w/w colloidal silicon dioxide for 10 min in a 
first mixing step and with 0.5% w/w magnesium stearate for 5 min in a second mixing step. 
Glidant, lubricant and spray dried powders were sieved (375 μm) before blending. The 
powder mixtures were compacted (n: 10, 500 ± 5 mg) on an excentric tablet press, Type EKO 
(Korsch, Berlin, Germany) equipped with 13.0 mm circular flat punches. The tablet properties 
were evaluated at two different compaction pressures (74 MPa and 111 MPa).  
Based on the diametral crushing strength of the tablets, determined using a hardness tester, 
Type PTB (Pharma Test, Hainburg, Germany), the tensile strength of the tablets was 
calculated according to Fell and Newton [36]. 
 
2.2.4 Heckel analysis 
 
The porosity-compression pressure function according to Heckel was calculated. Flat-faced 
compacts (n: 3, 500 ± 5 mg, diameter: 13 mm) of drug/excipient mixtures produced according 
to process 1 and 2 were prepared on a compaction simulator (ESH, Brierley Hill, UK) at a 
maximum load of 110 MPa. While the lower punch was stationary during compaction, the 
upper punch displacements followed a sine wave. The average punch speed during 
compaction was 3 mm/s. Data were compensated for punch deformation during compression. 
Final thickness and diameter of the tablets were measured with an electronic digital calliper 
(Bodson, Luik, Belgium). The true density was defined using a helium gas pycnometer, 
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Accupyc 1330 (Micromeritics, Norcross). The following analysis parameters were used: 10 
purges, 10 runs and 19.5 psig as purge and run fill pressure.  
The Heckel equation (Eq. 1) [37] is based on the assumption that powder compression 
follows first-order kinetics, with the interparticulate pores as the reactant and the 
compactability of the powder bed as the product. 
 
Ln (1/ (1 – D) = kP + A                                                                                                            (1) 
 
where D is the relative density of a powder compact at pressure P. Slope k is a measure of the 
plasticity of a compacted material. Constant A is related to the die filling and particle 
rearrangement before deformation and bonding of the discrete particles. Thus, a Heckel plot 
allows for the interpretation of the mechanism of compression. 
 
3 Results and discussion 
 
Acetaminophen was used as model drug because of its poor compactability as evidenced 
during this study by the low tablet tensile strength (0.38 and 0.67 MPa at a compression 
pressure of 74 MPa and 111 MPa, respectively) as well as capping and lamination problems 
after compaction of pure spray dried acetaminophen. This behaviour was due to the formation 
of monoclinic acetaminophen crystals during spray drying, exhibiting a relatively high elastic 
deformation [38]. Therefore, acetaminophen was coprocessed with water soluble 
carbohydrates to improve tablet tensile strength and to overcome capping and lamination 
problems.  
The screened drug/excipient mixtures (1/1) were divided in three groups according to their 
spray drying processibility. Spray drying of drug/excipient mixtures (1/1) containing isomalt 
and sorbitol was not feasible because of process problems. Coprocessing of aqueous 
acetaminophen/sorbitol solutions (1/1) resulted in vitrification of sorbitol forming a 
transparent layer on the surface of the drying chamber wall, pipings and cyclone. Powder 
mixtures containing isomalt completely blocked pipings and cyclone during spray drying as 
too much material accumulated in the pipings and cyclone. The second group consists of 
drug/excipient mixtures (1/1) composed of lactitol, maltitol and xylitol, which could be spray 
dried despite some process problems. Due to their gummy-like and thermoplastic nature, and 
high residual moisture content (Table 5), an important fraction of these binary powder 
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mixtures adhered to the drying chamber wall surfaces, pipings and/or cyclone, resulting in 
low process yields (lactitol: 40%, maltitol: 43%, xylitol: 61%)(Table 5).  
These problems occur regularly in spray drying operations [39] and can be caused by various 
factors: inappropriate drying resulting in high water content and sticky character of the spray 
dried powder, thermoplastic and/or hygroscopic nature of the dried product under the 
temperature and humidity conditions within the drying chamber. The third group consists of 
erythritol, lactose, maltodextrin and mannitol, which yielded non-sticky powders after co-
spray drying with acetaminophen. In contrast to erythritol-, maltodextrin- and mannitol-
containing powders, lactose mixtures had a low yield probably caused by low drying 
temperatures. Normally lactose solutions or suspensions are spray dried at higher inlet and 
outlet drying temperatures of e.g. 170–190°C and 85–100°C, respectively [40–42]. Even for 
the best binary drug/excipient mixtures the process yield was below 90% (70, 82 and 75% for 
erythritol, maltodextrin and mannitol, respectively)(Table 5), which is economically 
unprofitable. However, it should be emphasised that spray drying was performed in a lab-
scale drier which typically has a lower yield – in comparison to production-scale spray dryers 
– due to higher wall deposits, since air residence times and radial distances from the atomiser 
to the drying chamber wall are shorter [39].  
 
Table 5 – Spray drying process yield and residual moisture content after spray drying 
Formulation Yield Residual Moisture Content 
 (% w/w) (% w/w) 
Acetaminophen/Lactitol 40 2.90 
Acetaminophen/Maltitol 43 7.40 
Acetaminophen/Xylitol 61 4.72 
Acetaminophen/Erythritol 70 0.60 
Acetaminophen/Lactose 54 3.12 
Acetaminophen/Maltodextrin 82 7.10 
Acetaminophen/Mannitol 75 0.89 
 
Because aqueous drug/excipient solutions (1/1) composed of isomalt, lactitol, maltitol, 
sorbitol and xylitol were ineffective to coprocess via spray drying, only binary mixtures 
containing erythritol, lactose, maltodextrin and mannitol were evaluated on powder 
hygroscopicity. Spray drying drug/excipient solutions (1/1) containing erythritol and mannitol 
 
CHAPTER 1 
36
DEVELOPMENT OF DIRECTLY COMPRESSIBLE POWDERS VIA CO-SPRAY DRYING 
 
resulted in crystalline non-hygroscopic powder mixtures (Fig. 11). Modulated DSC 
experiments showed fractions of amorphous lactose and completely amorphous maltodextrin 
in their corresponding spray dried drug/excipient mixtures. However, the drug/lactose 
mixtures were non-hygroscopic, while the use of maltodextrin resulted in a hygroscopic 
powder absorbing about 8.5% water at a relative humidity above 50% (Fig. 11).  
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Fig. 11. Hygroscopicity of acetaminophen/excipient powder mixtures (1/1) containing erythritol 
({), lactose (z), maltodextrin () and mannitol () 
 
A good flowability of the powders is required to ensure a consistent tablet weight. Erythritol 
and mannitol binary mixtures were characterised by a powder flow time of 4.8 ± 0.7 and 5.9 ± 
0.5 s/100g, respectively, indicating acceptable flowability. Binary mixtures (1/1) containing 
maltodextrin illustrated poor flowability with a powder flow time of 76.6 ± 30.4 s/100g. 
Powders containing lactose did not flow through the nozzle. Consequently, drug/lactose 
mixtures (1/1) were eliminated for further evaluation. The bulk densities of drug/excipient 
mixtures (1/1) containing erythritol, maltodextrin and mannitol were 0.526, 0.192 and 0.439 
g/ml, respectively. SEM pictures (Fig. 12) of drug/excipient mixtures containing erythritol 
and mannitol showed large oblong particles and irregular agglomerates, respectively, resulting 
in better powder flowability in comparison with the cohesive powder mixtures containing 
maltodextrin and lactose which consisted of small particles.  
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Fig. 12. SEM pictures of acetaminophen/excipient powder mixtures (1/1) containing erythritol 
(A), mannitol (B), maltodextrin (C) and lactose (D)  
 
Coprocessing of acetaminophen with erythritol, maltodextrin or mannitol prevented tablet 
capping and lamination, despite the fact that X-ray diffraction showed that these binary 
mixtures contained monoclinic acetaminophen crystals. Powder X-ray data of pure 
monoclinic and orthorhombic acetaminophen have been proposed by Nichols and Frampton 
[43]. The orthorhombic acetaminophen polymorph, having better tabletting properties [44], 
was not formed during co-spray drying. The addition of maltodextrin and mannitol to the 
formulation improved tablet tensile strength in comparison with pure spray dried 
acetaminophen, whereas drug/erythritol mixtures provided comparable tablet tensile strength 
(Table 6). One-way ANOVA (SPSS 12.0) showed significant differences in tablet tensile 
strength between pure spray dried acetaminophen and drug/carbohydrate mixtures containing 
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maltodextrin and mannitol as well as between binary mixtures composed of maltodextrin and 
mannitol. 
Process conditions during spray drying (drying temperatures and atomisation pressure) 
affected the tabletting properties of acetaminophen/carbohydrate mixtures: at a compaction 
pressure of 74 MPa the tablet tensile strength was significantly higher when both the process 
temperatures and the atomisation pressure were higher (Table 6). Compaction at 111 MPa 
showed a similar trend. 
 
Table 6 – Influence of spray drying parameters on tablet tensile strength (n: 10, mean ± st.dev.) 
(compression pressure: 74 MPa) 
Formulation Tablet Tensile Strength (MPa) 
 Process 1 Process 2 
Pure Spray Dried Acetaminophen 0.38 ± 0.14 / 
Acetaminophen/Erythritol 0.45 ± 0.09 0.64 ± 0.16 
Acetaminophen/Maltodextrin 0.88 ± 0.15 2.39 ± 0.52 
Acetaminophen/Mannitol 0.72 ± 0.11 1.49 ± 0.21 
 
Fig. 13. Heckel plots of acetaminophen/excipient powder mixtures (1/1) containing erythritol 
(A), maltodextrin (B), mannitol (C) produced via process 1 (______) and process 2 (- - - - -) 
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The influence of these process conditions (drying temperatures and atomisation pressure) on 
the powder compactability was investigated using Heckel analysis (Table 7) (Fig. 13). As 
most pharmaceutical materials undergo particle fragmentation during initial loading followed 
by elastic and/or plastic deformation at higher loads [45], the fragmentation behaviour was 
evaluated by linear regression (R²) of the initial phase of the compression (2–50 MPa). A 
decrease of R² indicates an increase of particle fragmentation, resulting in increased particle 
bonding surfaces. The reciprocal of the slope (Py, yield pressure) of the linear part of the 
compression curve (40–110 MPa) reflected the total deformation [46], a decrease in yield 
pressure pointing to more plastic deformation behaviour [47].  
 
Table 7 – Heckel analysis (n: 3, mean ± st.dev.) of 2-component mixtures after co-spray drying 
using different process parameters 
Formulation 
Spray 
Drying  
Process 
True 
Density  
(g/ml) 
Heckel Analysis 
   R² PY (MPa) 
Process 1 1.3723 0.9663 ±0.00156 129.1 ± 0.97
Acetaminophen/Erythritol 
Process 2 1.3762 0.9579 ± 0.00052 145.8 ± 2.91
Process 1 1.4507 0.9720 ± 0.00063 135.7 ± 2.79
Acetaminophen/Maltodextrin 
Process 2 1.4776 0.9958 ± 0.00070 93.6 ± 1.65 
Process 1 1.3844 0.9785 ± 0.00058 129.9 ± 1.02
Acetaminophen/Mannitol 
Process 2 1.3864 0.9697 ± 0.00074 133.3 ± 0.53
PY: (Yield Pressure) 
 
Heckel analysis confirmed that the improved tablet tensile strength at higher process 
temperatures and atomisation pressure (process 2) was caused by an increased particle 
fragmentation of crystalline erythritol and mannitol mixtures, while an increased plastic 
deformation of amorphous maltodextrin formulations provided stronger tablets. Amorphous 
particles were less prone to fragment but more deformable in comparison to crystalline 
particles [48–49]. 
Based on the characterisation of the spray dried binary powders and the influence of the 
different carbohydrates on tablet properties, erythritol, maltodextrin and mannitol were 
selected as excipients for the coprocessing of ternary mixtures with acetaminophen. In 
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addition to the active ingredient, mannitol was used as the main fraction of these ternary 
mixtures, based on its positive effects on powder hygroscopicity, flowability and 
compactability observed for the binary mixture. Erythritol or maltodextrin were added as third 
component to improve flowability and tablet strength, respectively, without a strong negative 
effect on process yield and/or powder hygroscopicity. The lower content limit of erythritol 
and maltodextrin (drug/mannitol/excipient ratio: 1/0.9/0.1) was chosen to realise a significant 
improvement of flowability and tablet tensile strength, respectively, while the maximum 
content of erythritol and maltodextrin (drug/mannitol/excipient ratio: 1/0.7/0.3) was limited to 
avoid a strong negative influence on tablet tensile strength and hygroscopicity, respectively.  
Spray drying of ternary mixtures containing erythritol and maltodextrin was extremely 
efficient and provided similar process yields (71 to 74%) in comparison with the reference 
formulation containing only drug and mannitol (ratio 1/1) (73%). The hygroscopic behaviour 
of the ternary mixtures was also similar with drug/mannitol mixtures (1/1): all were 
characterised as non-hygroscopic, only the maltodextrin formulations had a slightly higher but 
acceptable water uptake as a function of maltodextrin content (Fig. 14).  
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Fig. 14. Hygroscopicity of reference formulation (acetaminophen/mannitol powder mixture 
(1/1)) () and acetaminophen/mannitol/excipient powder mixtures containing erythritol 
(1/0.7/0.3) (z) and erythritol (1/0.9/0.1) ({), maltodextrin (1/0.7/0.3) (▲) and maltodextrin 
(1/0.9/0.1) (U) 
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Powder flowability (Fig. 15) of all spray dried ternary mixtures was improved in comparison 
with the binary reference formulation. Using a higher concentration of erythritol or 
maltodextrin (ratio 1/0.7/0.3) showed better flowability in comparison with their 
corresponding formulations (ratio 1/0.9/0.1) because of increased particle size (Fig. 16). 
Similar to the binary mixtures the best flowability was obtained for formulations containing 
erythritol.  
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Fig. 15. Flowability of reference formulation (acetaminophen/mannitol powder mixture (1/1)) 
and acetaminophen/mannitol/excipient powder mixtures (1/0.7/0.3) and (1/0.9/0.1) 
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Fig. 16. SEM pictures of acetaminophen/mannitol/excipient powder mixtures containing 
erythritol (1/0.7/0.3) (A), maltodextrin (1/0.7/0.3) (B), erythritol (1/0.9/0.1) (C) and maltodextrin 
(1/0.9/0.1) (D)  
 
Tablet capping and lamination were not observed for compacts prepared from ternary 
powders. As expected from the evaluation of the binary mixtures, maltodextrin had a 
significantly positive effect on tablet tensile strength at the highest concentration, while 
erythritol had a significantly negative effect on compactability (Table 8).  
Based on these results the compactability of powder mixtures containing acetaminophen and 
mannitol could be improved via the addition of maltodextrins, whereas a ternary mixture 
containing erythritol resulted in a strong improvement of flowability. 
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Table 8 – Tablet tensile strength (n: 10, mean ± st.dev) of reference formulation and ternary 
mixtures (compression force: 74 MPa) 
Formulation Tablet Tensile Strength (MPa)
Reference Formulation: Acetaminophen/Mannitol (1/1) 1.49 ± 0.21 
Acetaminophen/Mannitol/Maltodextrin (1/0.9/0.1) 1.50 ± 0.30 
Acetaminophen/Mannitol/Maltodextrin (1/0.7/0.3) 2.19 ± 0.21 
Acetaminophen/Mannitol/Erythritol (1/0.9/0.1) 0.99 ± 0.18 
Acetaminophen/Mannitol/Erythritol (1/0.7/0.1) 1.12 ± 0.14 
 
4 Conclusions 
 
Coprocessing of acetaminophen/carbohydrate solutions via spray drying has demonstrated the 
efficiency of erythritol, maltodextrin and mannitol to improve the physical properties and 
compactability of acetaminophen. Formulations containing mannitol had good flowability, a 
low hygroscopicity and an acceptable tablet tensile strength. When formulating ternary 
drug/carbohydrate mixtures the powder flowability and tablet tensile strength could be 
improved by replacing part of the mannitol fraction by erythritol or maltodextrin, 
respectively. 
Based on these observations a combination of mannitol, erythritol and maltodextrin was 
selected for further formulation (ratio of different excipients) and process optimisation 
(process yield, flowability and compactability) of these co-spray dried powders intended for 
direct compression.   
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Abstract 
A 4-component mixture containing a fixed concentration of acetaminophen and variable 
concentrations of mannitol, erythritol and maltodextrin was produced by co-spray drying and 
further processed by direct compression. Experimental design was applied to evaluate powder 
flowability, median particle size, density, hygroscopicity, moisture content, spray drying 
process yield, tablet tensile strength, friability and disintegration time. A D-optimal mixture 
design was constructed using a special cubic design order. The mannitol content varied 
between 0 and 32.55% w/w, while the erythritol and maltodextrin fraction changed from 9.3 
to 41.85% w/w and from 4.65 to 23.25% w/w, respectively. An increasing mannitol and 
erythritol content improved powder flowability and density. However, a higher erythritol 
concentration in the spray dried powder mixture had a negative influence on tablet tensile 
strength and friability. A higher maltodextrin content increased tablet tensile strength and 
improved tablet friability, while disintegration time, median particle size, powder flowability, 
density and hygroscopicity were negatively influenced. A combination of mannitol, erythritol 
and maltodextrin was suitable to improve the tablet properties of acetaminophen. Numerical 
optimisation was applied to determine the optimal contents for mannitol (11.6% w/w), 
erythritol (20.9% w/w) and maltodextrin (13.9% w/w). 
 
Keywords: Co-spray drying; Mixture design; Acetaminophen; Carbohydrates; 
Compression 
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CHAPTER 2 
MIXTURE DESIGN APPLIED TO OPTIMISE A DIRECTLY 
COMPRESSIBLE POWDER PRODUCED VIA CO-SPRAY DRYING  
 
 
1 Introduction 
 
In Chapter 1 co-spray drying of drug substance and carbohydrates has been applied to prepare 
binary and ternary spray dried powder mixtures in order to improve the physico-chemical 
properties (flowability, hygroscopicity and compactability) of the drug compared to its pure 
form. Coprocessing via spray drying of acetaminophen/carbohydrate solutions has 
demonstrated the efficiency of mannitol, erythritol and maltodextrin to improve the physical 
properties and compactability of acetaminophen. Acetaminophen/mannitol spray dried 
powders showed increased powder flowability, lowered moisture uptake, and resulted in 
tablets with an acceptable tablet tensile strength. When formulating ternary drug/carbohydrate 
mixtures the powder flowability and tablet tensile strength could be improved by replacing 
part of the mannitol fraction by erythritol or maltodextrin, respectively. 
Based on these observations a combination of mannitol, erythritol and maltodextrin was 
selected for further formulation optimisation (residual moisture content, process yield, powder 
flowability, median particle size, density, hygroscopicity and compactability) of these co-
spray dried powders intended for direct compression.   
The goal is to optimise the ratio of the different excipients in a formulation containing 
acetaminophen in order to improve the physico-chemical properties of the spray dried powder 
and their corresponding tablet properties. Mixture design was used as the statistical tool for 
finding the optimal composition [1]. 
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2 Materials and methods 
 
2.1 Materials 
 
Acetaminophen (median particle size: 50 µm) was received from Mallinckrodt Chemical 
(Hazelwood, USA). Erythritol (C*Eridex 16955) and mannitol (C*Mannidex 16700) were 
donated by Cerestar (Mechelen, Belgium). Maltodextrin (Glucidex® 2, DE: maximum 5) was 
a gift from Roquette (Lestrem, France). This maltodextrin grade consisted of 1-5% amylose 
and 95-99% amylopectin. Crospovidone (Kollidon® CL) was kindly donated by BASF 
(Ludwigshafen, Germany). Magnesium stearate and colloidal silicon dioxide (Aerosil® 200) 
were purchased from Federa (Brussels, Belgium). 
 
2.2 Methods 
 
2.2.1 Preparation of the spray dried particles 
 
Aqueous 4-component solutions (total solid content: 2.6% w/w) containing a fixed 
concentration of acetaminophen (46.5% w/w of tablet composition) and variable 
concentrations of mannitol, erythritol and maltodextrin were prepared by dissolving all 
components in demineralised water at room temperature. The contents of the carbohydrates in 
the formulations are listed in Table 1.  
Spray drying of these solutions was performed in a lab-scale Mobile Minor spray dryer (GEA 
NIRO, Copenhagen, Denmark). The dimensions of the drying chamber were 0.84 m 
cylindrical height with a diameter of 0.80 m and 60° conical base. The solutions were fed to a 
two-fluid nozzle (diameter: 1 mm) at the top of the spray dryer by means of a peristaltic 
pump, type 520U (Watson Marlow, Cornwall, UK) and a Marprene® tube (inside diameter: 
4.8 mm)(Watson Marlow, Cornwall, UK). The spray dryer operated in co-current air flow. 
The spray dried particles were collected in a reservoir attached to a cyclone, cooled down to 
room temperature, sieved (375 μm) and stored in sealed vials (room temperature, ambient 
relative humidity) prior to their characterisation and further use. The solutions were spray 
dried according to the process conditions shown in Table 2. 
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Table 1 – Compositions of the mixture design experiments. In addition to the carbohydrates, 
each formulation contained 46.5% (w/w of tablet composition) acetaminophen. After spray 
drying the powders were blended with colloidal silicon dioxide (0.5% w/w), crospovidone (6% 
w/w) and magnesium stearate (0.5% w/w) 
Run Components 
 
A: X1: Mannitol 
(% of tablet composition) 
B: X2: Erythritol 
(% of tablet composition) 
C: X3: Maltodextrin 
(% of tablet composition) 
1 23.25 9.30 13.95 
2 16.28 25.58 4.65 
3 0 41.85 4.65 
4 0 23.25 23.25 
5 11.63 20.93 13.95 
6 0 32.55 13.95 
7 32.55 9.30 4.65 
8 17.44 15.11 13.95 
9 5.81 26.74 13.95 
10 6.98 16.27 23.25 
11 32.55 9.30 4.65 
12 16.28 25.58 4.65 
13 0 41.85 4.65 
14 0 23.25 23.25 
15 13.95 9.30 23.25 
 
Table 2 – Process conditions during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
Process Parameters Setting 
Feed Rate 46.6 g/min
Inlet Drying Air Temperature 220°C
Outlet Drying Air Temperature 70°C
Drying Gas Rate 80 kg/h
Atomising Air Pressure 2 bar
Compressed Air Flow 50%
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2.2.2 Experimental design 
 
Data from Chapter 1 were used to construct the mixture design. In addition to the active 
ingredient, mannitol was used because of its positive effects on powder hygroscopicity, 
flowability and compactability observed for the binary and ternary mixtures. Erythritol and 
maltodextrin were added to improve flowability and tablet tensile strength, respectively. The 
mannitol content varied between 0 and 32.55% w/w, while the erythritol and maltodextrin 
fraction changed from 9.30 to 41.85% w/w and from 4.65 to 23.25% w/w, respectively. The 
lower content limit of erythritol was chosen to realise a significant improvement of 
flowability and density, while a minimum maltodextrin content of 4.65% w/w was used to 
increase tablet tensile strength. The maximum content of erythritol and maltodextrin was 
limited to avoid a strong negative influence on tablet tensile strength and hygroscopicity, 
respectively.  
Because the experimental space is irregular, classical mixture designs such as the simplex 
lattice and the simplex centroid could not be applied. Therefore, a D-optimal mixture design 
was selected [2–3].  
Because interactions between the variables were expected, the following special cubic model 
in Eq. [1] was proposed: 
 
Y = β∑
=
3
1i
iXi + β∑∑
= +=
2
1
3
1i ij
ijXiXj + β123X1X2X3                                                                         (1) 
 
where Y is the response, Xi, Xj are the relative fractions of components ‘i’ and ‘j’, 
respectively, in the mixture and βi, βij and β123 are the coefficients. 
The candidate points were chosen by the software (Design-Expert version 6.0.10, Stat-Ease, 
Minneapolis, USA) and were: vertices (4), centers of the edges (4), thirds of the edges (8), 
axial check blends (4), interior blends (4) and overall centroid (1). From the 25 candidate 
points, 7 runs were chosen to establish the model, 4 runs for measuring the lack-of-fit and 4 
runs were replicated for the experimental error, generating a total of 15 runs. This enabled the 
evaluation of the appropriate regression model. Manual regression was performed. The 
highest order significant polynomial (significance threshold: 0.05) was selected, where only 
significant model terms were included without destroying the model hierarchy. Outlier-t limit 
was set at 3.5. The significant model was used for fitting the response. The lack-of-fit test and 
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a normal probability plot of the residuals were performed in order to evaluate the model and 
to detect outliers. The models provide several comparative measures for model selection. R² 
statistics, which give a correlation between the experimental response and the predicted 
response, should be high for a particular model to be significant. Adjusted R², which gives 
similar correlation after ignoring the insignificant model terms, should have good agreement 
with predicted R² for the model to be fit [4].  Predicted and adjusted R² should be within 0.20 
of each other [5]. Contour plots for the response were drawn for determination of the optimal 
content levels of the components.  
The different responses were residual moisture content, process yield, powder flowability, 
median particle size, density, hygroscopicity, tablet tensile strength, disintegration time and 
friability.  
 
2.2.3 Evaluation of spray dried powders 
 
The flowability (n: 3)(expressed as the flowability index ffc in Eq. [2]) and bulk density (n: 3) 
of the powders were measured with a ring shear tester, Type RST-XS (Dietmar Schulze, 
Schüttgutmesstechnik, Wolfenbuttel, Germany). A detailed explanation of this technique can 
be found in Röck and Schwedes [6].  
 
 
Fig. 1. Uniaxial compression test 
 
The main goal of a shear test is to measure the compressive strength of a consolidated powder 
as shown in Fig. 1. This test is called a uniaxial compression test. In the first step the powder 
specimen, contained in a hollow cylinder with frictionless walls and cross-sectional area A, is 
consolidated with a consolidation stress σ1. Then the hollow cylinder is removed and the 
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compressive strength is measured by pressing on top of the specimen with increasing vertical 
stress. The stress resulting in failure of the specimen is called the compressive strength or a 
confined yield strength, σc. 
The powders were tested using three different consolidation stresses σ1 (400, 1000, 1600 Pa) 
and a preshear of 2000 Pa. An ffc-value below 1 indicates a non-flowing powder, between 1 
and 2 a very cohesive powder, between 2 and 4 a cohesive powder, between 4 and 10 an easy 
flowing powder and higher than 10 a free flowing powder. 
 
ffc = σ1/σc                                                                                                                                 (2) 
 
where σ1 is the consolidation stress and σc the unconfined yield strength (compressive 
strength) of a bulk solid. 
The higher the consolidation stress σ1 is, the higher is the unconfined yield strength σc. The 
ratio of the consolidation stress σ1 to the unconfined yield strength σc is defined as the 
flowability ffc: 
A shear test a performed in two steps: in the first step, a powder sample is consolidated at a 
defined consolidation stress, in the second step the shear strength of the consolidated powder 
is measured. The difference to the uniaxial compression test is that the powder specimen is 
not only loaded by a static normal stress σ, but also subjected to a shear deformation (Fig. 2), 
for which a shear stress τ has to be applied. For consolidation, the specimen is sheared under a 
higher normal stress σ until the shear stress τ becomes constant. This is called “steady-state 
flow”. Afterwards, the consolidated sample is sheared again, but under a smaller normal 
stress. Thereby, the sample will “break” when a certain shear stress τ is attained (incipient 
flow). This way, the yield limit, called yield locus, of the consolidated powder is measured. 
 
 
Fig. 2. Shear deformation 
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In Fig. 3 yield locus is drawn in a shear stress – normal stress diagram (σ-τ-diagram). The 
circles represent the measured points of incipient flow, the squares represent the shear and 
normal stresses at steady-state flow. A curve through the points of incipient flow is the yield 
locus, i.e. the yield limit of the consolidated sample. The large half circles represent the upper 
part of so-called Mohr stress circles. They represent the stresses acting in the powder in 
different cutting planes. The larger of the two Mohr stress circles represents the stresses at the 
consolidation of the powder.  
 
 
 
Fig. 3. Yield locus, analogy to the uniaxial compression test 
 
The median particle size (D50) and span of each spray dried powder was determined using dry 
powder (jet pressure: 2.8 bar, feed rate: 2 g) laser diffraction (Mastersizer, Malvern, 
Worchestershire, UK). During method development jet pressure and feed rate were increased 
until the median particle size was constant e.g. breaking up of agglomerates in order to 
measure the particle size of the individual spray dried particles. 
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The moisture content and hygroscopic behaviour of the spray dried powders were measured 
and SEM pictures were recorded according to the methods described in Chapter 1 (2.2.2). 
 
2.2.4 Tabletting process and evaluation 
 
The spray dried powders were blended (TSA Turbula mixer, W.A. Bachofen 
Maschinenfabrik, Basel, Switzerland) with 0.5% w/w colloidal silicon dioxide and 6.0% w/w 
crospovidone for 10 min in a first mixing step and with 0.5% w/w magnesium stearate for 5 
min in a second mixing step. Glidant, disintegrant, lubricant and spray dried powder were 
sieved (375 μm) before blending. The powder mixtures were compacted on an excentric tablet 
press, Type EKO (Korsch, Berlin, Germany) equipped with 13.0 mm circular flat punches. 
The tablet properties were evaluated at a compression pressure of 74 MPa. 
The tablet tensile strength was measured and calculated according to the method described in 
Chapter 1 (2.2.3). In addition, tablets (n: 6) were tested for disintegration time using a 
disintegrator, Type PTZ (Pharma Test, Hainburg, Germany). The test was performed in 900 
ml demineralised water (37.0°C ± 0.5°C). Tablet friability was tested on 10 tablets (n: 3) 
using a friabilator, Type PTF (Pharma Test, Hainburg, Germany).  
 
3 Results and discussion 
 
3.1 Summary statistics for the model 
 
Analysis of variance of the responses (Table 3) indicated that response surface models 
developed for powder flowability, median particle size, density, hygroscopicity, tablet tensile 
strength, disintegration time and friability were significant and adequate, without significant 
lack of fit. Transformation of median particle size (power transformation, λ: 2.31) and tablet 
disintegration time (logarithmic transformation) responses was needed because the residuals 
were a function of the magnitude of the predicted values.  
Table 4 details the model summary statistics for the selected significant models. It can be 
observed that, with exception of tablet friability, R² is high for all responses, which indicates a 
high degree of correlation between the experimental and predicted responses. In addition, the 
predicted R² value is in good agreement with the adjusted R² value, resulting in reliable 
models. 
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Table 3 – ANOVA – Influence of formulation composition on the response factors 
Response factor Model F-value Prob>F Lack of Fit F-value Prob>F
Flowability 18.31 0.0002 3.31 0.1347 
Median Particle Size (D50) (μm) 36.80 <0.0001 1.68 0.3220 
Density (g/ml) 57.71 <0.0001 4.29 0.0889 
Hygroscopicity (33% RH) (%) 30.54 <0.0001 1.56 0.3511 
Hygroscopicity (52% RH) (%) 231.78 <0.0001 0.41 0.8682 
Hygroscopicity (65% RH) (%) 207.46 <0.0001 1.69 0.3214 
Hygroscopicity (75% RH) (%) 446.55 <0.0001 0.99 0.5415 
Hygroscopicity (85% RH) (%) 178.98 <0.0001 2.59 0.1873 
Tablet Tensile Strength (MPa) 53.82 <0.0001 2.35 0.2130 
Tablet Disintegration Time (s) 101.93 <0.0001 1.30 0.4126 
Tablet Friability (%) 10.69 0.0026 1.23 0.4784 
 
Table 4 – Model summary statistics – Influence of formulation composition on the response 
factors 
Response factor St.Dev. R² Adjusted R² Predicted R² 
Flowability 0.51 0.9105 0.8608 0.7826 
Median Particle Size (D50) (μm) 892.13 0.8700 0.8464 0.7867 
Density (g/ml) 0.029 0.9130 0.8972 0.8413 
Hygroscopicity (33% RH) (%) 0.29 0.8358 0.8084 0.7476 
Hygroscopicity (52% RH) (%) 0.19 0.9748 0.9706 0.9554 
Hygroscopicity (65% RH) (%) 0.21 0.9719 0.9672 0.9591 
Hygroscopicity (75% RH) (%) 0.19 0.9867 0.9845 0.9769 
Hygroscopicity (85% RH) (%) 0.36 0.9676 0.9622 0.9495 
Tablet Tensile Strength (MPa) 0.25 0.8997 0.8830 0.8572 
Tablet Disintegration Time (s) 0.087 0.9826 0.9730 0.9462 
Tablet Friability (%) 0.22 0.6602 0.5984 0.4944 
 
Since the ability to spray dry a product to a specific residual moisture content at a given outlet 
drying air temperature depends upon the humidity of the air leaving the drying chamber 
(which is the sum of the moisture in the atmospheric air entering the dryer and the amount of 
moisture created during the spray evaporation), daily changes of ambient humidity conditions 
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could affect the residual moisture content in the spray dried powder (Table 5) [7]. As a result, 
the model estimating residual moisture content was not significant. 
In addition, no significant relationship was obtained for process yield (Table 5). In Chapter 1 
it was already observed that the effect of these carbohydrates on the process yield of spray 
dried drug/carbohydrate mixtures (ratio: 1/1) was limited.  
 
Table 5 – Response results (residual moisture content, process yield, ffc (n: 3, mean ± st.dev.), 
median particle size (D50 / span) and bulk density (n: 3, mean ± st.dev.) for mixture design 
experiments 
Run Responses 
 
Residual  
Moisture Content 
(% w/w) 
Process Yield  
(% w/w) 
ffc
Median 
Particle Size  
(μm) 
Bulk Density 
(g/ml) 
1 1.21 70.6 6.73 ± 0.60 26.9 / 1.9 0.394 ± 0.002 
2 0.71 68.9 7.30 ± 0.20 43.6 / 2.0 0.513 ± 0.008 
3 0.20 68.1 5.70 ± 0.10 44.0 / 2.2 0.574 ± 0.005 
4 2.00 69.7 3.57 ± 0.15 12.5 / 1.8 0.283 ± 0.002 
5 1.60 70.5 6.80 ± 0.10 38.6 / 2.0 0.442 ± 0.005 
6 1.60 69.1 5.67 ± 0.42 35.1 / 2.0 0.462 ± 0.001 
7 1.05 71.0 6.90 ± 0.36 43.6 / 2.3 0.461 ± 0.002 
8 1.10 73.4 7.17 ± 0.06 34.0 / 1.9 0.407 ± 0.007 
9 1.10 70.0 7.23 ± 0.55 38.7 / 2.1 0.462 ± 0.003 
10 4.10 55.8 5.53 ± 0.29 42.8 / 4.2 * 0.450 ± 0.003 *  
11 1.19 67.6 7.73 ± 0.64 37.5 / 2.2 0.496 ± 0.002 
12 1.70 64.8 7.70 ± 0.79 46.8 / 2.0 0.535 ± 0.004 
13 2.10 71.2 5.90 ± 0.46 43.5 / 2.1 0.554 ± 0.002 
14 1.40 73.7 3.40 ± 0.17 12.6 / 1.9 0.292 ± 0.003 
15 3.20 56.4 4.93 ± 0.21 23.3 / 4.3 0.352 ± 0.002 
*: identified as outlier 
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3.2 Powder flowability and median particle size 
 
Flowability index (ffc) is a measure of the flow properties of spray dried powder mixtures. 
The median particle size of run 10 was classified as an outlier.  Runs 4, 14, 15 with a high 
maltodextrin fraction (23.25% w/w) had a significantly lower flowability index and median 
particle size compared with formulations with a low maltodextrin fraction (4.65% w/w for 
runs 2, 3, 7, 11, 12, 13)(Table 5).  
 
 
Fig. 4. SEM pictures of mixture design experiments containing 4.65% w/w (run 13), 13.95% w/w 
(run 6) and 23.25 % w/w (run 4) maltodextrin and a constant mannitol content 
 
Since spray drying acetaminophen/carbohydrate solutions (1/1) containing erythritol and 
mannitol resulted in crystalline non-hygroscopic powders and modulated DSC experiments in 
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Chapter 1 showed completely amorphous maltodextrin in its corresponding co-spray dried 
drug/carbohydrate mixture, the formulations containing a higher maltodextrin fraction are 
more hygroscopic and more cohesive, resulting in poor powder flowability [8–10].  
SEM pictures (Fig. 4) of formulations with increasing maltodextrin content (4.65, 13.95 and 
23.25% w/w in run 13, 6 and 4, respectively) showed that the smaller particle size caused a 
decrease of the powder flowability. At a constant maltodextrin concentration in the spray 
dried powders, the flowability index was adversely affected by the erythritol content (e.g. run 
7 versus 13 at 4.65% w/w maltodextrin) probably because of the formation of oblong powder 
particles in comparison with a more spherical particle shape of the formulation containing 
mainly mannitol. At a high maltodextrin fraction (23.25% w/w), a decreasing erythritol 
concentration resulted in a higher median particle size. 
The prediction equations in terms of pseudo components for the flowability index (ffc) and 
median particle size (D50) were: 
 
ffc = 7.17 * A + 5.80 * B – 2.10 * C + 4.67 * AB + 12.89 * AC + 10.54 * BC                      (3) 
 
(D50)2.31 = 5629.2 * A + 6604.8 * B – 3146.8 * C                                                                    (4) 
 
where A is the relative mannitol fraction, B is the relative erythritol fraction and C is the 
relative maltodextrin fraction in the final compact. The contour plots and 3D surface plots 
based on Eq. [3] and [4] are given in Fig. 5 and 6. 
 
 
CHAPTER 2 
64
MIXTURE DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA CO-SPRAY DRYING 
 
 
Fig. 5. Contour plot and 3D surface plot for flowability 
 
Fig. 6. Contour plot and 3D surface plot for median particle size (D50) 
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3.3 Powder bulk density 
 
Bulk density of run 10 was classified as an outlier. Run 2, 3, 11, 12 and 13 containing a low 
maltodextrin fraction (4.65% w/w) had a significantly higher bulk density in comparison with 
formulations with a medium (13.95% w/w for run 1, 5, 6, 8 and 9) and high (23.25% w/w for 
run 4, 14, 15) maltodextrin fraction (Table 5). At a constant maltodextrin content (4.65 or 
13.95% w/w), the bulk density increased with higher erythritol content. Similar observations 
were shown in Chapter 1, where co-spray dried acetaminophen/excipient mixtures (1/1) 
containing erythritol or mannitol had higher bulk densities in comparison with binary 
mixtures containing maltodextrin.  
The prediction equation in terms of pseudo components for the bulk density (BD) was: 
 
BD = 0.490 * A + 0.560 * B + 0.150 * C                                                                                (5) 
 
where A is the relative mannitol fraction, B is the relative erythritol fraction and C is the 
relative maltodextrin fraction in the final compact. The contour plot and 3D surface plot based 
on Eq. [5] are given in Fig. 7. 
 
Fig. 7. Contour plot and 3D surface plot for bulk density 
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3.4 Powder hygroscopicity 
 
Water uptake depended on the maltodextrin fraction due to its hygroscopic properties (Table 
6). In Chapter 1 spray drying acetaminophen/maltodextrin solutions (1/1) resulted in a 
hygroscopic powder absorbing about 8.5% water at a relative humidity above 50%, while 
mixtures containing erythritol and mannitol were crystalline and non-hygroscopic.  
 
Table 6 – Response results (water uptake at 33, 52, 65, 75 and 85% relative humidity) for 
mixture design experiments 
Run Water uptake (%) at specific relative humidity 
 33% RH 52% RH 65% RH 75% RH 85% RH 
1 1.60 2.60 2.87 2.81 4.27 
2 1.01 1.07 1.18 1.20 1.57 
3 0.67 1.02 0.99 0.78 1.12 
4 2.48 3.69 3.82 4.50 4.82 
5 1.62 2.37 2.11 3.03 3.41 
6 1.77 2.50 2.62 2.80 3.11 
7 0.90 0.68 0.97 1.31 1.79 
8 1.21 2.37 2.49 3.01 3.78 
9 0.91 2.21 2.32 2.81 4.03 
10 2.11 3.39 3.61 4.83 6.32 
11 0.40 1.29 1.08 0.87 1.90 
12 0.81 0.89 0.87 1.18 1.57 
13 0.39 0.91 0.90 0.98 0.87 
14 2.13 3.48 3.47 4.28 5.48 
15 1.89 3.58 3.91 4.92 6.43 
 
Formulations containing a low maltodextrin content (4.65% w/w) had a significantly lower 
water uptake compared to compositions containing 13.95 or 23.25% w/w maltodextrin. At 
constant maltodextrin fraction the water uptake at 85% relative humidity decreased with 
higher erythritol contents. At lower relative humidity no significant relationship was found 
between erythritol and mannitol content and the water uptake of the spray dried powders. 
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The prediction equations in terms of pseudo components for the hygroscopicity (WU) at 
different relative humidity levels (33, 52, 65, 75 and 85%) were: 
 
WU (33% RH) = 0.69 * A + 0.70 * B + 3.24 * C                                                                    (6) 
 
WU (52% RH) = 1.05 * A + 0.99 * B + 5.54 * C                                                                    (7) 
 
WU (65% RH) = 1.13 * A + 0.94 * B + 5.81 * C                                                                    (8) 
 
WU (75% RH) = 1.21 * A + 0.92 * B + 7.37 * C                                                                    (9) 
 
WU (85% RH) = 2.05 * A + 0.93 * B + 9.13 * C                                                                  (10) 
 
where A is the relative mannitol fraction, B is the relative erythritol fraction and C is the 
relative maltodextrin fraction in the final compact. The contour plots and 3D surface plots 
based on Eq. 6, 7, 8, 9 and 10 are given in Fig. 8, 9, 10, 11 and 12, respectively. 
 
 
Fig. 8. Contour plot and 3D surface plot for hygroscopicity (33% RH after 2 weeks) 
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Fig. 9. Contour plot and 3D surface plot for hygroscopicity (52% RH after 2 weeks) 
 
Fig. 10. Contour plot and 3D surface plot for hygroscopicity (65% RH after 2 weeks) 
 
 
CHAPTER 2 
69
MIXTURE DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA CO-SPRAY DRYING 
 
 
Fig. 11. Contour plot and 3D surface plot for hygroscopicity (75% RH after 2 weeks) 
 
Fig. 12. Contour plot and 3D surface plot for hygroscopicity (85% RH after 2 weeks) 
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3.5 Tablet tensile strength, disintegration time and friability 
 
Acetaminophen was used as model drug because of its poor compactability as evidenced by 
the low tablet tensile strength (0.38 and 0.67 MPa at a compression pressure of 74 MPa and 
111 MPa, respectively) as well as capping and lamination problems after compaction of pure 
spray dried acetaminophen.  
 
Table 7 – Response results (tablet tensile strength (n: 10, mean ± st.dev.), tablet disintegration 
time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean ± st.dev.)) for mixture design 
experiments (compression pressure: 74 MPa) 
 
Run Responses 
 
Tablet Tensile Strength 
(MPa) 
Tablet Disintegration Time 
(s) 
Tablet Friability 
(%) 
1 2.13 ± 0.21 453 ± 49 0.87 ± 0.19  
2 1.44 ± 0.12 117 ± 14 1.29 ± 0.52 
3 1.10 ± 0.07 41 ± 2 1.28 ± 0.16 
4 2.75 ± 0.40 843 ± 141 0.60 ± 0.30 
5 1.91 ± 0.13 702 ± 201 0.57 ± 0.08 
6 2.32 ± 0.17 647 ± 220 0.58 ± 0.17 
7 2.03 ± 0.11 86 ± 10 1.03 ± 0.34 
8 2.84 ± 0.22 591 ± 2 0.81 ± 0.05 
9 2.14 ± 0.18 495 ± 52 0.98 ± 0.17 
10 2.91 ± 0.21 1022 ± 290 0.56 ± 0.06 
11 1.67 ± 0.21 73 ± 8 1.28 ± 0.27 
12 1.43 ± 0.12 72 ± 23 1.68 ± 0.10 
13 1.00 ± 0.10 45 ± 12 2.39 ± 0.34 * 
14 3.09 ± 0.37 776 ± 113 0.78 ± 0.18 
15 3.24 ± 0.13 979 ± 218 0.67 ± 015 
*: identified as an outlier 
 
Tablet friability of run 13 was classified as an outlier. The tensile strength and disintegration 
time of tablets formulated with low maltodextrin content was significantly lower compared to 
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tablets containing medium or high fractions of maltodextrin, while friability was higher 
(Table 7). At 4.65% w/w maltodextrin in the spray dried powders the tablet tensile strength 
and disintegration time were reduced at higher erythritol contents (41.85% w/w). At higher 
levels of maltodextrin no significant relationship was seen between the erythritol and 
mannitol content and the tablet properties. Mollan and Çelik [11–12] stated that the slow 
disintegration of tablets containing high maltodextrin concentrations (25.0-99.5% w/w) was 
not controlled by the porosity of the tablet, but by a gel layer which formed around the tablet 
on immersion into water. 
The prediction equations in terms of pseudo components for the tablet tensile strength (TTS), 
disintegration time (TDT) and friability (TF) were, respectively: 
 
TTS = 1.78 * A + 1.13 * B + 4.24 * C                                                                                   (11) 
 
Log10(TDT) = 1.88 * A + 1.65 * B + 1.97 * C + 0.76 * AB + 4.06 * AC + 4.58 BC           (12) 
 
TF = 1.22 * A + 1.27 * B + 0.047 * C                                                                                   (13) 
 
where A is the relative mannitol fraction, B is the relative erythritol fraction and C is the 
relative maltodextrin fraction in the final compact. The contour plots and 3D surface plots 
based on Eq. [11], [12] and [13] are given in Fig. 13, 14 and 15, respectively. 
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Fig. 13. Contour plot and 3D surface plot for tablet tensile strength 
 
Fig. 14. Contour plot and 3D surface plot for tablet disintegration time 
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Fig. 15. Contour plot and 3D surface plot for tablet friability 
 
3.6 Formulation optimisation and validation 
 
Numerical optimisation was performed using statistical models to find the optimal 
formulation. For optimisation of the formulation the following targets were set: the 
flowability index and density must be higher than 7.0 and 0.400, respectively, the tablet 
tensile strength must be maximised while disintegration time and friability must be 
minimised. According to the statistical prediction the optimal formulation was: 
 
 Acetaminophen: 46.5% w/w 
Mannitol: 11.6% w/w 
Erythritol: 20.9% w/w 
Maltodextrin: 13.9% w/w 
 
An experiment was performed using the selected mixture to validate the different response 
models. In addition, point predictions were constructed by entering the optimal content level 
(% w/w of tablet composition) of each component into the models. The Design-Expert 
software package (version 6.0.10, Stat-Ease, Minneapolis, USA) then calculated the expected 
 
CHAPTER 2 
74
MIXTURE DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA CO-SPRAY DRYING 
 
responses and associated confidence and prediction intervals (Table 8) based on the prediction 
equations (Eq. [3-13]). The prediction interval had a wider spread than the confidence interval 
since more scatter can be expected in individual values than in averages. All the observed 
results (Table 8) of the measured responses were within in good agreement with the predicted 
results with exception of tablet tensile strength and disintegration time. The deviations for 
tablet tensile strength and disintegration time were probably caused by seasonal changes in 
temperature and humidity of the drying air between the period the design experiments were 
performed and the day the conformational experiment was conducted. These seasonal changes 
influenced the residual moisture content of the spray dried powder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
75
MIXTURE DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA CO-SPRAY DRYING 
 
Table 8 – Observed responses and point prediction of the optimal formulation (Mannitol: 11.6% 
w/w, Erythritol: 20.9% w/w, Maltodextrin: 13.9% w/w). 
 Observed Predicted
95%  
Confidence 
Interval 
95% 
Prediction 
Interval 
Response factor   Low High Low High 
Flowability 6.53 7.02 6.45 7.59 5.73 8.31 
Median Particle Size (D50) 
(μm) 
37.1 34.1 31.7 36.3 23.3 41.6 
Density (g/ml) 0.433 0.421 0.400 0.440 0.350 0.490 
Hygroscopicity  
at 33% RH (%) 
1.45 1.42 1.26 1.59 0.77 2.08 
Hygroscopicity  
at 52% RH (%) 
2.52 2.31 2.20 2.42 1.89 2.73 
Hygroscopicity  
at 65% RH (%) 
2.76 2.40 2.28 2.52 1.93 2.87 
Hygroscopicity  
at 75% RH (%) 
2.95 2.86 2.76 2.97 2.44 3.29 
Hygroscopicity  
at 85% RH (%) 
3.61 3.67 3.46 3.88 2.85 4.49 
Tablet Tensile Strength 
(MPa) 
1.70 2.25 2.11 2.39 1.69 2.80 
Tablet Disintegration Time 
(s) 
412 637 510 797 384 1058 
Tablet Friability (%) 1.23 0.90 0.77 1.03 0.40 1.40 
 
4 Conclusions 
 
Regression models were developed for powder flowability, median particle size, density and 
hygroscopicity. In addition, tablet tensile strength, friability and disintegration time were 
modelled, while there was no significant relationship between formulation composition on the 
one side and residual moisture content and process yield on the other side. Numerical 
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optimisation was applied to determine the optimal contents for mannitol (11.6% w/w), 
erythritol (20.9% w/w) and maltodextrin (13.9% w/w). 
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Abstract 
The effect of maltodextrins and superdisintegrants on the tablet properties was evaluated in 
directly compressible powders coprocessed via spray drying. Powder mixtures containing 
acetaminophen, mannitol, erythritol and different maltodextrin types were prepared via co-
spray drying and physically mixed with crospovidone (6% w/w, Kollidon® CL) in order to 
evaluate the influence of maltodextrin grade (amylose/amylopectin ratio) on powder 
hygroscopicity, flowability, density and compactability. In addition, different 
superdisintegrant types and grades (6% w/w) were co-spray dried to evaluate their effect on 
tablet disintegration time. Tablet disintegration was affected by the amylose/amylopectin ratio 
of the maltodextrins. Tablets containing Glucidex® 2 (1–5% amylose) had a longer 
disintegration time compared to Glucidex® 9 (20% amylose) (11.8 min versus 5.7 min) and 
Unipure DC (50–70% amylose) (1 min). The disintegration time of tablets containing a 
coprocessed superdisintegrant was long due to loss of superdisintegrant during processing 
(preferential deposition of superdisintegrant on the spray dryer wall) and was in the following 
order: Kollidon® CL < Polyplasdone® XL < Explotab® < Kollidon® CL-M < Polyplasdone® 
XL-10 = Ac-Di-Sol®. A combination of acetaminophen, mannitol, erythritol, Glucidex® 9 and 
Kollidon® CL was selected for further formulation and process optimisation of co-spray dried 
powders intended for direct compression. 
 
Keywords: Co-spray drying; Continuous processing; Maltodextrin; Superdisintegrant; 
Acetaminophen; Carbohydrates; Compression 
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1 Introduction 
 
Coprocessing of acetaminophen with carbohydrates (mannitol, erythritol, maltodextrin) 
improved the physical properties and compactability of acetaminophen. Formulations 
containing mannitol had a good flowability, low hygroscopicity and acceptable tablet tensile 
strength (Chapter 1). A combination of mannitol, erythritol and maltodextrin was selected for 
further formulation optimisation of these co-spray dried powders intended for direct 
compression. In Chapter 2 was stated that an increasing mannitol and erythritol content 
improved powder flowability and density. However, a higher erythritol concentration in the 
spray dried powder mixture had a negative influence on tablet tensile strength and friability. 
A higher maltodextrin content increased tablet tensile strength and improved tablet friability, 
while disintegration time, median particle size, powder flowability, density and 
hygroscopicity were negatively influenced. Numerical optimisation was applied to determine 
the optimal contents for mannitol (11.6% w/w), erythritol (20.9% w/w) and maltodextrin 
(13.9% w/w). 
Maltodextrin, a partially hydrolysed starch, is composed of a mixture of amylose and 
amylopectin, both having a different influence on hygroscopicity and tablet properties such as 
tensile strength, friability and disintegration time [1–3]. Therefore, this research work 
describes the influence of the maltodextrin grade (different amylose/amylopectin ratios) on 
powder hygroscopicity, flowability, density and compactability. 
Since tablet disintegration is a prerequisite for a fast release of active ingredients from solid 
oral dosage forms, a disintegrant is routinely integrated into a formulation [4–6]. Based on 
this, the purpose is also to improve the disintegration behaviour of tablets formulated using 
coprocessed powders via the incorporation of different superdisintegrants (type, particle size 
distribution) in the co-spray dried dispersion.  
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2 Materials and methods 
 
2.1 Materials 
 
Acetaminophen (median particle size: 50 µm) was received from Mallinckrodt Chemical 
(Hazelwood, USA). Erythritol (C*Eridex 16955) and mannitol (C*Mannidex 16700) were 
donated by Cerestar (Mechelen, Belgium). Maltodextrin (Glucidex® 2, 9) was a gift from 
Roquette (Lestrem, France). Maltodextrin (Unipure DC HBA-28) was obtained from National 
Starch (Bridgewater, USA). Glucidex® 9 is a potato starch conversion product, containing 
20% amylose and 80% amylopectin. Glucidex® 2 is a waxy maize starch conversion product, 
containing 1-5% amylose and 95-99% amylopectin, while Unipure DC is a high amylose 
maltodextrin (50-70% amylose and 30-50% amylopectin). Magnesium stearate and colloidal 
silicon dioxide (Aerosil® 200) were purchased from Federa (Brussels, Belgium). 
 
2.1.1 Croscarmellose sodium 
 
Croscarmellose sodium (Ac-Di-Sol®) was donated by FMC (Brussels, Belgium). It is a water 
insoluble superdisintegrant for tablets [7–9], capsules [10] and granules. During wet 
granulation, croscarmellose sodium should be added intra- and extragranularly to make 
maximum use of the wicking and swelling ability of the disintegrant [11]. It has a median 
particle size (D50) of 49 µm. 
 
2.1.2 Sodium starch glycolate 
 
Sodium starch glycolate (Explotab®) was received from JRS Pharma (Rosenberg, Germany). 
Disintegration occurs by rapid uptake of water, followed by rapid and enormous swelling 
[12]. Sodium starch glycolate is a water insoluble superdisintegrant incorporated in capsules 
and tablet formulations [13].  
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2.1.3 Crospovidone 
 
Crospovidone was kindly donated by BASF (Kollidon® CL, CL-M, Ludwigshafen, Germany) 
or purchased from ISP (Polyplasdone® XL, XL-10, Baar, Switzerland). Median particle size, 
bulk and tapped density were shown in Table 1. 
 
Table 1 – Median particle size (D50), bulk and tapped density of crospovidone grades 
 Median particle size
(µm) 
Bulk density 
(g/ml) 
Tapped density 
(g/ml) 
Kollidon® CL 99 0.30-0.40 0.40-0.50 
Kollidon® CL-M 6 0.15-0.25 0.30-0.50 
Polyplasdone® XL 107 0.21 0.27 
Polyplasdone® XL-10 21 0.32 0.46 
 
Crospovidone is a water insoluble superdisintegrant used in tablets [11, 14–15]. Due to their 
porous particle morphology, crospovidone particles quickly wick water into their capillaries 
to generate the rapid volume expansion and hydrostatic pressures that causes tablet 
disintegration, with little tendency to form a gel. 
  
2.2 Methods 
 
2.2.1 Preparation of spray dried particles 
 
Aqueous solutions of acetaminophen, mannitol, erythritol and maltodextrin (Glucidex® 2, 9, 
Unipure DC HBA-28) (total solid content: 2.6% w/w) were prepared to evaluate the effect of 
the maltodextrin grade. The contents of drug substance and carbohydrates in the formulations 
are listed in Table 2. 
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Table 2 – Composition of the feed solution for the coprocessed formulations. The ratio between 
the different components is expressed as a percentage of the final tablet composition. Kollidon® 
CL (6% w/w) was physically mixed with the spray dried powders. 
 
Maltodextrin Grade Selection 
(% of tablet composition) 
Acetaminophen 46.5
Mannitol  11.6
Erythritol 20.9
Maltodextrin 14.0
 
In addition to the evaluation of maltodextrins, where crospovidone was physically mixed with 
the spray dried powder mixture, aqueous suspensions (Table 3) of acetaminophen, mannitol, 
erythritol, maltodextrin (Glucidex® 9) and a superdisintegrant (croscarmellose sodium (Ac-
Di-Sol®), sodium starch glycolate (Explotab®) and crospovidone (Kollidon® CL, CL-M, 
Polyplasdone® XL, XL-10)) (total solid content: 2.8% w/w) were coprocessed to evaluate the 
feasibility of co-spray drying with superdisintegrants and their effect on tablet disintegration 
time. Spray drying of these feeds was performed in lab-scale Mobile Minor spray dryer (GEA 
NIRO, Copenhagen, Denmark). The dimensions of the drying chamber were 0.84 m 
cylindrical height with a diameter of 0.80 m and 60° conical base. The solutions/suspensions 
were fed to a two-fluid nozzle (diameter: 1 mm for maltodextrin experiments, 2 mm for 
superdisintegrant experiments) at the top of the spray dryer by means of a peristaltic pump, 
type 520U (Watson Marlow, Cornwall, UK) and a Marprene® tube (inside diameter: 4.8 
mm)(Watson Marlow, Cornwall, UK). The spray dryer operated in co-current air flow.  
 
Table 3 – Composition of the feed suspension for the coprocessed formulations. The ratio 
between the different components is expressed as a percentage of the final tablet composition 
 
Superdisintegrant Type and Grade Selection 
(% of tablet composition) 
Acetaminophen 46.5 
Mannitol  24.6 
Erythritol 13.9 
Maltodextrin 7.9 
Superdisintegrant 6.0 
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The aqueous feeds were processed via a spray drying process, shown in Table 4. The spray 
dried particles were collected in a reservoir attached to a cyclone, cooled down to room 
temperature and stored (room temperature, ambient relative humidity) prior to their 
characterisation and further use. 
 
Table 4 – Process conditions during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
Process Parameters Setting
  
Feed Rate (g/min) 46.6
Inlet Drying Air Temperature (°C)  220
Outlet Drying Air Temperature (°C) 70
Drying Gas Rate (kg/h) 80
Atomising Air Pressure (bar) 2
Compressed Air Flow (%) 50
 
2.2.2 Evaluation of spray dried powders 
 
The moisture content and hygroscopic behaviour of the spray dried powders were measured 
according to the methods described in Chapter 1 (2.2.2), while the flowability, bulk density 
and median particle size were measured according to the methods described in Chapter 2 
(2.2.3). 
The superdisintegrant concentration (n: 5) in the co-spray dried powders was gravimetrically 
determined via a filtration procedure. A powder sample of 1.5 g was dispersed in 100 ml 
demineralised water. The fraction remaining in suspension (representing only the 
superdisintegrant since all other components dissolved in water) was isolated via filtration of 
the dispersion using glass fiber filters (GF 51, Scheicher & Schuell MicroScience, Dassel, 
Germany). The filters retained particles down to 1 µm and were oven-dried (40°C, 2h) prior 
to use. After filtration these glass fiber filters were dried for 72h at 40°C and the amount of 
superdisintegrant retained by the filters was gravimetrically determined. 
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2.2.3 Tabletting process and evaluation 
 
When evaluating the maltodextrin grade, the spray dried powders were blended (TSA Turbula 
mixer, W.A. Bachofen Maschinenfabrik, Basel, Switzerland) with 0.5% w/w colloidal silicon 
dioxide and 6.0% w/w crospovidone (Kollidon® CL) for 10 min in a first mixing step and 
with 0.5% w/w magnesium stearate for 5 min in a second mixing step.  
Formulations containing different superdisintegrant types and grades (theoretical disintegrant 
concentration in coprocessed powder: 6% w/w) were also co-spray dried to evaluate their 
effect on disintegration time. These co-spray dried powders were blended with 0.5% w/w 
colloidal silicon dioxide for 10 min in a first mixing step and with 0.5% w/w magnesium 
stearate for 5 min in a second mixing step. Glidant, disintegrant, lubricant and spray dried 
powders were sieved (375 μm) before blending. The powder mixtures were compacted on an 
excentric tablet press, Type EKO (Korsch, Berlin, Germany) equipped with 13.5 mm circular 
edged punches. The tablet properties were evaluated at a compression pressure of 74 MPa. 
The tablet tensile strength was measured and calculated according to the method described in 
Chapter 1 (2.2.3), while tablet disintegration time and friability were measured according to 
the methods described in Chapter 2 (2.2.4). 
 
3 Results and discussion 
 
3.1 Maltodextrin grade selection 
 
In Chapter 2 a mixture design was applied to develop regression models for powder 
flowability, density, hygroscopicity, tablet tensile strength, disintegration time and friability 
of powder mixtures containing acetaminophen, mannitol, erythritol and maltodextrin 
(Glucidex® 2) produced via co-spray drying. Numerical optimisation was performed using 
statistical models to find the optimal formulation. According to the statistical prediction this 
optimal formulation (Table 2) was selected to evaluate the effect of maltodextrins on the 
hygroscopicity, flowability, density and compactability in directly compressible powders 
coprocessed via spray drying. 
Spray drying 4-component solutions containing Glucidex® 2 or 9 resulted in a similar water 
uptake of all formulations, absorbing about 3.5% water (Fig. 1). Similar to Chapter 1 the 
water sorption in drug/carbohydrate mixtures (ratio: 1/1) containing mannitol and erythritol 
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was limited, the hygroscopicity of these 4-component mixtures at a relative humidity of 85% 
is mainly due to the maltodextrin fraction in the spray dried powder. In the spray dried 
powder containing high amylose maltodextrin (Unipure DC), water uptake was significantly 
lower compared to formulations containing Glucidex® 2 and 9. Mani and Bhattacharya [3] 
described that the water absorption of injection moulded starch/synthetic polymer 
blends decreased as the amylose content increased in the starch blends. Similarly, Ke 
et al. [16] stated that blends of polylactic acid and high amylose starch had a lower water 
absorption than blends of normal and waxy corn starches (high amylopectin starches). 
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Fig. 1. Hygroscopicity of acetaminophen/mannitol/erythritol/maltodextrin powder mixtures 
(1/0.25/0.45/0.30) containing Glucidex® 2 ({), Glucidex® 9 (z) and Unipure DC HBA-28 () 
 
The flowability index (ffc) and density of the spray dried mixtures composed of Glucidex® 2 
(6.8 ± 0.1, 0.442 ± 0.005 g/ml, respectively) and Glucidex® 9 (7.2 ± 0.1, 0.472 ± 0.007 g/ml, 
respectively) were similar, while formulations containing Unipure DC showed a significantly 
higher powder density (0.524 ± 0.007 g/ml) and lower powder flowability (ffc: 6.4 ± 0.2).  
Coprocessing of acetaminophen with erythritol, maltodextrin and mannitol prevented tablet 
capping and lamination, despite the fact that these co-spray dried mixtures contained 
monoclinic acetaminophen crystals. As stated in Chapter 2 tablet properties were mainly 
determined by the maltodextrin content. Tablet tensile strength and friability (Table 5) of 
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formulations containing Glucidex® 2 and 9 were similar. However, Unipure DC lowered 
tablet tensile strength, whereas friability was increased. One-way ANOVA (SPSS 12.0) 
showed significant differences in tablet tensile strength between all three formulations. In 
addition, disintegration time was significantly affected by the amylose/amylopectin ratio 
(Table 5).  
 
Table 5 – Influence of maltodextrin grade on tablet tensile strength (n: 10, mean ± st.dev.), tablet 
friability (n: 3, mean ± st.dev.) and tablet disintegration time (n: 6, mean ± st.dev.) 
Compression pressure: 74 MPa 
Formulation 
Tensile Strength
(MPa) 
Friability 
(%) 
Disintegration Time 
(min) 
Glucidex® 2 1.92 ± 0.13 0.46 ± 0.12 11.8 ± 3.2 
Glucidex® 9 2.15 ± 0.16 0.56 ± 0.12 5.7 ± 0.1 
Unipure DC 1.41 ± 0.12 1.07 ± 0.26 1.0 ± 0.1 
 
Tablets containing Glucidex® 2 (1–5% amylose) had a longer disintegration time compared to 
Glucidex® 9 (20% amylose)(11.8 min versus 5.7 min) and Unipure DC (50–70% amylose)(1 
min). Mollan and Çelik [17–18] stated that the slow disintegration of maltodextrin-containing 
(25.0-99.5% w/w) tablets was not controlled by the porosity of the tablet, but by a gel layer 
which formed around the tablet on immersion into water. This layer limited water penetration 
and was the controlling factor for disintegration of maltodextrin-containing tablets. Herman et 
al. [1–2] evaluated the influence of amylose/amylopectin ratio on the drug release of starch-
containing tablet. A low amount of amylose seemed to be an essential component to achieve 
high gel hardness while amylopectin seemed to be responsible for the cohesive character of 
the gel [1].  
Based on the characterisation of the powder mixtures containing different maltodextrin 
grades, Glucidex® 9 was selected as maltodextrin for coprocessing in combination with 
acetaminophen, mannitol and erythritol. Glucidex® 9 provided an excellent tablet 
disintegration time in combination with a high tablet tensile strength, low friability and 
acceptable powder hygroscopicity, flowability and density of the spray dried powders. 
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3.2 Superdisintegrant type and grade selection 
 
Because tablet disintegration was mainly determined by the maltodextrin content and type, 
the maltodextrin content in the selected formulation was decreased in order to optimise 
disintegration time. Therefore, numerical optimisation was applied to adjust the levels of 
mannitol, erythritol and maltodextrin resulting in the formulation in Table 3. Aqueous 
suspensions of acetaminophen, mannitol, erythritol, maltodextrin (Glucidex® 9) and a 
superdisintegrant (croscarmellose sodium, sodium starch glycolate, crospovidone) were 
prepared. Whereas the drug and polyols dissolved in the aqueous medium, the dispersed 
superdisintegrants swelled in the aqueous feed. Zhao and Augsburger [4] reported that the 
aqueous swelling capacity of superdisintegrant was in the following order: sodium starch 
glycolate (increase in diameter: 251%) > croscarmellose sodium (104%) >> crospovidone 
(29%). These coarser droplets dried insufficiently during processing to acquire dry surfaces 
and therefore deposited on the wall of the spray dryer. The concentration of the three 
superdisintegrants (Ac-Di-Sol®, Explotab®, Kollidon® CL) ranged from 20 to 77% w/w in 
relation to their initial content in the feed. The higher the median particle size of swollen 
superdisintegrant in the aqueous feed, the lower the content of superdisintegrant in the spray 
dried powder, resulting in lower process yields (Table 6, 7). 
However, it should be emphasised that spray drying was performed in a lab-scale drier which 
typically has a lower yield – in comparison to production-scale spray dryers – due to higher 
wall deposits, since air residence time and radial distance from the atomiser to the drying 
chamber wall are shorter [19]. Thus, smaller spray dryers (Mobile Minor) limit the particle 
size that can be successfully dried. Coarser powder from the same atomiser device can be 
handled in larger industrial dryers, and thus the inability to produce a desired particle 
specification in a lab-scale test does not automatically rule out a successful operation on a 
larger scale. Co-spray drying of acetaminophen, mannitol, erythritol, maltodextrin and a 
superdisintegrant in a production-scale spray dryer will be presented in Chapter 5. 
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Table 6 – Median particle size (D50) of disintegrant (after swelling in an aqueous medium 
according to the swelling coefficients of Zhao and Augsburger [4]) and disintegrant content in 
spray dried powder in relation to its initial content in the feed (n: 5, mean ± st.dev.) 
Disintegrant 
 
Median Particle Size 
(µm) 
Concentration in Spray Dried Powder 
(% w/w) 
Ac-Di-Sol® 49.0 (96.1) 76.7 ± 5.0 
Explotab® 46.4 (162.9) 20.0 ± 1.7 
Kollidon® CL 99.1 (127.8) 41.7 ± 6.7 
Kollidon® CL-M 6.1 (7.9) 135.0 ± 5.0 
Polyplasdone® XL 107.4 (138.5) 26.7 ± 8.3 
Polyplasdone® XL-10 21.1 (27.2) 68.3 ± 8.3 
 
Table 7 – Yield, residual moisture content and tablet disintegration time (n: 6, mean ± st.dev.) 
Compression pressure: 74 MPa 
Disintegrant Spray dried powder 
 
 Yield 
(% w/w)
Residual Moisture 
Content (% w/w) 
Tablet Disintegration Time
(min) 
Ac-Di-Sol® 78.1 2.5 * 
Explotab® 62.1 3.4 18.0 ± 1.7 
Kollidon® CL 68.1 2.1 14.5 ± 0.5 
Kollidon® CL-M 76.3 2.1 18.3 ± 0.7 
Polyplasdone® XL 66.5 1.6 17.0 ± 0.7 
Polyplasdone® XL-10 67.9 2.8 * 
*: Tablets were not completely disintegrated within 20 min 
 
Despite a decrease in maltodextrin concentration, the disintegration time of tablets containing 
co-spray dried superdisintegrant was high due to loss of disintegrant during processing (Table 
7) in combination with the specific disintegration mechanisms. In contrast, the concentration 
of Kollidon® CL-M in relation to its initial concentration in the feed was 135% because of the 
improved drying of the micronised crospovidone particles (median particle size after swelling 
in an aqueous medium according to the swelling coefficients of Zhao and Augsburger [4]: 7.9 
µm) in comparison with the spray dried particles formed in the drying chamber.  
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Tablet disintegration is based on mechanisms including water wicking, swelling, deformation 
recovery, repulsion and heat of wetting, and is dependent on the median particle size, 
porosity, swelling capacity, rate and extent of water uptake [4]. However, no single 
mechanism is applicable to all disintegrating agents. It is likely, that in most cases, a 
combination of mechanisms is taking place simultaneously [5]. Despite their high hydration 
capacities [4] Ac-Di-Sol® and Explotab® were less effective for tablet disintegration, probably 
their swelling formed to a gel which blocked tablet pores and prevented further penetration of 
water into the inner layers of the tablet. Tablets containing crospovidone (Kollidon® CL) 
disintegrated faster (Table 7). Kornblum and Stoopak [20] observed that crospovidone 
swelled very little in comparison with Ac-Di-Sol® and Explotab®, yet absorbed water rapidly 
into its pore network. Crospovidone particles with their porous particle morphology quickly 
wick water into their capillaries to generate the rapid volume expansion and hydrostatic 
pressures that caused tablet disintegration. Due to its faster disintegration crospovidone was 
selected for further evaluation and crospovidone grades having different median particle size 
were compared. The disintegration time of tablets containing different coprocessed 
crospovidone grades was in the following order: Kollidon® CL < Polyplasdone® XL < 
Kollidon® CL-M < Polyplasdone® XL-10 (Table 7). Although the loss of crospovidone during 
co-spray drying depended on their median particle size in the feed suspension, formulations 
containing different crospovidone grades showed no correlation between the residual 
disintegrant content in the spray dried powder and tablet disintegration time, because the 
disintegration potential is also depending on median particle size, porosity, swelling capacity, 
rate and extent of water uptake of the disintegrant [4].  
It has been reported in literature that larger disintegrant particles are more efficient than 
smaller particles of the same material due to a difference in swelling pressure [21]. Although 
the coarse crospovidone grades (Kollidon® CL and Polyplasdone® XL) had a similar median 
particle size (99 versus 107 µm, respectively), formulations containing Kollidon® CL resulted 
in a faster tablet disintegration because of the higher disintegrant concentration in the spray 
dried powder in comparison with Polyplasdone® XL.  
In comparison with Kollidon® CL and Polyplasdone® XL, tablets containing Polyplasdone® 
XL-10 had a longer disintegration time related to the reduction in median particle size and 
thus disintegration potential [14], despite their higher content in the spray dried powder. 
Kollidon® CL-M and Polyplasdone® XL tablets had comparable disintegration times, despite 
the limited disintegration potential of the smaller Kollidon® CL-M particles. This was 
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compensated by its feasibility for co-spray drying in a lab-scale spray dryer resulting in a high 
content of Kollidon® CL-M in the spray dried powder. 
 
4 Conclusions 
 
A combination of erythritol, mannitol, maltodextrin (Glucidex® 9) and a superdisintegrant 
(Kollidon® CL) was selected for further formulation and process optimisation (process yield, 
flowability and compactability) of co-spray dried powders for direct compression. Glucidex® 
9 was selected as maltodextrin type because it improved tablet disintegration in combination 
with acceptable physico-chemical powder properties, tablet tensile strength and friability, 
while Kollidon® CL minimised tablet disintegration time.  
Co-spray drying of acetaminophen, mannitol, erythritol, maltodextrin and a superdisintegrant 
in a lab-scale spray dryer resulted in a significant loss of superdisintegrant (related to the 
median size of the superdisintegrant particles after swelling in an aqueous medium) due to 
insufficient drying. However, coprocessing of an aqueous formulation containing 
superdisintegrant is probably feasible when increasing the dimensions of the spray dryer (i.e. 
production-scale spray dryer) since this will allow the swollen superdisintegrant particles to 
dry completely. This will be evaluated in Chapter 5.  
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Abstract 
Manufacturing of ‘ready-to-compress’ powder mixtures for direct compression was 
performed by spray drying, without granulation, milling and/or blending steps in between 
spray drying and compaction. Powder mixtures containing acetaminophen, mannitol, 
erythritol, maltodextrin, crospovidone, colloidal silicon dioxide and polyoxyethylene 20 
sorbitan monooleate were prepared via co-spray drying. A feed suspension having a solid 
content of 27.2% w/w was selected for further process optimisation because of its high 
process yield, excellent flowability and short tablet disintegration time. Experimental design 
was applied to evaluate processibility, physico-chemical properties and compactability of the 
spray dried powder mixtures. Significant and adequate regression models were developed for 
powder flowability, median particle size, bulk density, residual moisture content and process 
yield. An increasing inlet and outlet drying air temperature improved process yield. However, 
a higher inlet drying air temperature had a negative influence on density and moisture content, 
while the latter decreased at higher outlet drying air temperatures. Median particle size 
increased with a higher inlet temperature, while the outlet temperature had the opposite affect. 
Numerical optimisation determined the optimal spray drying process (inlet temperature: 
221°C, outlet temperature: 81°C and atomisation pressure: 6 bar) in order to produce ‘ready-
to-compress’ powder mixtures.  
 
Keywords: Co-spray drying; Process design; Continuous processing; Acetaminophen; 
Carbohydrates; Compression 
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1 Introduction 
 
Unlike the chemical, food, automotive and electronics industry where continuous processing 
has been employed for many years, conventional pharmaceutical manufacturing is generally 
performed using batch processing with laboratory testing conducted on collected samples to 
evaluate quality. The pharmaceutical industry has historically gained high profit margins and 
over the years limited efforts have been taken to implement time- and cost-reducing strategies 
and to change the manufacturing concept from batch-wise to continuous processing [1]. A 
change towards innovative continuous processing in the pharmaceutical industry could create 
regulatory uncertainty about the approval of the product. Continuous manufacturing was only 
able to satisfy the high quality requirements within the pharmaceutical and healthcare industry 
by innovative real time quality assurance using in- and on-line measurement of critical 
process parameters and physico-chemical properties of the manufactured goods.  
Continuous processing has been preferred over batch-wise processing because of divers 
reasons. It reduces the time-to-market because of scale-up benefits and better quality (no 
batch-to-batch variations, clinical trial batches and production batches are produced on the 
same equipment) [1–3]. During transfer towards commercial production no bioequivalence 
study is demanded. Material handling is simplified since less time is required for filling, 
emptying and cleaning machines and a continuous process benefits from a reduced capital 
investment and reductions in labour costs, floor space and minimal wastage [4].  
Since the traditional concept of tablet manufacturing consists of several batch-wise steps 
(granulation, blending, tabletting), a coprocessing technique via spray drying was developed 
in previous chapters to allow continuous manufacturing of ‘ready-to-compress’ mixtures, 
without intermediate granulation, milling or blending. Using acetaminophen as a poorly 
compressible drug a mixture of carbohydrates (mannitol, erythritol, maltodextrin), 
disintegrant (crospovidone), glidant (colloidal silicon dioxide) and surfactant 
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(polyoxyethylene 20 sorbitan monooleate) was selected for process optimisation of ‘ready-to-
compress’ co-spray dried powders intended for direct compression [5–7]. 
The purpose of this chapter is to optimise the solid content of the feed used for co-
spray drying since this increases the process capacity and minimises energy requirements, 
thus improving the economical profitability. Experimental design is applied to optimise the 
spray drying process regarding processibility, physico-chemical properties of the 
spray dried powder mixtures and tablet properties in order to achieve a continuous 
production process for solid dosage forms containing a poorly compressible drug 
substance. In addition, improving the manufacturing process (solid content of the feed, spray 
drying parameters) could improve flow properties (flowability index, density, particle size 
distribution, particle shape, residual moisture content). 
 
2 Materials and methods 
 
2.1 Materials 
 
Acetaminophen (median particle size: 15 µm) was purchased from Atabay (Istanbul, Turkey). 
Erythritol (C*Eridex 16955) and mannitol (C*Mannidex 16700) were donated by Cerestar 
(Mechelen, Belgium). Maltodextrin (Glucidex® 9) was a gift from Roquette (Lestrem, 
France). Crospovidone (Kollidon® CL) was kindly donated by BASF (Ludwigshafen, 
Germany). Colloidal silicon dioxide (Aerosil® 200) was obtained from Federa (Brussels, 
Belgium). 
 
2.1.1. Polyoxyethylene 20 sorbitan monooleate 
 
Polyoxyethylene 20 sorbitan monooleate (Polysorbate 80) was purchased from Certa (Braine 
L’Alleud, Belgium). Polyoxyethylene sorbitan fatty acid esters are widely used as surfactants. 
 
 
 
 
 
CHAPTER 4 
102
PROCESS DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA A CONTINUOUS 
MANUFACTURING PROCESS 
 
 
2.2 Methods 
 
2.2.1 Preparation of the spray dried particles 
 
Aqueous suspensions (Table 1) of acetaminophen, mannitol, erythritol, maltodextrin 
(Glucidex® 9), crospovidone (Kollidon® CL), colloidal silicon dioxide (Aerosil® 200) and 
polyoxyethylene 20 sorbitan monooleate (Polysorbate 80) (total solid content: 8.5, 15.7, 21.9 
and 27.2% w/w) were prepared to evaluate the effect of the solid concentration of the feed. 
The feed suspensions were spray dried according to the process conditions shown in Table 2.  
 
Table 1 – Composition of the feed suspension for the coprocessed formulations. The ratio 
between the different components is expressed as a percentage of the final tablet composition 
 
Concentration 
(% of solids content)
Acetaminophen 41.9
Mannitol  20.9
Erythritol 14.2
Maltodextrin 10.0
Crospovidone 12.0
Colloidal Silicon Dioxide 0.5
Polysorbate 80 0.5
 
Table 2 – Process conditions during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
Process Parameters Settings 
Feed Rate Variable (g/min)
Inlet Drying Air Temperature 220°C
Outlet Drying Air Temperature 80°C
Drying Gas Rate 80 kg/h
Atomising Air Pressure 6 bar
Rotary atomiser speed 31000 rpm
 
In addition, aqueous suspensions (total solid content: 27.2% w/w) were subjected to a process 
design. The spray drying process conditions of the process design experiments are listed in 
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Table 3. Spray drying of these suspensions was performed in lab-scale Mobile Minor spray 
dryer (GEA NIRO, Copenhagen, Denmark).  
 
Table 3 – Process parameters of the process design experiments. In addition to the variable 
parameters (inlet and outlet drying air temperature and atomisation pressure), each spray 
drying process used a drying gas rate of 80 kg/h 
Run Factors 
 A: X1 B: X2 C: X3
 
Inlet Temperature 
(°C) 
Outlet Temperature 
(°C) 
Atomisation Pressure 
(bar) 
1 200 60 6 
2 170 80 6 
3 170 60 5 
4 215 75 5 
5 215 75 4 
6 170 80 6 
7 170 60 6 
8 230 90 6 
9 170 60 4 
10 170 80 4 
11 200 60 4 
12 170 80 4 
13 205 90 6 
14 180 90 5 
15 200 60 6 
16 230 90 5 
17 205 90 6 
18 230 90 4 
 
The dimensions of the drying chamber were 0.84 m cylindrical height with a diameter of 0.80 
m and 60° conical base. In contrast with co-spray drying of aqueous solutions (batch size: 1 
kg demineralised water) containing acetaminophen and carbohydrates (Chapter 1-3) via 
pneumatic nozzle atomisation (two-fluid nozzle), the suspensions (Table 1) were fed to a 
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rotary atomiser at the top of the spray dryer by means of a peristaltic pump, type 520U 
(Watson Marlow, Cornwall, UK) and Marprene® tube (inside diameter: 4.8 mm) (Watson 
Marlow, Cornwall, UK). If the feed is an abrasive slurry of suspended solids of varying size, a 
rotary atomiser is more suited as a low pressure device with large flow areas and easy 
incorporation of wear resistant parts for prolonged trouble-free operation [8]. The spray dryer 
operated in co-current air flow. The spray dried particles were collected in a reservoir attached 
to a cyclone, cooled down to room temperature and stored (room temperature, ambient 
relative humidity) prior to their characterisation and further use. 
 
2.2.2 Experimental design 
 
Preliminary experiments were carried out to establish appropriate ranges for the processing 
variables. The inlet and outlet drying air temperatures varied from 170 to 230°C and from 60 
to 90°C, respectively, while the atomisation pressure varied between 4 and 6 bar. The lower 
limits of the atomisation pressure, inlet and outlet drying air temperature were chosen to avoid 
process problems (low yield, sticking on the dryer wall surfaces). In addition, the difference 
between inlet and outlet drying air temperature was fixed at 90–140°C. A minimum of 90°C 
was selected to obtain an acceptable process capacity taking into account the energy loss, 
while a maximum difference of 140°C was set to avoid condensation in the dryer chamber. 
The upper limits of the inlet and outlet drying air temperature were limited to avoid a strong 
negative influence on powder flowability and density, while an atomisation pressure of 6 bar 
was the operationally maximum working condition of the rotary atomiser. 
Because the experimental space is irregular, classical process designs such as the central 
composite or the Box-Behnken design could not be applied. Therefore, a D-optimal mixture 
design was selected [9–10]. Because interactions between the variables were expected, the 
following quadratic model was proposed Eq. (1): 
 
Y = β0 + β∑
=
3
1i
iXi + ∑∑ β
= +=
2
1
3
1i ij
ijXiXj + β∑
=
3
1i
iiXi²                                                               (1)
 
where Y is the response, Xi, Xj are the set points of the process variables ‘i’ and ‘j’, 
respectively, and β0, βi, βij and βii are the coefficients. 
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The candidate points were chosen by the software (Design-Expert version 6.0.10, Stat-Ease 
Inc., Minneapolis, USA) and were: vertices (10), centers of the edges (15), constraint plane 
centroids (7), check points (10), interior points (22) and overall centroid (1). From the 65 
candidate points, 10 runs were chosen to establish the model, 4 runs for measuring the lack-
of-fit and 4 runs were replicated for the experimental error, generating a total of 18 runs. This 
enabled the evaluation of the appropriate regression model. Manual regression was 
performed. The highest order significant polynomial (significance threshold: 0.05) was 
selected, where only significant model terms were included without destroying the model 
hierarchy. Outlier-t limit was set at 3.5. The significant model was used for fitting the 
response. The lack-of-fit test and a normal probability plot of the residuals were performed in 
order to evaluate the model and to detect outliers. The models provide several comparative 
measures for model selection. R² statistics, which give a correlation between the experimental 
response and the predicted response, should be high for a particular model to be significant. 
Adjusted R², which gives a similar correlation after ignoring the insignificant model terms, 
should have good agreement with predicted R² for the model to be fit [11].  Predicted and 
adjusted R² should be within 0.20 of each other [12]. Contour plots for the response were 
drawn for determination of the optimal variable settings.  
The different responses were powder flowability, median particle size, bulk density, residual 
moisture content, process yield, tablet tensile strength, disintegration time and friability.  
 
2.2.3 Evaluation of spray dried powders 
 
The moisture content of the spray dried powders was measured and SEM pictures were 
recorded according to the methods described in Chapter 1 (2.2.2), while the flowability, bulk 
density and median particle size were measured according to the methods described in 
Chapter 2 (2.2.3). 
The porosity of tablets composed of powder mixtures obtained via spray drying feed 
suspensions with different solid contents was defined using a helium gas pycnometer, 
Accupyc 1330 (Micromeritics, Norcross). The following analysis parameters were used: 10 
purges, 10 runs and 19.5 psig as purge and run fill pressure. Final thickness and diameter of 
the tablets were measured with an electronic digital calliper (Bodson, Luik, Belgium). 
In order to fluorescently label the amorphous phase of the spray dried particles FITC-dextran 
was added to the suspension at a 0.5 % w/w concentration of the maltodextrin fraction in the 
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suspension. The FITC-dextran was added to the solution of mannitol, erythritol, maltodextrin 
and polyoxyethylene 20 sorbitan monooleate and stirred until complete dissolution before the 
addition of acetaminophen, crospovidone and colloidal silicon dioxide. Confocal microscopy 
images of FITC-dextran labeled spray dried particles were recorded with a Nikon EZC1-si 
confocal microscope equipped with a 40x objective. Z-stacks were recorded over a total 
interval of 50 µm with a 1 µm step size.  
The thermal behaviour and X-ray diffraction spectra of the optimised spray dried mixture 
were investigated using the methods described in Chapter 1 (2.2.2).  
 
2.2.4 Tabletting process and evaluation 
 
The powder mixtures were compacted on an excentric tablet press, Type EKO (Korsch, 
Berlin, Germany) equipped with 13.5 mm circular edged punches. The tablet properties were 
evaluated at a compression pressure of 74 MPa (evaluation of the solid content of the feed) or 
111 MPa (process design). 
The tablet tensile strength was measured and calculated according to the method described in 
Chapter 1 (2.2.3), while tablet disintegration time and friability were measured according to 
the methods described in Chapter 2 (2.2.4). 
 
3 Results and discussion 
 
3.1 Increasing solid content 
 
Coprocessing of acetaminophen/carbohydrate solutions has demonstrated the efficiency of 
mannitol, erythritol and maltodextrin to improve the physical properties and compactability of 
acetaminophen (Chapter 1-2)[5–6]. Glucidex® 9 was selected as maltodextrin type because it 
improved tablet disintegration in combination with acceptable physico-chemical powder 
properties, tablet tensile strength and friability, while Kollidon® CL minimised tablet 
disintegration time (Chapter 3)[7]. Thus, a combination of acetaminophen, mannitol, 
erythritol, maltodextrin (Glucidex® 9), crospovidone (Kollidon® CL), colloidal silicon dioxide 
and polyoxyethylene 20 sorbitan monooleate was selected for process optimisation of ‘ready-
to-compress’ co-spray dried powders intended for direct compression. Colloidal silicon 
dioxide was used as yield-increasing agent. This compound facilitates drying by its capacity 
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to absorb large amounts of water into its pores, thus preventing sticking of semi-wet spray 
dried particles to the chamber walls [13]. Polyoxyethylene 20 sorbitan monooleate was 
included to improve the quality of the feed suspension used for co-spray drying in case of a 
highly dosed poorly water soluble drug substance (preventing agglomeration of suspended 
particles and sticking to the container surface) and to decrease tablet disintegration time. 
The flowability index (ffc), bulk density, residual moisture content, process yield and median 
particle size as a function of solid content are mentioned in Table 4. Increasing the solid 
content of the feed had no significant influence on the flowability index, while bulk density 
changed significantly: at a higher solid content of the feed, a lower bulk density of the spray 
dried powders was obtained. Although the bulk density of spray dried powders also depends 
on the dimensions of the drying chamber, atomisation device, process conditions and feed 
composition, the lower residual moisture content and larger particle size observed for 
formulations processed at higher solid content contributed to the lower bulk density. 
 
Table 4 – Influence of solid content of the feed on powder flowability, ffc, (n: 3, mean ± st.dev.), 
bulk density (n: 3, mean ± st.dev.), residual moisture content, process yield and median particle 
size ( D50 / span). 
Solid 
Content 
(% w/w) 
ffc
Bulk Density 
(g/ml) 
Residual 
Moisture Content 
(% w/w) 
Process Yield 
(% w/w) 
Median  
Particle Size 
(µm) 
8.5 6.87 ± 0.15 0.352 ± 0.015 2.1 53.1 25.4 
15.7 7.67 ± 0.31 0.338 ± 0.008 2.0 60.7 27.2 
21.9 7.80 ± 0.61 0.315 ± 0.009 1.0 67.0 30.8 
27.2 8.50 ± 0.89 0.326 ± 0.006 1.0 65.4 35.5 
 
A higher solid content of the feed increased the median particle size due to the larger volume 
occupied by the solid fraction, resulting in more particle collisions and agglomeration. In 
addition, a higher solid content of the feed suspension increased the viscosity forming larger 
droplets.  Similarly, the production of tomato powder from tomato paste showed a larger 
particle size at increasing solid content of the feed [14]. 
A higher solid content increased process yield, while residual moisture content of the spray 
dried powder mixtures was lowered. The atomisation of a concentrated feed suspension 
decreased the drying load since less water in a droplet needs to be evaporated. In addition, it 
is easier to achieve moisture removal from suspensions-type droplets than solution-type 
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droplets especially when the latter involves diffusion-limited film-forming characteristics at 
the surface [8]. Process yields mentioned in Table 4 are an underestimation as the duration of 
the spray drying experiments was limited to about 30 min. Processing a larger batch improved 
process yield as a large fraction of material is lost during the start-up phase before equilibrium 
process conditions are obtained: process yield increased from 65.4 to 84.1% when process 
time of a feed suspension at 27.2% solid content was extended from 31 to 84 min. 
Tablet tensile strength and disintegration time decreased significantly with increasing solid 
content of the feed (Table 5) although at higher solid concentration (15.7–27.2% w/w) no 
significant difference in disintegration time was measured. The decrease in tensile strength 
and disintegration time was correlated with an increasing tablet porosity. Tablets with a high 
porosity are prone to rapid disintegration due to the fast water penetration into the porous 
network [15]. The tablet friability was independent of the solid content of the feed suspension. 
 
Table 5 – Influence of solid content of the feed on tablet porosity, tablet tensile strength (n: 10, 
mean ± st.dev.), tablet disintegration time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean 
± st.dev.)(compression pressure: 74 MPa) 
Solid Content 
(% w/w) 
Tablet Porosity 
(%) 
Tensile Strength 
(MPa) 
Friability 
(%) 
Disintegration Time 
(min) 
8.5 18.0 1.53 ± 0.10 0.88 ± 0.08 7.0 ± 1.0 
15.7 22.8 1.20 ± 0.11 1.10 ± 0.19 2.9 ± 0.1 
21.9 23.4 1.05 ± 0.04 1.12 ± 0.04 2.4 ± 0.5 
27.2 24.1 0.95 ± 0.06 1.19 ± 0.15 2.0 ± 0.1 
 
A feed suspension having a solid content of 27.2% w/w was selected for further process 
optimisation because of its high process yield and short disintegration time in combination 
with excellent flow properties. SEM picture (Fig. 1) of a spray dried powder produced via 
coprocessing of a concentrated feed suspension (solid content of the feed: 27.2% w/w) 
showed large irregular agglomerates. In addition, confocal microscopy images of a spray 
dried particle showed agglomerates composed of individual acetaminophen crystals with a 
size corresponding to the average particle size of the micronised acetaminophen (D50: 15 µm) 
(Fig. 3). 
In addition, we were interested to know how if the amorphous maltodextrin compound (which 
acted as binder in the formulation) was distributed throughout the spray dried particles. 
Therefore, to visualize the amorphous phase of the spray dried particles fluorescent FITC-
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dextran was added to the suspension. As FITC-dextran is an amorphous compound it will be 
distributed within the amorphous phase of the spay dried particles. Therefore this approach is 
well suited for the visualization (by fluorescence microscopy) of the distribution of 
maltodextrin in a spray dried particle since no other amorphous materials were detected on a 
DSC thermogram of a spray dried mixture (Fig. 2).  
 
 
Fig. 1. SEM picture of spray dried powder (total solid content of the feed suspension: 27.2% 
w/w) 
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Fig. 2. Differential scanning calorimetry analysis of spray dried powder (total solid content of 
the feed suspension: 27.2% w/w) 
 
Fig. 3 shows confocal images (top) of a spray dried particle composed of individual 
acetaminophen particles (median particle size: 15 µm) and a Z-stack (i.e. a stack of confocal 
images taken at different heights through the sample) of a spray dried particle (bottom). The 
sequence of the images is from top (0 µm) to bottom (40 µm). As can be observed the 
fluorescence is distributed throughout the spray dried particle, indicating that amorphous 
maltodextrin is spread throughout the entire spray dried particle (taking into account the 
variation of fluorescence at the top and bottom because of the irregular shape of the spray 
dried particle). 
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Fig. 3. Confocal microscopy images of a spray dried particle (top) and fluorescently labelled 
spray dried particle (bottom) (total solid content of the feed suspension: 27.2% w/w) 
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Fig. 4 shows the X-ray diffraction spectra of pure acetaminophen, mannitol, erythritol, 
maltodextrin and the spray dried powder (composition specified in Table 1). Pure 
acetaminophen and acetaminophen in the spray dried powder mixture were of crystalline 
nature as identical sharp peaks were observed in both diffraction patterns (e.g. 2θ: 18.2°, 
24.3°, 26.6° and 32.8°).  
 
 
 
 
 
 
Fig. 4. X-ray diffraction patterns of acetaminophen (A) mannitol (B), erythritol (C), 
maltodextrin (D) and the spray dried powder mixture (total solid content of the feed suspension: 
27.2% w/w) (E)  
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In addition, pure erythritol and mannitol were crystalline as indicated by numerous distinct 
peaks. The prominent peaks from pure erythritol (2θ: 19.8° and 28.3°) and pure mannitol (2θ: 
18.8°, 23.4° and 44.1°) were also present in the diffraction spectrum of the spray dried 
powder. Maltodextrin was found to be amorphous, as indicated by the absence of diffraction 
peaks. 
 
3.2 Process optimisation design 
 
3.2.1 Summary statistics for the model 
 
Analysis of variance of the responses (Table 6) indicated that response surface models 
developed for powder flowability, median particle size, density, residual moisture content 
process yield, tablet tensile strength, disintegration time and friability were significant, 
without significant lack of fit. Transformation of median particle size (power transformation, 
λ: -2.54) response was needed because the residuals were a function of the magnitude of the 
predicted values.  
 
Table 6 – ANOVA – Influence of spray drying process variables on the response factors 
Response factor Model F-value Prob>F Lack of Fit F-value Prob>F
Flowability 45.92 <0.0001 0.58 0.7798 
Median Particle Size (D50) (μm) 73.54 <0.0001 0.33 0.9284 
Density (g/ml) 30.27 <0.0001 1.49 0.3743 
Moisture Content (%) 57.99 <0.0001 0.91 0.5976 
Spray Drying Yield (%) 45.92 <0.0001 0.58 0.7798 
Tablet Tensile Strength (MPa) 4.21 0.0275 0.76 0.6025 
Tablet Disintegration Time (s) 5.68 0.0113 0.72 0.6197 
Tablet Friability (%) 4.25 0.0185 1.77 0.3029 
 
Table 7 details the model summary statistics for the selected significant models. It can be 
observed that, with exception of tablet tensile strength, disintegration and friability, R², 
predicted R² and adjusted R² are in good agreement, resulting in reliable models. 
Moreover, the effect of process design variables on tablet properties is not of major 
importance because observed tablet properties were robust since tablet tensile strength, 
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disintegration time and friability of all process design runs were within acceptable ranges (> 
1.10 MPa, < 5 min and < 0.70%, respectively) (Table 8). Although reproducible results were 
obtained, the developed regression models for tablet tensile strength, disintegration time and 
friability did not evidence acceptable statistical measures because of limited differences in 
tablet properties between the different experimental settings. 
 
Table 7 – Model Summary Statistics – Influence of spray drying process variables on the 
response factors 
Response factor St.dev. R² Adjusted R² Predicted R²
Flowability 3.36 0.9077 0.8880 0.8576 
Median Particle Size (D50) (μm) 1.039E-005 0.9403 0.9275 0.9012 
Density (g/ml) 7.012E-003 0.8122 0.7854 0.7220 
Moisture Content (%) 0.44 0.8855 0.8702 0.8376 
Spray Drying Yield (%) 3.36 0.9077 0.8880 0.8576 
Tablet Tensile Strength (MPa) 0.11 0.8258 0.6298 0.1163 
Tablet Disintegration Time (s) 22.50 0.8647 0.7124 0.2497 
Tablet Friability (%) 0.088 0.6988 0.5346 0.1499 
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Table 8 – Response results (tablet tensile strength (n: 10, mean ± st.dev.), tablet disintegration 
time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean ± st.dev.)) for process design 
(compression pressure: 111 MPa) 
Run Responses 
 
Tablet Tensile Strength 
(MPa) 
Tablet Disintegration Time 
(s) 
Tablet Friability 
(%) 
1 1.11 ± 0.06 134 ± 9 0.58 ± 0.18 
2 1.47 ± 0.04 245 ± 63 0.57 ± 0.05 
3 1.84 ± 0.06 295 ± 4 0.51 ± 0.07 
4 1.37 ± 0.05 218 ± 12 0.66 ± 0.02 
5 1.35 ± 0.05 215 ± 9 0.68 ± 0.04 
6 1.52 ± 0.08 249 ± 16 0.54 ± 0.01 
7 1.50 ± 0.03 208 ± 10 0.62 ± 0.05 
8 1.35 ± 0.03 194 ± 11 0.44 ± 0.09 
9 1.59 ± 0.08 267 ± 26 0.50 ± 0.03 
10 1.34 ± 0.04 212 ± 21 0.23 ± 0.08 
11 1.15 ± 0.06 205 ± 24 0.54 ± 0.06 
12 1.57 ± 0.07 220 ± 14 0.30 ± 0.08 
13 1.37 ± 0.03 225 ± 22 0.36 ± 0.05 
14 1.63 ± 0.06 288 ± 17 0.45 ± 0.09 
15 1.31 ± 0.11 164 ± 21 0.58 ± 0.09 
16 1.44 ± 0.04 241 ± 18 0.33 ± 0.11 
17 1.45 ± 0.06 292 ± 14 0.55 ± 0.15 
18 1.28 ± 0.04 248 ± 20 0.65 ± 0.15 
 
3.2.2 Powder flowability 
 
The flowability index (ffc) is a measure of the flow properties of spray dried powder mixtures. 
The powder flowability of run 9 was classified as an outlier. Powder flowability is predicted 
by a 2-factor interaction model. Run 3 and 7 produced at low drying air temperatures (inlet 
temperature: 170°C, outlet temperature: 60°C) had a higher flowability index in comparison 
with formulations co-spray dried at high drying air temperatures (inlet temperature: 230°C, 
outlet temperature: 90°C for run 8, 16 and 18) (Table 9). 
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Table 9 – Response results (powder flowability: ffc (n: 3, mean ± st.dev.), bulk density (n: 3, 
mean ± st.dev.), residual moisture content, process yield and median particle size (D50 / span) for 
process design experiments 
Run Responses 
 ffc
Bulk Density 
(g/ml) 
Residual 
Moisture Content 
(% w/w) 
Process Yield 
(% w/w) 
Median  
Particle Size 
(µm) 
1 7.27 ± 0.15 0.314 ± 0.002 4.10 53.5 58.0 / 3.5 
2 6.50 ± 1.32 0.346 ± 0.000 1.05 60.1 31.6 / 3.5 
3 9.23 ± 0.55 0.372 ± 0.004 * 2.49 34.2 46.2 / 3.0 
4 6.67 ± 2.06 0.315 ± 0.002 1.29 63.6 36.4 / 2.9 
5 7.30 ± 0.26 0.316 ± 0.002 1.43 65.1 37.1 / 3.1 
6 7.37 ± 0.29 0.350 ± 0.001 1.61 49.5 33.3 / 3.7 
7 8.17 ± 0.31 0.345 ± 0.003 2.91 35.0 42.4 / 3.9 
8 7.70 ± 0.36 0.313 ± 0.003 0.88 57.6 40.8 / 2.9 
9 7.83 ± 0.31 * 0.328 ± 0.002 3.09 35.2 42.1 / 3.9 
10 7.80 ± 0.46 0.338 ± 0.001 1.21 50.0 32.8 / 3.4 
11 8.60 ± 0.85 0.313 ± 0.002 4.00 49.8 55.5 / 3.7 
12 7.87 ± 0.83 0.354 ± 0.001 0.91 50.0 32.6 / 4.0 
13 7.77 ± 1.07 0.319 ± 0.001 0.60 61.0 38.4 / 2.7 
14 6.83 ± 0.45 0.334 ± 0.001 0.00 58.4 32.4 / 3.1 
15 7.13 ± 0.15 0.316 ± 0.002 2.98 53.4 48.9 / 3.2 
16 7.53 ± 0.32 0.320 ± 0.003 0.96 57.0 42.1 / 2.8 
17 7.43 ± 0.21 0.315 ± 0.002 0.49 65.3 34.4 / 2.8 
18 6.93 ± 0.21 0.308 ± 0.002 1.04 62.4 39.8 / 3.3 
*: identified as outlier 
 
The fitted response surface model in terms of coded factors for the flowability index (ffc) was: 
 
ffc = 7.41 – 0.50 * A – 0.39 * B – 0.24 * C + 0.91 * AB + 0.31 * AC + 0.47 * BC               (2) 
 
where A is the inlet temperature, B is the outlet temperature and C is the atomisation pressure. 
The contour plots and 3D surface plots based on Eq. (2) are given in Fig. 5. 
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Fig. 5. Contour plots and 3D surface plots for flowability, and inlet temperature is constant at 
200°C, outlet temperature is constant at 75°C and atomisation pressure is constant at 5 bar. 
 
3.2.3 Median particle size 
 
At constant inlet drying air temperature (170°C) the median particle size was decreased by 
increasing outlet drying air temperature (e.g. run 3, 7 and 9 versus run 2, 6, 10 and 12) (Table 
9). In addition, coprocessing via spray drying at constant outlet drying air temperature yielded 
powders with larger median particle size at a higher inlet drying air temperature (run 1, 11, 15 
versus run 3, 7, 9 at constant outlet drying air temperature of 60°C). Although the effect of 
temperature on particle size is reported to be dependent on the material being dried [16], 
similar observations have been made by Ståhl et al. [17] during spray drying of insulin. 
Broadhead et al. [18] suggested that the increase in particle size might be an effect of 
increased agglomeration at the higher inlet drying air temperatures due to a higher feed rate 
(required to obtain a constant outlet drying air temperature if the inlet drying air temperature 
is increased). Atomisation pressure had no significant influence on the median particle size of 
the spray dried powders.  
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The fitted response surface model in terms of coded factors for the median particle size (D50) 
was: 
 
(D50)-2.54 = 1.124E-004 – 2.750E-005 * A + 3.580E-005 * B – 3.521E-005 * B²                    (3) 
 
where A is the inlet temperature and B is the outlet temperature. 
The contour plot and 3D surface plot based on Eq. (3) are given in Fig. 6. 
 
 
Fig. 6. Contour plot and 3D surface plot for median particle size (Atomisation pressure: 5 bar) 
 
3.2.4 Powder bulk density 
 
Bulk density of run 3 was classified as an outlier. Run 2, 6, 7, 9, 10 and 12 produced at an 
inlet drying air temperature of 170°C had a significantly higher bulk density in comparison 
with formulations coprocessed at medium (200°C for run 1, 11 and 15) and high (230°C for 
run 8, 16, 18) inlet drying air temperature (Table 9). Atomisation pressure had no significant 
influence on the bulk density of the spray dried powders. The decrease in bulk density with 
increasing inlet drying air temperature was due to case hardening of the droplet at higher 
temperatures followed by expansion of the entrapped air [19]. An increase in inlet drying air 
CHAPTER 4 
120
PROCESS DESIGN APPLIED TO OPTIMISE A DIRECTLY COMPRESSIBLE POWDER PRODUCED VIA A CONTINUOUS 
MANUFACTURING PROCESS 
 
 
temperature decreased powder bulk density for many feed formulations, but the extent was 
product dependent [8].  
 
 
Fig. 7. Contour plot and 3D surface plot for bulk density (Atomisation pressure: 5 bar) 
 
The fitted response surface model in terms of coded factors for the bulk density (BD) was: 
 
BD = 0.32 – 0.019 * A + 5.677E-003 * B                                                                                (4) 
 
where A is the inlet temperature and B is the outlet temperature. 
The contour plot and 3D surface plot based on Eq. (4) are given in Fig. 7. 
 
3.2.5 Residual moisture content 
 
Runs 1, 3, 7, 9, 11 and 15 dried at low outlet drying air temperature (60°C) had significantly 
higher moisture contents compared with powders produced at medium (run 4 and 5) and high 
(run 8, 13, 14, 16, 17 and 18) outlet drying air temperature (Table 9). The high moisture 
content at low outlet drying temperature was often linked to agglomerated and sticky spray 
dried products. The small drying chamber of the Mobile Minor spray dryer used in this study 
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is more prone to these problems at low drying temperatures. At constant outlet drying air 
temperature the moisture content was increased by the inlet drying air temperature, especially 
at low outlet drying air temperatures (e.g. run 7 and 9 versus run 1 and 11 at an outlet drying 
air temperature of 60°C in comparison with run 13 and 17 versus run 8, 16, 18 at an outlet 
drying air temperature of 90°C). In addition, Ersus and Yurdagel [20] stated that higher 
drying air temperatures reduced the residual moisture content, when the difference between 
inlet and outlet drying air temperature was constant. Atomisation pressure had no significant 
influence on the moisture content of the spray dried powders. 
The fitted response surface model in terms of coded factors for the residual moisture content 
during spray drying (RMC) was: 
 
RMC = 1.89 + 0.34 * A – 1.45 * B                                                                  (5) 
 
where A is the inlet temperature and B is the outlet temperature. 
The contour plot and 3D surface plot based on Eq. (5) are given in Fig. 8. 
 
 
Fig. 8. Contour plot and 3D surface plot for residual moisture content (Atomisation pressure: 5 
bar) 
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3.2.6 Spray drying yield 
 
Formulations prepared at low outlet drying air temperature (60°C) had significantly lower 
process yields compared to compositions dried at higher outlet drying temperatures (80°C) 
using similar inlet drying air temperatures (e.g. run 3, 7 and 9 versus run 2, 6, 10 and 12 at an 
inlet drying air temperature of 170°C) (Table 9). At constant outlet drying air temperature 
(60°C) the spray drying yield increased a higher inlet drying air temperature as more thermal 
energy was provided for the immediate evaporation of the solvent. Broadhead et al. [18] 
showed that during spray drying of β-galactosidase the process yield was increased by 
increasing inlet drying air temperature. Similarly, spray drying of insulin for inhalation 
resulted in higher process yields at higher inlet drying air temperature [17]. At high outlet 
drying air temperature (90°C) the yield was not significantly affected by inlet drying air 
temperature (e.g. run 8, 13, 14, 16, 17, 18). Atomisation pressure had no significant influence 
on the process yield. 
 
The fitted response surface model in terms of coded factors for the process yield (PY) was: 
 
PY = 57.20 + 9.28 * A + 3.72 * B – 9.84 * AB                                                                       (6) 
 
where A is the inlet temperature and B is the outlet temperature. 
The contour plot and 3D surface plot based on Eq. (6) are given in Fig 9. 
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Fig. 9. Contour plot and 3D surface plot for process yield (Atomisation pressure: 5 bar) 
 
3.2.7 Process optimisation and validation 
 
Numerical optimisation was performed using statistical models to find the optimal spray 
drying process. For optimisation of the process the following targets were set: the residual 
moisture content must be minimised while process yield must be maximised.  
 
 
According to the statistical prediction the optimal formulation process parameters were: 
 
Inlet Temperature: 221°C 
Outlet Temperature: 81°C 
Atomisation Pressure: 6 bar 
 
An experiment was performed for the selected process. In addition, point predictions were 
constructed by entering optimal process parameters into the current model. Design-Expert 
software package (version 6.0.10, Stat-Ease, Minneapolis, USA) then calculated the expected 
responses and associated confidence and prediction intervals (Table 10) based on the 
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prediction equations (Eq. [2-6]). The prediction interval has a wider spread than the 
confidence interval since more scatter can be expected in individual values than in averages. 
All the observed results (Table 10) of the measured responses were within the prediction 
intervals (with exception of powder flowability). 
 
Table 10 – Observed responses and point prediction of the optimal spray drying process (Inlet 
temperature: 221°C, Outlet temperature: 81°C, Atomisation pressure: 6 bar) 
 Observed Predicted
95% 
Confidence 
Interval 
95% 
Prediction 
Interval 
Response factor   Low High Low High 
Flowability (ffc) 8.77 7.32 6.93 7.71 6.52 8.11 
Median Particle Size (D50) 
(μm) 
35.44 37.30 35.73 39.16 34.19 41.73 
Density (g/ml) 0.330 0.312 0.310 0.320 0.300 0.330 
Moisture Content (%) 1.02 1.55 1.21 1.89 0.55 2.55 
Spray Drying Yield (%) 63.09 62.4 59.74 65.12 54.74 70.11 
 
4 Conclusions 
 
Economic profitability was improved by increasing the solid content of the feed suspension 
(27.2% w/w) resulting in a high process yield, excellent flowability and short tablet 
disintegration time. Regression models were developed for powder bulk density, moisture 
content and spray drying process yield, whereas modelling of tablet hardness, friability and 
disintegration time was unreliable. The atomisation pressure had no significant influence on 
the process yield, moisture content and density. The optimised spray drying process had an 
atomisation pressure of 6 bar and an inlet and outlet drying air temperature of 221 and 81°C, 
respectively. These process settings were selected for process scale-up in order to 
manufacture ‘ready-to-compress’ powder mixtures via continuous spray drying. 
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Abstract 
It was evaluated if coprocessing via spray drying can be used as a formulation platform to 
improve the compactability of formulations containing drug substance (acetaminophen, 
ibuprofen, cimetidine) and excipients (carbohydrates, disintegrant, glidant, surfactant). 
Experimental design was applied to optimise the drug concentration and solid content of the 
feed suspension. In addition, scaling-up of acetaminophen- and ibuprofen-containing 
formulations was performed on a production-scale spray dryer. Optimised acetaminophen 
(drug concentration: 70% w/w), ibuprofen (drug concentration: 75% w/w) and cimetidine 
(drug concentration: 70% w/w) powders were obtained via co-spray drying of aqueous 
suspensions with a high solid content of the feed (35% w/w) and the resulting powders were 
directly compressed. Scaling-up of optimised acetaminophen and ibuprofen formulations was 
performed successfully, resulting in a robust and reproducible manufacturing process. It can 
be concluded that a combination of mannitol, erythritol, Glucidex® 9, Kollidon® CL, 
(colloidal silicon dioxide) and polyoxyethylene 20 sorbitan monooleate allowed the spray 
drying of highly dosed drug substances (acetaminophen, ibuprofen, cimetidine) in order to 
obtain ‘ready-to-compress’ powder mixtures on lab-scale and production-scale equipment.  
 
Keywords: Co-spray drying; Scaling-up; Continuous processing; Compression; 
Acetaminophen; Ibuprofen; Cimetidine; Carbohydrates 
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1 Introduction 
 
Improving the compactability of drugs via co-spray drying is an interesting manufacturing 
technique for the pharmaceutical industry since it uses a one-step process to dry and 
agglomerate powder, thus obtaining a homogeneous powder which can become free-flowing 
through process optimisation (Chapter 1–4)[1–4]. Using this technique the number of unit 
operations is reduced, improving production efficiency and reducing costs, especially since 
spray drying is a technique which can be easily automated and equipped for in-line product 
analysis. In addition, spray drying can be considered a continuous process, thus reducing 
time-to-market because of scale-up benefits and better quality (no batch-to-batch variations, 
clinical trial batches and production batches are manufactured on the same equipment). These 
features of coprocessing via spray drying offer many obvious economic benefits for a 
pharmaceutical production facility. 
The purpose of this study is to optimise the solid content of the feed suspension used for co-
spray drying in order to maximise the drug concentration of the spray dried powder. 
Experimental design of the spray drying process is applied to optimise the processibility and 
physico-chemical properties of the spray dried powder (and corresponding tablets) in order to 
achieve a continuous production process of solid dosage forms containing a poorly 
compressible drug substance. In addition, scaling-up of acetaminophen and ibuprofen 
formulations was performed on a production-scale spray dryer and rotary tablet press. 
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2 Materials and methods 
 
2.1 Materials 
 
Two acetaminophen-grades (median particle size: 15 µm (Atabay, Istanbul, Turkey) and 50 
µm (Mallinckrodt Chemical, Hazelwood, USA)), 2 ibuprofen-grades and cimetidine were 
used as model drugs. Micronised acetaminophen, ibuprofen and cimetidine were selected for 
coprocessing on a lab-scale Mobile Minor spray dryer (GEA NIRO, Copenhagen, Denmark), 
while coarser grades of acetaminophen and ibuprofen were used for scaling-up on a 
production-scale SD 28 spray dryer (GEA NIRO, Copenhagen, Denmark). Erythritol 
(C*Eridex 16955) and mannitol (C*Mannidex 16700) were donated by Cerestar (Mechelen, 
Belgium). Maltodextrin (Glucidex® 9) was a gift from Roquette (Lestrem, France). 
Crospovidone (Kollidon® CL) was kindly donated by BASF (Ludwigshafen, Germany). 
Polyoxyethylene 20 sorbitan monooleate (Polysorbate 80) was purchased from Certa (Braine 
L’Alleud, Belgium). Colloidal silicon dioxide (Aerosil® 200) was purchased from Federa 
(Brussels, Belgium). 
 
2.1.1 Ibuprofen 
 
Two ibuprofen-grades (median particle size: 25 µm (Knoll Pharmaceuticals, Nottingham, 
UK) and 50 µm (BASF, Ludwigshafen, Germany)) were purchased. It has an aqueous 
solubility of 0.049 g/l and a melting point of 75-78°C (Martindale, The Extra Pharmacopoeia 
28th Ed.). It is a highly dosed active pharmaceutical ingredient. Ibuprofen is a non-steroidal 
anti-inflammatory drug used to relief inflammation and pain. 
 
2.1.1 Cimetidine 
 
Cimetidine (median particle size: 11 µm) was purchased from Fagron (Waregem, Belgium). It 
has an aqueous solubility of 11 g/l and a melting point of 142°C (Martindale, The Extra 
Pharmacopoeia 28th Ed.). It is a highly dosed active pharmaceutical ingredient. Cimetidine is 
a histamine receptor antagonist and reduces the amount of acid produced by the stomach. It is 
used in the treatment and prevention of certain types of ulcer and gastro-oesophageal reflux. 
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2.2 Methods 
 
2.2.1 Preparation of the spray dried particles 
 
Aqueous suspensions of drug substance (acetaminophen, ibuprofen, cimetidine), mannitol, 
erythritol, maltodextrin (Glucidex® 9), crospovidone (Kollidon® CL), colloidal silicon dioxide 
(Aerosil® 200) and polyoxyethylene 20 sorbitan monooleate (Polysorbate 80) were prepared 
to optimise the drug concentration and the solid content of the feed suspension. The feed 
suspensions were spray dried according to the process conditions shown in Table 1.  
 
Table 1 – Process conditions during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
Process Parameters Acetaminophen Ibuprofen Cimetidine 
Feed Rate (kg/h) 2.9–3.7 0.8–1.1 2.8–3.7 
Inlet Drying Air Temperature (°C)  220 120 220 
Outlet Drying Air Temperature (°C) 80 65 80 
Drying Gas Rate (kg/h) 80 80 80 
Atomising Air Pressure (bar) 6 6 6 
Rotary Atomiser Speed (rpm) 31000 31000 31000 
 
Spray drying of these suspensions was performed in lab-scale Mobile Minor spray dryer 
(GEA NIRO, Copenhagen, Denmark). The dimensions of the drying chamber were 0.84 m 
cylindrical height with a diameter of 0.80 m and 60° conical base. The suspensions were fed 
to a rotary atomiser at the top of the spray dryer by means of a peristaltic pump, type 520U 
(Watson Marlow, Cornwall, UK) and a Marprene® tube (inside diameter: 4.8 mm)(Watson 
Marlow, Cornwall, UK). The spray dryer operated in co-current air flow and the powder is 
collected using a cyclone. 
In addition, aqueous suspensions (total solid content: 35.0% w/w) containing acetaminophen 
and ibuprofen (Table 2) were processed on production-scale SD 28 spray dryer (GEA NIRO, 
Copenhagen, Denmark).  
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Table 2 – Composition of the feed suspension for the coprocessed formulations in a lab-scale 
spray dryer (Mobile Minor, GEA NIRO) and production-scale spray dryer (SD 28, GEA NIRO) 
The ratio between the different components is expressed as a percentage of the total amount of 
solids 
 Mobile Minor SD 28 
 
Acetaminophen, ibuprofen and 
cimetidine formulations 
Acetaminophen Ibuprofen
 
Concentration 
(% of solids content) 
Drug Substance ConcentrationDrug 70.0 75.0
Mannitol  (93 – ConcentrationDrug) * 0.463 10.9 8.6
Erythritol (93 – ConcentrationDrug) * 0.315 7.4 5.8
Maltodextrin (93 – ConcentrationDrug) * 0.221 5.2 4.1
Crospovidone 6.0 6.0 6.0
Colloidal Silicon 
Dioxide 
0.5  
Polysorbate 80 0.5 0.5 0.5
 
In comparison with co-spray drying in a lab-scale spray dryer, coarser drug particles were 
used during scaling-up to obtain maximum flowability and median particle size of the spray 
dried powder and to minimise the loss of non-agglomerated drug particles discharged with the 
drying air. The dimensions of the drying chamber were 1.95 m cylindrical height with a 
diameter of 2.67 m and 60° conical base. In order to improve flowability, density and median 
particle size of the spray dried powder, the feed suspension containing acetaminophen was fed 
to a pressure nozzle (type: SDX, Delavan, Illzach, France, nozzle diameter: 1.0, 1.4, 1.6 mm) 
at the top of the spray dryer by means of a monopump (Netzsch, Waldkraiburg Germany). 
Because of insufficient drying with a pressure nozzle (nozzle diameter: 1.0 mm), the 
ibuprofen formulation was spray dried using a rotary atomiser (type: A-4-150, GEA NIRO, 
Copenhagen, Denmark). The spray dryer operated in co-current air flow and the powder is 
collected at the bottom of the drying chamber. Pneumatic hammers are mounted on the 
cylindrical and conical part of the chamber to remove powder sticking to the chamber wall. 
The spray drying conditions are listed in Table 3 and 4.  
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Table 3 – Process conditions during spray drying of acetaminophen formulations in the SD 28 
spray dryer (GEA NIRO) using a pressure nozzle (type: Delavan SDX) 
 Experiment Number 
Process Parameters 1 2 3 4 5 
Nozzle Diameter (mm) 1.0 1.4 1.6 1.6 1.4 
Nozzle Pressure (bar) 13 14 14 6 6 
Feed Rate (l/h) 46 66 81 60 47 
Drying Gas Rate (kg/h) 2200 2200 2200 2200 2200 
Inlet Drying Air Temperature (°C) 150 170 180 160 155 
Outlet Drying Air Temperature (°C) 104 107 103 102 105 
Residual Moisture Content (%) 0.81 0.67 1.21 6.66 1.69 
 
Table 4 – Process conditions during spray drying of ibuprofen formulations in the SD 28 spray 
dryer (GEA NIRO) using a pressure nozzle (type: Delavan SDX) in test 1 and a rotary atomiser 
(type: A-4-150) in test 2, 3, 4 and 5 
 Experiment Number 
Process Parameters 1 2 3 4 5 
Nozzle Diameter (mm) 1.0 - - - - 
Nozzle Pressure (bar) 13 - - - - 
Rotary Atomiser Speed (rpm) - 20.000 20.000 20.000 15.000 
Feed Rate (l/h) 58 79 79 54 54 
Drying Gas Rate (kg/h) 2200 2200 2200 2200 2200 
Inlet Drying Air Temperature (°C) 140 150 135 115 115 
Outlet Drying Air Temperature (°C) 92 75 66 65 64 
Residual Moisture Content (%) 2.70 0.35 0.56 0.46 0.69 
 
The spray dried powders were cooled down to room temperature and stored (room 
temperature, ambient relative humidity) prior to their characterisation and further use. 
 
2.2.2 Experimental design 
 
Preliminary experiments were carried out to establish appropriate ranges for the solid content 
of the feed suspension and the drug concentration of the spray dried powder (Table 5).  
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Table 5 – Design ranges during spray drying in the Mobile Minor spray dryer (GEA NIRO) 
 Experimental Design Ranges 
Drug 
Solid Content of the Feed 
(% w/w of total feed) 
Drug Concentration 
(% w/w of solid content) 
Acetaminophen 25 – 40 45 – 70 
Ibuprofen 25 – 35 45 – 75 
Cimetidine 25 – 40 45 – 70 
 
The lower limits of the solid content (25% w/w) of the feed and the drug concentration (45% 
w/w) were chosen to obtain a minimum production capacity. The upper limit (35 to 40% w/w) 
of the solid content was selected to avoid pumping problems and blocking of the atomisation 
device due to high viscosity suspensions. Drug concentration of acetaminophen and 
cimetidine formulations was limited to 70% w/w because of low tablet tensile strength and 
high friability at higher drug concentrations, whereas poor powder flowability and low bulk 
density restricted the ibuprofen concentration to 75% w/w. The design runs for the 
acetaminophen, ibuprofen and cimetidine formulations are listed in Table 6.  
A classical central composite design was applied. Because interactions between the variables 
were expected, the following quadratic model was proposed Eq. (1): 
 
Y = β0 + β∑
=
2
1i
iXi + ∑∑ β
= +=
1
1
2
1i ij
ijXiXj + β∑
=
2
1i
iiXi²                                                                (1)
 
where Y is the response, Xi Xj are the set points of the factors ‘i’ and ‘j’, respectively, in the 
mixture and β0, βi, βij and βii are the coefficients. 
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Table 6 – Design runs of the central composite design experiments.  
Run Factors 
 Acetaminophen Ibuprofen 
 A: X1 B: X2 A: X1 B: X2
 Solid Content of the 
Feed 
(% w/w) 
Content of Drug 
Substance 
(% w/w) 
Solid Content of the 
Feed 
(% w/w) 
Content of Drug 
Substance 
(% w/w) 
1 32.5 45.0 26.5 49.4 
2 27.2 66.3 30.0 60.0 
3 37.8 66.3 30.0 60.0 
4 32.5 57.5 30.0 45.0 
5 40.0 57.5 25.0 60.0 
6 37.8 48.7 33.5 70.6 
7 32.5 70.0 35.0 60.0 
8 32.5 57.5 30.0 60.0 
9 32.5 57.5 33.5 49.4 
10 25.0 57.5 30.0 75.0 
11 27.2 48.7 26.5 70.6 
 Cimetidine 
1 37.8 48.7 
2 32.5 45.0 
3 27.2 48.7 
4 25.0 57.5 
5 32.5 57.5 
6 32.5 70.0 
7 37.8 66.3 
8 32.5 57.5 
9 32.5 57.5 
10 27.2 66.3 
11 40.0 57.5 
 
The design points were chosen by the software (Design-Expert version 6.0.10, Stat-Ease Inc., 
Minneapolis, USA). Manual regression was performed. The highest order polynomial, where 
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the additional interaction terms were significant (significance threshold= 0.05), was selected 
without destroying the model hierarchy. Outlier-t limit was set at 3.5. The significant model 
was used for fitting the response. The lack-of-fit test and a normal probability plot of the 
residuals were performed in order to evaluate the model and to detect outliers. The models 
provide several comparative measures for model selection. R² statistics, which give a 
correlation between the experimental response and the predicted response, should be high for 
a particular model to be significant. Adjusted R², which gives a similar correlation after 
ignoring the insignificant model terms, should have good agreement with predicted R² for the 
model to be fit [5].  Predicted and adjusted R-squares should be within 0.20 of each other [6]. 
Contour plots for the response were drawn for determination of the optimal variable settings.  
The different responses were powder flowability, median particle size, bulk density, residual 
moisture content, process yield, tablet tensile strength, disintegration time and friability. 
 
2.2.3 Evaluation of spray dried powders 
 
SEM pictures were recorded according to the methods described in Chapter 1 (2.2.2), while 
the flowability, bulk density and median particle size were measured according to the 
methods described in Chapter 2 (2.2.3). 
The residual moisture content of the spray dried powders was determined via loss-on-drying 
using a Mettler LP16 moisture analyser, including an infrared dryer and a Mettler PM460 
balance (Mettler-Toledo, Zaventem, Belgium). A sample of 1.5 g was dried at 105 
(acetaminophen, cimetidine) or 70°C (ibuprofen) during 15 min. 
The thermal behaviour and X-ray diffraction spectra of the optimised spray dried mixtures 
were investigated using the methods described in Chapter 1 (2.2.2).  
The superdisintegrant concentration (n: 5) in the co-spray dried powders containing 
acetaminophen and ibuprofen produced on a production-scale spray dryer was gravimetrically 
determined via a filtration procedure. A powder sample (1.5 g) containing acetaminophen was 
dispersed in 100 ml demineralised water, while spray dried powder (0.5 g) containing 
ibuprofen was dispersed in 300 ml phosphate buffer KH2PO4 (pH: 7.2). The fraction 
remaining in suspension (representing only the superdisintegrant since all other components 
dissolved in water) was isolated via filtration of the dispersion using glass fiber filters (GF 51, 
Scheicher & Schuell MicroScience, Dassel, Germany). The filters retained particles down to 1 
µm and prior to use these filters were oven-dried (40°C) for 2h. After filtration the glass fiber 
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filters were dried at 40°C for 72h and the amount of superdisintegrant retained by the filters 
was gravimetrically determined. 
 
2.2.4 Tabletting process and evaluation 
 
The powder mixtures produced on a lab-scale spray dryer were compacted on an excentric 
tablet press, Type EKO (Korsch, Berlin, Germany) equipped with 13.5 mm circular edged 
punches (tablet weight: 500 ± 5 mg). The tablet properties were evaluated at a compression 
pressure of 130 (acetaminophen), 86 (ibuprofen) and 120 MPa (cimetidine). The powders 
produced on a production-scale spray dryer were also compacted on an excentric tablet press 
at the same compression pressure to compare their dissolution behaviour. Spray dried 
powders containing cimetidine were blended with 2.0% w/w magnesium stearate for 5 min 
prior to compression in order to avoid lubrication problems. 
The spray dried powders prepared on a production-scale spray dryer were compacted on a 
rotary ModulTM P tablet press (Courtoy, Halle, Belgium) equipped with 7 mm circular convex 
punches (tablet weight: 100 ± 2.5 mg). The powders were compacted according to the process 
conditions shown in Table 7. 
 
Table 7 – Process conditions and tablet properties after tablet manufacturing of acetaminophen 
and ibuprofen spray dried powders on the rotary ModulTM P tablet press (GEA Courtoy) 
Process Parameters Acetaminophen Ibuprofen 
Production Speed (tablets/min) 250 650 
Feeder1 Speed (rpm) 20 60 
Feeder2 Speed (rpm) 30 72 
Fill Depth (mm) 5.04 5.10 
Pre-compression force (kN) 8.97 / 
Main Measured Compression force (kN) 11.05 18.96 
Tablet Properties  
Tablet Tensile Strength (MPa) 1.08 ± 0.14 0.92 ± 0.03 
Tablet Disintegration Time (s) 269 ± 58 376 ± 31 
Tablet Friability (%) 0.85 ± 0.12 0.82 ± 0.08 
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The tablet tensile strength was measured and calculated according to the method described in 
Chapter 1 (2.2.3), while tablet disintegration time was measured according to the methods 
described in Chapter 2 (2.2.4). Tablet friability was tested on 10 (500 ± 5 mg) or 20 (100 ± 
2.5 mg) tablets (n: 3) using a friabilator, Type PTF (Pharma Test, Hainburg, Germany).  
 
2.2.5 In-vitro drug release 
 
The tablets manufactured on the excentric tablet press were introduced in a basket (USP 27, 
dissolution apparatus 1). The dissolution was performed in a VK 7010 dissolution system 
combined with a VK 8000 automatic sampling station (VanKel Industries, New Jersey, USA). 
Demineralised water was used as dissolution medium for formulations containing 
acetaminophen and cimetidine, while dissolution of ibuprofen-containing formulations was 
performed in phosphate buffer KH2PO4 (pH: 7.2). The temperature of the medium (900 ml) 
was kept at 37 ± 0.5°C, while the rotational speed of the baskets was set at 100 rpm. Samples 
of 5 ml were withdrawn at 5, 10, 15, 30, 45, 60, 75, 90, 120 min and spectrophotometrically 
analysed for acetaminophen (243 nm), ibuprofen (221 nm) and cimetidine (219 nm) 
concentration by means of a Perkin-Elmer Lambda 12 UV-VIS double beam 
spectrophotometer (Zaventem, Belgium). The dissolution was simultaneously performed in 6 
dissolution vessels, each vessel containing 1 tablet. 
 
3 Results and discussion 
 
3.1 Co-spray drying on a lab-scale spray dryer  
 
3.1.1 Summary statistics for the models 
 
Since the ability to spray dry a product to a specific residual moisture content at a given outlet 
drying air temperature depends upon the humidity of the air leaving the drying chamber 
(which is the sum of the moisture in the atmospheric air entering the dryer and the amount of 
moisture created during the spray evaporation) daily changes of ambient humidity conditions 
could affect the residual moisture content in the spray dried powder (Table 8, 9, 10) [7]. As a 
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result, the models estimating residual moisture content of spray dried powder mixtures 
containing acetaminophen, ibuprofen and cimetidine were not significant. 
 
Table 8 – Response results (powder flowability: ffc (n: 3, mean ± st.dev.), bulk density (n: 3, 
mean ± st.dev.), residual moisture content, process yield and median particle size (D50 / span)) 
for co-spray dried powders containing acetaminophen 
Run Responses 
 ffc
Bulk Density 
(g/ml) 
Residual 
Moisture Content 
(% w/w) 
Process Yield 
(% w/w) 
Median  
Particle Size 
(µm) 
1 7.93 ± 0.31 0.361 ± 0.002 * 0.69 59.9 42.5 / 2.2 
2 6.30 ± 0.36 0.308 ± 0.004 0.58 76.2 21.6 / 2.3 
3 6.43 ± 0.35 0.303 ± 0.002 0.50 81.3 26.1 / 2.1 
4 6.67 ± 0.21 0.315 ± 0.005 0.54 72.7 30.3 / 2.2 
5 6.80 ± 0.10 0.305 ± 0.001 0.59 69.2 34.9 / 2.1 
6 7.20 ± 1.13 0.319 ± 0.006 0.59 62.5 44.3 / 2.1 
7 5.93 ± 0.06 0.313 ± 0.006 0.40 81.9 20.0 / 2.1 
8 6.73 ± 0.31 0.323 ± 0.006 1.04 75.6 28.6 / 2.1 
9 7.30 ± 0.46 0.320 ± 0.001 0.69 76.6 28.5 / 2.0 
10 6.73 ± 0.06 0.311 ± 0.001 1.14 73.1 24.5 / 2.2 
11 7.03 ± 0.12 0.330 ± 0.005 0.79 62.8 35.0 / 2.4 
*: identified as outlier 
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Table 9 – Response results (powder flowability: ffc (n: 3, mean ± st.dev.), bulk density (n: 3, 
mean ± st.dev.), residual moisture content, process yield and median particle size (D50 / span)) 
for co-spray dried powders containing ibuprofen 
Run Responses 
 ffc
Bulk Density 
(g/ml) 
Residual 
Moisture Content 
(% w/w) 
Process Yield 
(% w/w) 
Median  
Particle Size 
(µm) 
1 7.90 ± 0.70 0.379 ± 0.002 0.68 65.4 29.6 / 3.0 
2 6.73 ± 0.21 0.334 ± 0.002 0.31 69.4 24.5 / 2.5 
3 7.00 ± 0.30 0.338 ± 0.005 0.70 70.2 24.6 / 2.4 
4 7.50 ± 0.30 0.369 ± 0.001 0.50 65.9 32.2 / 2.9 
5 6.43 ± 0.21 0.326 ± 0.002 0.68 64.9 23.8 / 2.5 
6 5.73 ± 0.25 0.296 ± 0.004 0.31 73.2 20.5 / 2.2 
7 6.67 ± 0.78 0.306 ± 0.010 0.42 74.9 25.8 / 2.3 
8 6.90 ± 046 0.310 ± 0.001 0.68 68.8 25.0 / 2.4 
9 7.63 ± 0.12 0.362 ± 0.004 0.63 69.7 32.0 / 2.7 
10 5.73 ± 0.25 0.296 ± 0.003 0.50 70.4 19.6 / 2.2 
11 5.80 ± 0.20 0.306 ± 0.001 0.30 65.9 20.9 / 2.3 
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Table 10 – Response results (powder flowability: ffc (n: 3, mean ± st.dev.), bulk density (n: 3, 
mean ± st.dev.), residual moisture content, process yield and median particle size (D50 / span)) 
for co-spray dried powders containing cimetidine 
Run Responses 
 ffc
Bulk Density 
(g/ml) 
Residual 
Moisture Content 
(% w/w) 
Process Yield 
(% w/w) 
Median  
Particle Size 
(µm) 
1 7.27 ± 0.35 0.309 ± 0.002 0.59 66.1 52.2 / 2.1 
2 7.20 ± 0.40 0.322 ± 0.003 0.91 64.9 55.4 / 2.4 
3 7.23 ± 1.03 0.323 ± 0.001 0.82 60.0 48.4 / 2.4 
4 7.93 ± 0.31 0.316 ± 0.002 0.92 71.3 38.3 / 2.2 
5 7.83 ± 0.57 0.307 ± 0.002 0.57 76.0 40.7 / 2.1 
6 7.07 ± 0.35 0.306 ± 0.005 0.48 82.0 29.4 / 2.2 
7 7.57 ± 0.29 0.317 ± 0.001 0.72 83.5 33.3 / 1.9 * 
8 7.27 ± 0.29 0.297 ± 0.001 0.38 76.1 40.7 / 2.1 
9 7.27 ± 0.87 0.301 ± 0.002 0.32 70.0 40.4 / 2.1 
10 7.10 ± 0.36 0.304 ± 0.007 0.39 79.7 31.2 / 2.2 
11 7.43 ± 0.29 0.295 ± 0.000 0.50 73.3 44.0 / 2.0 
*: identified as outlier 
 
Analysis of variance of the responses (Table 11) indicated that for the optimisation of the 
acetaminophen formulation response surface models developed for powder flowability, 
median particle size, bulk density, process yield, tablet tensile strength, disintegration time 
and friability were significant, without significant lack of fit. Transformation of median 
particle size (logarithmic transformation) was needed because the residuals were a function of 
the magnitude of the predicted values.  
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Table 11 – ANOVA – Influence of solid content of the feed and acetaminophen concentration on 
the response factors 
Response factor Model 
F-value 
Prob>F Lack of Fit 
F-value 
Prob>F 
Flowability 37.46 0.0002 0.38 0.8599 
Median Particle Size (D50) (μm) 266.90 < 0.0001 1.03 0.5681 
Density (g/ml) 14.61 0.0036 0.68 0.6666 
Spray Drying Yield (%) 68.27 < 0.0001 2.02 0.3711 
Tablet Tensile Strength (MPa) 59.64 < 0.0001 0.20 0.9342 
Tablet Disintegration Time (s) 20.88 0.0007 1.50 0.4522 
Tablet Friability (%) 29.52 0.0002 1.15 0.5354 
 St.dev. R² Adjusted R² Predicted R² 
Flowability 0.25 0.8063 0.7847 0.6924 
Median Particle Size (D50) (μm) 0.015 0.9852 0.9815 0.9717 
Density (g/ml) 3.589  
E-003 
0.8796 0.8194 0.6883 
Spray Drying Yield (%) 2.71 0.8835 0.8706 0.8400 
Tablet Tensile Strength (MPa) 0.043 0.9624 0.9462 0.9277 
Tablet Disintegration Time (s) 35.11 0.8392 0.7990 0.6710 
Tablet Friability (%) 0.11 0.8807 0.8508 0.7281 
 
In addition, the model summary statistics for the selected significant models were detailed 
(Table 11). It can be observed that for powder flowability, median particle size, bulk density, 
process yield, tablet tensile strength, disintegration time and friability, R², predicted R² and 
adjusted R² were in good agreement, resulting in reliable models.  
Reliable and adequate regression models (Table 12) were developed for powder flowability, 
median particle size, bulk density and process yield of spray dried powders containing 
ibuprofen. Although the response surface model for tablet disintegration time was significant, 
R², predicted R² and adjusted R² were not in good agreement. Thus, the developed regression 
models for tablet tensile strength (not significant), disintegration time and friability (not 
significant) did not show acceptable statistical measures. Moreover, tablet tensile strength, 
friability and disintegration time of all design runs were within acceptable ranges. (> 1.23 
MPa, < 0.59% and < 15 min, respectively). 
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Table 12 – ANOVA – Influence of solid content of the feed and ibuprofen concentration on the 
response factors 
Response factor Model 
F-value 
Prob>F Lack of Fit 
F-value 
Prob>F 
Flowability 87.18 < 0.0001 3.90 0.2193 
Median Particle Size (D50) (μm) 744.67 < 0.0001 0.43 0.7558 
Density (g/ml) 42.17 0.0001 0.69 0.7029 
Spray Drying Yield (%) 41.45 < 0.0001 2.99 0.2720 
Tablet Disintegration Time (s) 10.28 0.0107 0.93 0.6080 
 St.dev. R² Adjusted R² Predicted R² 
Flowability 0.25 0.9064 0.8960 0.8425 
Median Particle Size (D50) (μm) 0.21 0.9983 0.9970 0.9884 
Density (g/ml) 0.013 0.8241 0.8046 0.7541 
Spray Drying Yield (%) 1.08 0.9120 0.8900 0.8149 
Tablet Disintegration Time (s) 67.06 0.5331 0.4812 0.2514 
 
The median particle size, spray drying yield, tablet tensile strength, disintegration time and 
friability of spray dried powders composed of cimetidine could be modelled, whereas no 
significant relationship was discovered between solid content of the feed suspension and 
cimetidine concentration of the spray dried powder on the one side and flowability index and 
bulk density on the other side (Table 13).  
The tablet tensile strength, disintegration time and friability of the acetaminophen, ibuprofen 
and cimetidine formulations produced on a lab-scale spray dryer were shown in Table 14, 15 
and 16, respectively. 
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Table 13 - ANOVA – Influence of solid content of the feed and cimetidine concentration on the 
response factors 
Response factor Model 
F-value 
Prob>F Lack of Fit 
F-value 
Prob>F 
Median Particle Size (D50) (μm) 1198.10 < 0.0001 8.16 0.1121 
Spray Drying Yield (%) 53.15 < 0.0001 0.64 0.7230 
Tablet Tensile Strength (MPa) 24.24 0.0005 0.83 0.6276 
Tablet Disintegration Time (s) 36.77 < 0.0001 0.48 0.7931 
Tablet Friability (%) 64.77 < 0.0001 2.54 0.3094 
 St.dev. R² Adjusted R² Predicted R² 
Median Particle Size (D50) (μm) 0.42 0.9983 0.9975 0.9920 
Spray Drying Yield (%) 2.97 0.8552 0.8391 0.7743 
Tablet Tensile Strength (MPa) 0.061 0.9122 0.8746 0.7466 
Tablet Disintegration Time (s) 11.40 0.9019 0.8774 0.8195 
Tablet Friability (%) 0.045 0.9418 0.9273 0.8979 
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Table 14 – Response results (tablet tensile strength (n: 10, mean ± st.dev.), tablet disintegration 
time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean ± st.dev.)) for formulations containing 
acetaminophen (compression pressure: 130 MPa) 
Run Responses 
 
Tablet Tensile Strength 
(MPa) 
Tablet Disintegration Time 
(s) 
Tablet Friability 
(%) 
1 1.36 ± 0.12 352 ± 10 0.90 ± 0.01 
2 0.91 ± 0.12 225 ± 4 1.36 ± 0.24 
3 0.89 ± 0.13 195 ± 3 1.21 ± 0.05 
4 1.02 ± 0.12 256 ± 17 0.82 ± 0.07 
5 1.01 ± 0.08 263 ± 19 0.92 ± 0.04 
6 1.12 ± 0.09 337 ± 13 0.76 ± 0.09 
7 0.84 ± 0.03 177 ± 18 1.40 ± 0.15  
8 1.09 ± 0.07 263 ± 18 0.78 ± 0.07 
9 1.15 ± 0.22 311 ± 7 0.63 ± 0.04 
10 1.25 ± 0.20 405 ± 24 0.76 ± 0.05 
11 1.39 ± 0.15 404 ± 13 0.65 ± 0.15 
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Table 15 – Response results (tablet tensile strength (n: 10, mean ± st.dev.), tablet disintegration 
time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean ± st.dev.)) for formulations containing 
ibuprofen (compression pressure: 86 MPa) 
Run Responses 
 
Tablet Tensile Strength 
(MPa) 
Tablet Disintegration Time 
(s) 
Tablet Friability 
(%) 
1 1.45 ± 0.07  854 ± 25 0.53 ± 0.02 
2 1.41 ± 0.16 769 ± 14 0.59 ± 0.06 
3 1.41 ± 0.06 808 ± 44 0.48 ± 0.01 
4 1.49 ± 0.07  703 ± 20 0.56 ± 0.05 
5 1.36 ± 0.18 686 ± 12 0.52 ± 0.02 
6 1.45 ± 0.08 568 ± 20 0.55 ± 0.04 
7 1.32 ± 0.06 662 ± 22 0.46 ± 0.01 
8 1.46 ± 0.07 674 ± 23 0.44 ± 0.11 
9 1.31 ± 0.05 746 ± 19 0.51 ± 0.02 
10 1.23 ± 0.13 563 ± 8 0.47 ± 0.10 
11 1.28 ± 0.19 622 ± 36 0.48 ± 0.02 
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Table 16 – Response results (tablet tensile strength (n: 10, mean ± st.dev.), tablet disintegration 
time (n: 6, mean ± st.dev.) and tablet friability (n: 3, mean ± st.dev.)) for formulations containing 
cimetidine (compression pressure: 120 MPa) 
Run Responses 
 
Tablet Tensile Strength 
(MPa) 
Tablet Disintegration Time 
(s) 
Tablet Friability 
(%) 
1 1.45 ± 0.19 357 ± 3 0.52 ± 0.03 
2 1.73 ± 0.10 375 ± 7 0.47 ± 0.04  
3 1.80 ± 0.08 370 ± 6 0.50 ± 0.05 
4 1.77 ± 0.09 362 ± 10 0.64 ± 0.08 
5 1.64 ± 0.08 348 ± 5 0.62 ± 0.04 
6 1.32 ± 0.16 281 ± 14 0.95 ± 0.08 
7 1.41 ± 0.04 280 ± 10 0.81 ± 0.05 
8 1.58 ± 0.13 327 ± 16 0.60 ± 0.05 
9 1.51 ± 0.17 320 ± 9 0.56 ± 0.03 
10 1.41 ± 0.07 330 ± 6 0.93 ± 0.07 
11 1.35 ± 0.07 323 ± 5 0.67 ± 0.03 
 
3.1.2 Combined effect of solid content of the feed and drug concentration 
 
The prediction equations of the developed response surface models in function of the solid 
content of the feed suspension and the drug (acetaminophen, ibuprofen, cimetidine) 
concentration are mentioned in Table 17, while the corresponding contour plots are given in 
Fig. 1–9. 
At a constant solid content of the feed suspension, the median particle size of the spray dried 
powders was negatively affected by the acetaminophen concentration (e.g. run 2 versus 11 
and run 3 versus 6 at a solid content of the feed of 27.2 and 37.8% w/w, respectively)(Table 
8) as there is less mannitol and maltodextrin available in the formulation to agglomerate the 
suspended acetaminophen particles. At a constant acetaminophen concentration, the median 
particle size increased with the solid content of the feed suspension (e.g. run 10, 8 and 5 at a 
solid content of the feed suspension of 25.0, 32.5 and 40.0% w/w, respectively) due to the 
larger volume occupied by the solid fraction, resulting in more particle collisions and 
agglomeration. In addition, a higher solid content of the feed suspension increased the 
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viscosity of the feed, forming larger droplets. Identical observations were made for ibuprofen 
and cimetidine formulations (Table 9, 10). Similarly, in Chapter 4 a higher median particle 
size was measured at higher solid content of the feed suspension, while the production of 
tomato powder from tomato paste showed an increased median particle size at increasing 
solid content of the feed suspension [8]. 
 
Table 17 – Prediction equations in terms of coded factors for reliable and adequate regression 
models (A: solid content of the feed suspension, B: drug concentration) 
Acetaminophen 
Flowability = 6.82 – 0.54 * B                                                                                                          
Log10(Median Particle Size (D50)) = 1.47 + 0.05 * A – 0.11 * B                                                   
Density = 0.32 – 3.061E-003 * A – 8.180E-003 * B – 6.224E-003 * A²                                        
Spray Drying Yield = 71.98 + 7.92 * B                                                                                           
Tablet Tensile Strength = 1.09 – 0.08 * A – 0.18 * B + 0.06 * AB                                               
Tablet Disintegration Time = 290 – 37 * A – 71 * B                                                                     
Tablet Friability = 0.79 + 0.23 * B + 0.19 * B²                                                                               
Ibuprofen 
Flowability = 6.73 – 0.81 * B                                                                                                          
Median Particle Size (D50) = 24.74 + 0.61 * A – 5.04 * B + 1.00 * B² – 0.71 *AB                       
Density = 0.33 – 0.03 * B                                                                                                               
Spray Drying Yield = 68.98 + 3.22 * A + 1.30 * B                                                                        
Cimetidine 
Median Particle Size (D50) = 40.81 + 1.90 * A – 8.95 * B + 0.79 * B²                                           
Spray Drying Yield = 72.99 + 7.66 * B                                                                                          
Tablet Tensile Strength = 1.54 – 0.12 * A – 0.13 * B + 0.087 * AB                                              
Tablet Disintegration Time = 334 – 15 * A – 31 * B                                                                     
Tablet Friability = 0.62 + 0.17 * B + 0.051 * B²                                                                            
 
Formulations with a high acetaminophen concentration resulted in a lower bulk density of the 
spray dried powder, probably caused by the large fraction of non-agglomerated 
acetaminophen particles having a low bulk density (ρpure micronised acetaminophen: 0.228 g/ml) due to 
their cohesive and fluffy nature. Although an increasing solid content of the feed normally 
results in a higher bulk density [8], the specific quadratic relationship between solid content 
CHAPTER 5 
150
COPROCESSING VIA SPRAY DRYING AS A FORMULATION PLATFORM TO IMPROVE THE COMPACTABILITY OF VARIOUS 
DRUGS 
 
 
of the feed suspension and bulk density (Table 17) resulted in an optimal bulk density (ρ: 
0.321 g/ml) at a solid content of 31.2% w/w (e.g. run 10, 5 versus run 4, 8, 9 at an 
acetaminophen concentration of 57.5% w/w)(Table 8). At higher solid content of the feed 
suspension, the fraction solid material remaining in suspension (mainly the acetaminophen 
particles since mannitol, erythritol and maltodextrin dissolved in water) was higher, yielding 
more non-agglomerated acetaminophen particles and resulting in a lower bulk density. In 
contrast to acetaminophen-containing particles, the bulk density of ibuprofen formulations 
only depended on the drug concentration (Table 9). 
 
 
Fig. 1. Influence of solid content of the feed suspension and acetaminophen concentration on 
density 
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Fig. 2. Influence of solid content of the feed suspension and acetaminophen concentration on 
median particle size 
 
 
Fig. 3. Influence of solid content of the feed suspension and acetaminophen concentration on 
tablet tensile strength 
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Fig. 4. Influence of solid content of the feed suspension and acetaminophen concentration on 
tablet disintegration time 
 
 
Fig. 5. Influence of solid content of the feed suspension and ibuprofen concentration on median 
particle size 
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Fig. 6. Influence of solid content of the feed suspension and ibuprofen concentration on process 
yield 
 
 
Fig. 7. Influence of solid content of the feed suspension and cimetidine concentration on median 
particle size 
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Fig. 8. Influence of solid content of the feed suspension and cimetidine concentration on tablet 
tensile strength 
 
 
Fig. 9. Influence of solid content of the feed suspension and cimetidine concentration on tablet 
disintegration time 
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At a constant solid content of the feed suspension, runs 1, 11 with a low acetaminophen 
concentration (45.0 and 48.7% w/w, respectively) had a significantly higher tablet tensile 
strength and disintegration time compared with highly dosed formulations (70.0% w/w for 
run 7 and 66.3% w/w for run 2)(Table 14). At higher acetaminophen concentration, less 
binder (mannitol, maltodextrin) is available and weaker tablets are produced because of the 
poor compactability of acetaminophen. In addition, the solid content of the feed decreased 
tablet tensile strength and disintegration time (e.g. run 10, 8 and 5 at a solid concentration of 
25.0, 32.5 and 40.0% w/w, respectively). Similarly, Chapter 4 stated a lower tablet tensile 
strength and disintegration time at higher solid content of the feed suspension. Identical 
observations were made for the cimetidine formulation (Table 16), while tablet tensile 
strength and disintegration time of ibuprofen formulations were independent of the solid 
content of the feed suspension and drug concentration.  
 
3.1.3 Effect of drug concentration 
 
The prediction equations for the developed response surface models in function of the drug 
(acetaminophen, ibuprofen, cimetidine) concentration are mentioned in Table 17, while the 
corresponding contour plots are given in Fig. 10–16. 
Formulations containing a high acetaminophen content (66.3% w/w for runs 2, 3 and 70% 
w/w for run 7) had a significantly higher process yield and tablet friability compared to 
compositions containing less drug substance (45% w/w for run 1 and 48.7% w/w for run 6, 
11)(Table 8, 14), while the solid content of the feed suspension had no significant influence 
on the process yield and tablet friability. At higher acetaminophen concentration the fraction 
solid material remaining in suspension (mainly drug substance since mannitol, erythritol and 
maltodextrin dissolved in water) increased and because it is easier to achieve moisture 
removal from suspensions-type droplets than solution-type droplets (especially when the latter 
involves diffusion-limited film-forming characteristics at the surface [7]), process yield 
improved. In addition, tablet friability increased at higher acetaminophen concentration: the 
lower content of binding material (mannitol, maltodextrin) weakened the tablets. Similar 
observations were made for cimetidine formulations (Table 9, 15). The process yield of 
ibuprofen formulations was also determined by the solid content of the feed suspension.  
Runs 2, 3, 7 with a high acetaminophen concentration (66.3–70.0% w/w) had a significantly 
lower flowability index compared with low dosed formulations (48.7% w/w for runs 6, 11 and 
45% w/w for run 1)(Table 8). The solid content of the feed had no influence on the 
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flowability index. Since a higher drug concentration resulted in smaller spray dried particles 
having a lower bulk density, the flowability index was negatively influenced. Similar 
observations were made for ibuprofen formulations (Table 9). 
 
 
Fig. 10. Influence of acetaminophen concentration on flowability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
157
COPROCESSING VIA SPRAY DRYING AS A FORMULATION PLATFORM TO IMPROVE THE COMPACTABILITY OF VARIOUS 
DRUGS 
 
 
 
Fig. 11. Influence of acetaminophen concentration on process yield 
 
 
Fig. 12. Influence of acetaminophen concentration on tablet friability 
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Fig. 13. Influence of ibuprofen concentration on flowability 
 
 
Fig. 14. Influence of ibuprofen concentration on density 
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Fig. 15. Influence of cimetidine concentration on process yield 
 
 
Fig. 16. Influence of cimetidine concentration on tablet friability 
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3.2 Co-spray drying on a production-scale spray dryer 
 
3.2.1 Scaling-up of acetaminophen formulation 
 
Numerical optimisation was performed using statistical models (Table 17) to find the optimal 
solid content of the feed suspension (35.0% w/w) and drug concentration (70% w/w) for 
coprocessing on a production-scale spray dryer. Different experimental conditions were 
studied (Table 3). Spray dried powder produced using experiment 2 (nozzle diameter: 1.4 
mm, inlet drying air temperature: 170°C, outlet drying air temperature: 107°C) was selected 
for further characterisation and tablet production, because of its excellent median particle size 
(203 µm), powder flowability (ffc: 11.67 ± 0.58) and bulk density (ρbulk: 0.464 ± 0.006 g/ml) 
without the formation of deposits on the surface inside the drying chamber. Co-spray drying 
using a 1.0 mm pressure nozzle (experiment 1) resulted in a powder mixture with a median 
particle size of 176 µm because of the lower feed rate yielding smaller droplets which dried 
too fast to allow particle agglomeration. Although the median particle size increased up to 
239 (experiment 3), 243 (experiment 4) and 264 µm (experiment 5), deposits were formed on 
the surface of the drying chamber because of the larger diameter of nozzle and/or the low 
nozzle pressure. 
During tablet production on a rotary ModulTM P tablet press, different process conditions 
(production speed, feeder speed, pre-compression and compression force) were tested, 
resulting in an optimised tablet production process using a pre-compression force of 8.97 kN 
(Table 7). Tablet tensile strength, disintegration time and friability were within acceptable 
ranges: 1.08 ± 0.14 MPa, 269 ± 58 s, 0.85 ± 0.12 %, respectively (Table 7). 
 
3.2.2 Scaling-up of ibuprofen formulation 
 
Similarly to acetaminophen, numerical optimisation was performed using statistical models 
(Table 17) to find the optimal solid content of the feed suspension (35.0% w/w) and drug 
concentration (75% w/w) for coprocessing on a production-scale spray dryer. Different sets of 
experimental conditions were studied (Table 4). During experiment 1 the concentrated feed 
was fed to a pressure nozzle (nozzle diameter: 1 mm), but no powder was collected due to 
extensive material deposition on the surface of the drying chamber. Therefore, a rotary 
atomiser (speed: 15000–20000 rpm) was used for further experiments. Agglomerated powder 
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manufactured using experiment 2 was selected for further characterisation and tablet 
production due to its excellent powder flowability (ffc: 9.27 ± 0.78) and high bulk density 
(ρbulk: 0.391 ± 0.004 g/ml). Reducing the drying temperatures (experiments 3 and 4) to 136–
115°C and 66–65°C resulted in smaller spray dried particles (median particle size: ± 100 µm). 
A reduction of the rotary atomiser speed to 15000 rpm (experiment 5) increased the median 
particle size (120 µm). Nevertheless, spray dried powders produced using process parameters 
in test 3, 4 and 5 showed poor powder flowability. 
During tablet production on a rotary ModulTM P tablet press, different process conditions 
(production speed, feeder speed, pre-compression and compression force) were tested, 
resulting in an optimised tablet production process shown in Table 7. Tablet tensile strength, 
disintegration time and friability were within acceptable ranges: 0.92 ± 0.03 MPa, 376 ± 31 s, 
0.82 ± 0.08 %, respectively (Table 7). 
 
3.3 Physico-chemical properties of the optimised formulations 
 
 
Fig. 17. SEM picture of acetaminophen formulation (total solid content of the feed suspension: 
35% w/w, drug concentration: 70% w/w) 
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SEM pictures of the powder mixtures containing acetaminophen (Fig. 17) and ibuprofen (Fig. 
18) processed on a production-scale spray dryer using optimal process conditions showed 
spherical agglomerates containing acetaminophen, while the ibuprofen formulation resulted in 
irregular agglomerates. 
 
 
Fig. 18. SEM picture of ibuprofen formulation (total solid content of the feed suspension: 35% 
w/w, drug concentration: 75% w/w) 
 
After lab-scale production of powder mixtures containing cimetidine, SEM pictures (Fig. 19) 
showed irregular agglomerates with a lower powder flowability (ffc: 7.07 ± 0.35) and bulk 
density (ρbulk: 0.306 ± 0.005 g/ml) compared with acetaminophen- and ibuprofen-
formulations, mainly caused by the lower median particle size and manufacturing on a lab-
scale spray dryer of the cimetidine formulation. 
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Fig. 19. SEM picture of cimetidine formulation (total solid content of the feed suspension: 35% 
w/w, drug concentration: 70% w/w) 
 
Modulated DSC experiments of the optimised spray dried mixtures identified crystalline drug 
substance (acetaminophen, ibuprofen, cimetidine), mannitol and erythritol. 
In addition, Fig. 20 showed the X-ray diffraction spectra of selected spray dried powders 
containing acetaminophen (top), ibuprofen (middle) and cimetidine (bottom). 
Acetaminophen, ibuprofen and cimetidine in the spray dried powder mixture were of 
crystalline nature as sharp peaks were observed in the diffraction pattern. Erythritol and 
mannitol were crystalline as identified by their prominent peaks in the diffraction spectra, 
while maltodextrin was amorphous. 
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Fig. 20. X-ray diffraction pattern of optimal acetaminophen (top), ibuprofen (middle) and 
cimetidine (bottom) formulation 
 
Dissolution results (Fig. 21) on tablets produced from the acetaminophen and ibuprofen 
powder mixtures manufactured on a lab-scale and production-scale spray dryer were 
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compared. Tablets containing spray dried particles produced on a production-scale spray 
dryer had a faster drug dissolution caused by a faster tablet disintegration. In Chapter 3 loss of 
superdisintegrant during coprocessing was reported on a lab-scale spray dryer: compared to 
its initial content in the feed suspension 20 to 77% w/w disintegrant was lost due to deposition 
of insufficiently dried particles on the inner surface of the spray dryer. In contrast, the larger 
dimensions of the production-scale spray dryer allowed sufficient drying and the 
crospovidone concentration in the spray dried particles averaged 6.12 ± 0.04 % w/w and 6.07 
± 0.07 % w/w for acetaminophen and ibuprofen formulations, respectively (theoretical 
disintegrant concentration: 6.0% w/w). The dissolution profiles of acetaminophen- and 
ibuprofen-containing tablets complied with the requirements of the U.S. Pharmacopoeia, i.e. 
more than 80% acetaminophen and ibuprofen released after 30 and 60 min, respectively. 
Dissolution profiles of the optimised cimetidine formulation produced on a lab-scale spray 
dryer showed a complete release within 15 min.  
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Fig. 21. Dissolution of acetaminophen- (top), ibuprofen- (middle) and cimetidine- (bottom) 
containing tablets produced on a lab scale (……) and production scale (______) spray dryer. 
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4 Conclusions 
 
A combination of mannitol, erythritol, Glucidex® 9, Kollidon® CL, colloidal silicon dioxide 
and polyoxyethylene 20 sorbitan monooleate was successful in improving the compactability 
of drug substances such as acetaminophen, ibuprofen and cimetidine via continuous co-spray 
drying. A highly dosed cimetidine formulation (drug concentration: 70% w/w) was produced 
on lab-scale equipment, while powder mixtures composed of acetaminophen (drug 
concentration: 70% w/w) and ibuprofen (drug concentration: 75% w/w) were successfully 
manufactured on a production-scale spray dryer. Direct compression of these ‘ready-to-
compress’ powder mixtures containing acetaminophen and ibuprofen was performed without 
granulation, milling and/or blending steps in between spray drying and compaction, resulting 
in a fully continuous manufacturing process. 
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Coprocessing via spray drying was developed as an alternative manufacturing technique to 
improve the compactability of highly dosed and poorly compressible drug substances. In 
contrast to (wet) granulation techniques, this production process is fully continuous and 
requires no intermediate milling or blending steps in between particle formation and 
compression. Coprocessing via spray drying of drug substance, carbohydrates (erythritol, 
maltodextrin, mannitol), superdisintegrant (crospovidone), glidant (colloidal silicon dioxide) 
and surfactant (polyoxyethylene 20 sorbitan monooleate) was feasible to improve the 
processibility, hygroscopicity, flowability and compactability of powders in comparison with 
physical mixtures of the different components. 
Using the newly developed coprocessing technique the number of process steps is reduced, 
production efficiency is improved and costs are cut to increase profit. In addition, continuous 
manufacturing reduces the time-to-market (scale-up benefits, better quality), capital 
investment, labour costs, floor space and wastage. These features of coprocessing via spray 
drying offer many obvious economic benefits for a pharmaceutical production facility. 
Some drawbacks of the newly developed manufacturing technique are: 
- the developed formulation platform consisted of a two-step process (co-spray drying 
and compaction) for acetaminophen and ibuprofen formulations, but in the case of 
cimetidine an additional blending step with magnesium stearate needed to be 
incorporated in order to avoid lubrication problems during compaction. 
- no relationship between the physico-chemical properties of the tested drug substances 
and the properties of the spray dried particles has been established. Although such a 
correlation would increase the value of this manufacturing platform, the number of 
drug substances tested so far is too limited and this work must be extended before 
such a relationship can be defined. 
 
CHAPTER 1 described a detailed screening of the coprocessing of acetaminophen with a 
wide range of water soluble filler/binders (erythritol, isomalt, lactitol, lactose, maltitol, 
maltodextrin, mannitol, sorbitol and xylitol). Coprocessing via spray drying was performed to 
prepare binary and ternary powder mixtures containing acetaminophen and carbohydrates in 
order to improve the drug compactability. Acetaminophen was used as model drug because of 
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its poor compactability, capping and lamination problems. Evaluation was based on 
processibility, powder hygroscopicity, flowability, compactability and Heckel analysis. 
Erythritol, maltodextrin and mannitol yielded non-sticky powders after co-spray drying with 
acetaminophen in combination with excellent process yields, whereas coprocessing of 
acetaminophen with isomalt, lactitol, maltitol, sorbitol and xylitol resulted in several process 
problems: vitrification (sorbitol), blocking of pipings and cyclone (isomalt), low process 
yields due to their gummy-like and thermoplastic nature (lactitol, maltitol, xylitol). 
Maltodextrin and mannitol improved compactability, while erythritol increased powder 
flowability and density. Thus, a combination of erythritol, maltodextrin and mannitol was 
selected for further formulation optimisation and process development. 
 
CHAPTER 2 reported the use of experimental design to optimise the ratio of the selected 
excipients (erythritol, maltodextrin, mannitol) in a 4-component powder mixture (containing 
acetaminophen) produced via co-spray drying. Evaluation was based on spray drying process 
yield, residual moisture content, powder flowability, density, hygroscopicity, median particle 
size and compactability. Significant models were constructed for powder flowability, median 
particle size, density, hygroscopicity, tablet tensile strength, friability and disintegration time. 
Changes in maltodextrin content strongly influenced median particle size, density, 
hygroscopicity and tablet properties, while the erythritol and mannitol concentration had less 
influence on the physico-chemical properties of the spray dried powder mixtures and tablets. 
Consequently, an optimised formulation was selected for further development and process 
optimisation. A combination of mannitol, erythritol and maltodextrin was suitable to improve 
the tablet properties of acetaminophen. Numerical optimisation was applied to determine the 
optimal contents of mannitol (11.6% w/w), erythritol (20.9% w/w) and maltodextrin (13.9% 
w/w). 
 
In CHAPTER 3 different maltodextrin grades were studied with special focus on the 
influence of amylose/amylopectin ratio on tablet properties. In addition, the effect of 
superdisintegrant type and grade (croscarmellose sodium (Ac-Di-Sol®), sodium starch 
glycolate (Explotab®), crospovidone (Kollidon® CL, Kollidon® CL-M, Polyplasdone® XL, 
Polyplasdone® XL-10) on powder and tablet properties was investigated. The 
amylose/amylopectin ratio had a strong influence on the tablet tensile strength, disintegration 
time and friability. Tablet tensile strength and friability of formulations containing Glucidex® 
2 (1–5% amylose) and 9 (20% amylose) were similar. However, the high amylose 
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maltodextrin (Unipure DC, 50–70 amylose) lowered tablet tensile strength, whereas friability 
was increased. The higher the amylose/amylopectin ratio, the lower the tablet disintegration 
time. Thus, Glucidex® 9 was selected as optimal maltodextrin grade because of improved 
tablet disintegration time compared to Glucidex® 2 and lower tablet friability in comparison 
with Unipure DC. Co-spray drying of acetaminophen, carbohydrates and a superdisintegrant 
in a lab-scale spray dryer yielded powders with a significant loss of superdisintegrant due to 
preferential deposition of the disintegrant on the wall of drying chamber during processing. 
Croscarmellose sodium and sodium starch glycolate were less effective for tablet 
disintegration than crospovidone, probably their swelling formed a gel which blocked tablet 
pores and prevented further penetration of water into the inner layers of the tablet. 
Crospovidone did not form a gel which retarded disintegration and dissolution. Kollidon® CL 
minimised tablet disintegration time in comparison with other crospovidone grades because of 
its excellent wicking and swelling properties due to its larger particle size and high porosity. 
 
In CHAPTER 4 the optimisation of the co-spray drying process was described. A 
combination of acetaminophen, mannitol, erythritol, maltodextrin (Glucidex® 9), 
crospovidone (Kollidon® CL), colloidal silicon dioxide and polyoxyethylene 20 sorbitan 
monooleate was selected for process optimisation (solid content of the feed suspension, 
atomisation pressure, inlet and outlet drying air temperature) of ‘ready-to-compress’ co-spray 
dried powders intended for direct compression. Colloidal silicon dioxide was used as yield-
increasing agent, while polyoxyethylene 20 sorbitan monooleate was included to improve the 
quality of the feed suspension used for co-spray drying in case of highly dosed poorly water 
soluble drug substance (preventing agglomeration of suspended particles and sticking to the 
container surface) and to decrease tablet disintegration time. Significant models were 
constructed for powder flowability, median particle size, density, residual moisture content 
and spray drying process yield. Atomisation pressure only influenced the powder flowability, 
while tablet tensile strength, disintegration time and friability were robust and independent of 
the process conditions. An optimised spray drying process with an atomisation pressure of 6 
bar and an inlet and outlet drying air temperature of 221 and 81°C, respectively, was selected 
for further scale-up trials. 
 
CHAPTER 5 evaluated if coprocessing via spray drying could be used as a formulation 
platform to improve the compactability of various drugs. Formulations containing 
acetaminophen, ibuprofen and cimetidine were produced on a lab-scale spray dryer, while the 
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optimised acetaminophen and ibuprofen formulations were scaled-up on a production-scale 
spray dryer. In addition, drug concentration and solid content of the feed suspension were 
optimised. These highly dosed acetaminophen (drug load: 70% w/w), ibuprofen (drug load: 
75% w/w) and cimetidine (drug load: 70% w/w) directly compressible powders were 
produced by co-spray drying aqueous suspensions with a solid content of 35% w/w and the 
resulting powders were directly compressed. Scaling-up of optimised acetaminophen and 
ibuprofen formulations on a production-scale spray dryer and rotary tablet press was 
performed, resulting in a fully continuous manufacturing process. During tablet production on 
a rotary ModulTM P tablet press, tablet tensile strength, disintegration time and friability of 
acetaminophen and ibuprofen formulations were within acceptable ranges. 
 
Based on the work performed during this project a number of topics can be identified for 
future research dealing with coprocessing via spray drying and the improvement of drug 
compactability: 
- although a fully continuous manufacturing process without intermediate milling or 
blending steps was developed for acetaminophen and ibuprofen formulations (Chapter 
5), process problems due to insufficient lubrication can occur when incorporating 
other drug substances. A future challenge is to immediately incorporate a lubricant 
during coprocessing of drug and excipients, effectively improving the lubrication of 
the directly compressible coprocessed powder mixtures without an additional blending 
step. During preliminary work we already incorporated a lubricant (Mg-stearate) in the 
feed suspension. However, the amount of magnesium stearate at the surface of the 
spray dried particles was insufficient to have efficient lubrication. This problem can 
possibly be overcome by adding the lubricant to the system after the spray dried 
particles have been formed (e.g. by continuously nebulisation of magnesium stearate 
powder in the piping before the cyclone or in a horizontal fluid-bed dryer connected to 
the cyclone), thus coating the particles with a layer of lubricant particles. 
- besides the use of polyols and maltodextrin, excipients such as starch, (silicified) 
microcrystalline cellulose, dicalcium phosphate, hydroxypropylmethylcellulose, 
hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, ethylcellulose, 
polyvinylpyrrolidone and its copolymers and polyethylene glycol could be evaluated 
on their ability to improve the compactability of drugs via coprocessing. 
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- the development of a similar formulation platform for poorly water soluble drug 
substances based on organic solutions/suspensions in order to prepare ‘ready-to-
compress’ solid dispersions and to improve drug dissolution and bioavailability. 
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‘Coprocessing’ door middel van sproeidrogen werd ontwikkeld als een alternatieve 
productietechniek om de compacteerbaarheid van hoog gedoseerde en slecht comprimeerbare 
geneesmiddelen te verhogen. In tegenstelling tot (natte) granulatietechnieken is een dergelijk 
productieproces volledig continu. Er zijn geen additionele maal- of mengstappen vereist 
tussen deeltjesvorming en compressie. Door middel van cosproeidrogen van een 
geneesmiddel met koolhydraten (erythritol, maltodextrine, mannitol), superdesintegrant 
(crospovidone), glijmiddel (colloïdaal silicium dioxide) en surfactant (polyoxyethyleen 20 
sorbitan monooleaat) verbeterde de produceerbaarheid, hygroscopiciteit, vloeibaarheid en 
compacteerbaarheid van de geproduceerde poeders voor directe compressie in vergelijking 
met de individuele componenten. 
Door gebruik te maken van de nieuw ontwikkelde productietechniek werd het aantal 
processtappen gereduceerd en de productie-efficiëntie verbeterd. Tevens worden de 
productiekosten verminderd zodat de winst verhoogt. Daarenboven reduceert continue 
productie de ‘time-to-market’ (voordelen bij opschalen, betere kwaliteit), 
kapitaalinvesteringen, werkingskosten, vereist oppervlak en productverlies. Deze kenmerken 
van ‘coprocessing’ via sproeidrogen leveren talrijke duidelijke economische voordelen op 
voor een farmaceutische productiefaciliteit. 
Enkele gebreken van de nieuw ontwikkelde productietechniek zijn: 
- het ontwikkeld formulatieplatform bestaat uit een 2-staps proces (cosproeidrogen en 
compactie) voor acetaminophen- en ibuprofen-formulaties, maar in het geval van 
cimetidine is een bijkomende mengstap met magnesium stearaat vereist om 
smeringsproblemen tijdens compactie te voorkomen. 
- er kon geen relatie vastgesteld worden tussen de fysico-chemische eigenschappen van 
de geteste geneesmiddelen en de eigenschappen van de gesproeidroogde deeltjes. 
Alhoewel een dergelijke correlatie de waarde van dit productieplatform zou verhogen, 
is het aantal geteste geneesmiddelen te beperkt en zou dit werk moeten uitgebreid 
worden om een dergelijk relatie te definiëren. 
 
HOOFDSTUK 1 beschreef een gedetailleerd onderzoek betreffende ‘coprocessing’ van 
acetaminophen met water oplosbare vul- en/of bindmiddelen (erythritol, isomalt, lactitol, 
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lactose, maltitol, maltodextrine, mannitol, sorbitol and xylitol). Binaire en ternaire 
poedermengsels van acetaminophen en koolhydraten werden bereid door middel van 
‘coprocessing’ via sproeidrogen met als doel de compacteerbaarheid van het geneesmiddel te 
verbeteren. Acetaminophen werd gekozen als modelgeneesmiddel omwille van zijn beperkte 
compacteerbaarheid, ‘capping’ en ‘laminatie’ problemen. De produceerbaarheid, 
hygroscopiciteit, vloeibaarheid, compacteerbaarheid werden geëvalueerd. Erythritol, 
maltodextrine en mannitol resulteerden in niet-kleverige poeders na cosproeidrogen met 
acetaminophen in combinatie met uitstekende procesopbrengsten. ‘Coprocessing’ van 
acetaminophen met isomalt, lactitol, maltitol, sorbitol and xylitol bracht verscheidene 
procesproblemen met zich mee: vitrificatie (sorbitol), blokkeren van buizen en cycloon 
(isomalt), lage procesopbrengsten vanwege hun gomachtige en thermoplastische aard 
(lactitol, maltitol, xylitol). Maltodextrine en mannitol verbeterde de compacteerbaarheid, 
terwijl erythritol de vloeibaarheid en densiteit verhoogde. Bijgevolg werd een combinatie van 
erythritol, maltodextrine en mannitol geselecteerd voor bijkomende formulatie-optimalisatie 
en procesontwikkeling. 
 
HOOFSTUK 2 vermeldde het gebruik van ‘experimental design’ om de verhouding van de 
geselecteerde excipiënten (erythritol, maltodextrin, mannitol) in een 4-componenten 
poedermengsel (bevattende acetaminophen) te optimaliseren. De procesopbrengst, 
vochtgehalte, vloeibaarheid, densiteit, hygroscopiciteit, gemiddelde deeltjesgrootte en 
compacteerbaarheid werden geëvalueerd. Significante modellen voor vloeibaarheid, 
gemiddelde deeltjesgrootte, densiteit, hygroscopiciteit, tabletsterkte, -friabiliteit en -desinte-
gratietijd werden opgebouwd. Concentratieveranderingen van maltodextrine beïnvloedden 
sterk de gemiddelde deeltjesgrootte, densiteit, hygroscopiciteit en tableteigenschappen, terwijl 
de concentratie van erythritol en mannitol minder invloed had op de fysico-chemische 
eigenschappen van de gesproeidroogde poedermengsels en tabletten. Bijgevolg werd een 
optimale formulatie geselecteerd voor verdere ontwikkeling en procesoptimalisatie. Een 
combinatie van mannitol, erythritol en maltodextrine was geschikt om de tableteigenschappen 
van acetaminophen te verbeteren. Numerieke optimalisatie werd aangewend om de optimale 
gehaltes aan mannitol (11.6% w/w), erythritol (20.9% w/w) en maltodextrine (13.9% w/w) te 
bepalen. 
 
In HOOFDSTUK 3 werden 3 verschillende maltodextrine types bestudeerd met speciale 
aandacht voor de invloed van de amylose/amylopectine verhouding op de 
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tableteigenschappen. Daarenboven werd het effect van de klasse en het type superdesintegrant 
(vernet carboxymethylcellulose (Ac-Di-Sol®), vernet carboxymethylzetmeel (Explotab®), 
vernet polyvinylpyrrolidone (Kollidon® CL, Kollidon® CL-M, Polyplasdone® XL, 
Polyplasdone® XL-10)) op de poeder- en tableteigenschappen onderzocht. De 
amylose/amylopectine verhouding had een sterke invloed op de tabletsterkte, -desinte-
gratietijd en -friabiliteit. De tabletsterkte en -friabiliteit van formulaties met Glucidex® 2 (1–
5% amylose) en 9 (20% amylose) waren vergelijkbaar. De maltodextrine met een hoog 
amylose gehalte (Unipure DC, 50–70 amylose) verlaagde de tabletsterkte, terwijl de tablet 
friabiliteit werd verhoogd. Hoe hoger de amylose/amylopectine verhouding, des te lager de 
tabletdesintegratietijd. Bijgevolg werd Glucidex® 9 geselecteerd als optimaal maltodextrine 
type omwille van een verbetering van de desintegratietijd in vergelijking met Glucidex® 2 en 
een lagere tabletfriabiliteit in vergelijking met Unipure DC. Cosproeidrogen van 
acetaminophen, koolhydraten en een superdesintegrant in een laboschaal sproeidroger 
resulteerde in poeders met een significant verlies aan superdesintegrant omwille van 
preferentiële afzetting van desintegrant op de wanden van de droogkamer tijdens productie. 
Vernet carboxymethylcellulose en vernet carboxymethylzetmeel waren minder effectief in 
tabletdesintegratie dan vernet polyvinylpyrrolidone. Vermoedelijk vormde hun zwelling een 
gel, welke de tabletporiën blokkeerde, en alzo een verdere penetratie van water voorkwam in 
diepere tabletlagen. Vernet polyvinylpyrrolidone vormde geen gel waardoor het desintegreren 
en oplossen vertraagde. Kollidon® CL minimaliseerde de tabletdesintegratie in vergelijking 
met andere polyvinylpyrrolidone types omwille van zijn uitstekende ‘wicking’ en 
zwellingseigenschappen vanwege zijn grotere deeltjesgrootte en hoge porositeit. 
 
In HOOFDSTUK 4 werd de optimalisatie van het sproeidroogproces beschreven. Een 
combinatie van acetaminophen, mannitol, erythritol, maltodextrine (Glucidex® 9), vernet 
polyvinylpyrrolidone (Kollidon® CL), colloïdale silicium dioxide en polyoxyethyleen 20 
sorbitan monooleaat werd geselecteerd voor procesoptimalisatie (vaste stof concentratie van 
de suspensie, atomisatiedruk, inlaat- en uitlaattemperatuur van de drogende lucht) van ‘ready-
to-compress’ gecosproeidroogde poeders. Colloïdale silicium dioxide werd gebruikt om de 
procesopbrengst te verhogen. Polyoxyethyleen 20 sorbitan monooleaat werd toegevoegd om 
de kwaliteit van de suspensie te verbeteren in geval van hoog gedoseerde en beperkt 
wateroplosbare geneesmiddelen en om de tabletdesintegratie te verlagen. Significante 
modellen voor vloeibaarheid, gemiddelde deeltjesgrootte, densiteit, vochtgehalte en 
procesopbrengst werden opgesteld. De atomisatiedruk beïnvloedde enkel de vloeibaarheid 
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van de poeders, terwijl tabletsterkte, -desintegratietijd en -friabiliteit robuust waren, 
onafhankelijk van de procescondities. Een geoptimaliseerd sproeidroogproces met een 
atomisatiedruk van 6 bar en een inlaat- en uitlaattemperatuur van respectievelijk 221 en 81°C, 
werd geselecteerd voor verdere opschalingsexperimenten. 
 
In HOOFDSTUK 5 werd nagegaan of ‘coprocessing’ via sproeidrogen kon gebruikt worden 
als een formulatieplatform om de compacteerbaarheid van talrijke geneesmiddelen te 
verbeteren. Acetaminophen-, ibuprofen- en cimetidine-formulaties werden geproduceerd in 
een laboschaal sproeidroger, terwijl de geoptimaliseerde acetaminophen- en ibuprofen-
formulaties werden opgeschaald in een productie-sproeidroger. Daarenboven werden de 
concentratie van het geneesmiddel en de vaste stof concentratie van de suspensie 
geoptimaliseerd. Deze direct comprimeerbare en hoog gedoseerde acetaminophen 
(geneesmiddelconcentratie: 70% w/w), ibuprofen (geneesmiddelconcentratie: 75% w/w) en 
cimetidine (geneesmiddelconcentratie: 70% w/w) poeders werden geproduceerd door middel 
van cosproeidrogen van waterige suspensies met een vaste stof concentratie van 35% w/w. 
Deze poeders waren direct comprimeerbaar. Het opschalen van de geoptimaliseerde 
acetaminophen- en ibuprofen-formulaties op een productieschaal sproeidroger en rotatieve 
tabletpers werd uitgevoerd met als resultaat een volledig continu productieproces. Tijdens 
tabletproductie op een rotatieve ModulTM P pers waren de tabletsterkte, -desintegratietijd en -
friabiliteit van de acetaminophen- en ibuprofen-formulaties binnen aanvaardbare grenzen. 
 
Op basis van het uitgevoerde werk tijdens dit project kunnen verscheidene onderwerpen voor 
toekomstig onderzoek geïdentificeerd worden: 
- alhoewel een volledig continu productieproces zonder additionele maal- of 
mengstappen ontwikkeld werd voor acetaminophen- en ibuprofen-formulaties 
(Hoofdstuk 5), kunnen procesproblemen voorkomen bij andere geneesmiddelen 
vanwege onvoldoende smering. Een toekomstige uitdaging is een directe opname van 
een smeermiddel tijdens ‘coprocessing’ van een geneesmiddel met excipiënten, 
waardoor de smering van direct comprimeerbare en gecoproduceerde poedermengsels 
effectief verbetert zonder bijkomstige mengstap. Tijdens voorafgaand onderzoek 
hebben we reeds een smeermiddel (Mg-stearaat) toegevoegd aan de suspensie. De 
hoeveelheid aan magnesium stearaat op het oppervlak van de gesproeidroogde deeltjes 
was echter onvoldoende voor een efficiënte smering. Dit probleem kan eventueel 
verholpen worden door een smeermiddel toe te voegen aan het systeem nadat de 
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gesproeidroogde deeltjes gevormd zijn (vb. door middel van continue 
poederverstuiving van magnesium stearaat in het buissysteem voor de cycloon of in 
een horizontale wervelbeddroger die verbonden is achter de cycloon), waardoor de 
deze gecoat worden met smeermiddeldeeltjes. 
- Naast het gebruik van polyolen en maltodextrine kunnen excipiënten zoals 
(gesilifieerde) microkristallijne cellulose, dicalciumfosfaat, hydroxypropylmethyl-
cellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, ethyl-
cellulose, polyvinylpyrrolidone (en zijn copolymeren) en polyethyleen glycol 
geëvalueerd worden op hun vermogen om de compacteerbaarheid van geneesmiddelen 
te verbeteren door middel van ‘coprocessing’. 
- De ontwikkeling van een gelijkaardig formulatieplatform voor slecht water oplosbare 
geneesmiddelen gebaseerd op organische oplossingen/suspensies met als doel ‘ready-
to-compress’ vaste dispersies te bereiden en het oplossen en de biobeschikbaarheid 
van het geneesmiddel te verbeteren. 
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